List of Artificial Intelligence Companies in United States - 772

20/20 GeneSystems (‘20/20’) was founded in May of 2000 to develop and promote an innovative proteomics product line that provides drug companies, biodefense specialists and life scientists with new tools for protein analysis. Our headquarters are in the heart of the biotechnology corridor in Rockville, Maryland in close proximity to the National Institutes of Health with which we have extensive collaborations. 20/20 GeneSystems develops and commercializes innovative, proprietary diagnostics tests that aid in the fight against cancer. These tests generally fall into two categories: Personalized Medicine: Our patented platform technology for measuring biomarkers in tumors is highly unique in that it combines the visual advantages of classical pathology with the multiplex capabilities needed as a result of genomics and proteomics. This technology is now being used to develop tests to predict responses to several new targeted therapies for kidney and lung cancer. Early detection of lung cancer: 20/20 is developing a blood test for the early detection of lung cancer. This product will be used for screening smokers and former smokers to pre-select or enrich the patient population to receive annual CT scanning long before the disease becomes symptomatic. Biological Detection: 20/20 is on the leading edge of developing technologies to help in the detection of biological toxins.

3CPM Corporation is a Medical Technology company that offers a non-invasive 45-minute test using AI-derived patented technology to accurately characterize gastrointestinal motility disorders such as gastroparesis and functional dyspepsia.

908 Devices is revolutionizing chemical analysis with its simple handheld and desktop devices, addressing life-altering applications. The Company’s devices are used at the point of need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in bioprocessing, pharma/biopharma, forensics, life sciences research and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of complementary analytical technologies, microfluidic sampling and separations, software automation, and machine learning.

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections. Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development. Our approach integrates interdisciplinary ingenuity with computational tools to design new drug candidates using our proprietary SCULPT platform. Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. Fragments are incorporated into the target-specific construction of combinatorial in silico libraries, which are designed based on synthetic feasibility. Libraries consisting of thousands to millions of small molecules are iteratively built, and computationally evaluated for potency and optimal ADMET properties. The final selection is made from dozens of iterations, totaling upwards of 100 million compounds.

A-Alpha Bio is a biotechnology company harnessing synthetic biology and machine learning to measure, predict, and engineer protein-protein interactions. Our experimental platform, AlphaSeq, enables the rapid and quantitative measurement of millions of protein-protein binding affinities simultaneously. Our computational platform, AlphaBind, is trained on the world’s largest protein-protein interaction database and predicts binding strength from sequence. A-Alpha Bio leverages AlphaSeq and AlphaBind for in-house therapeutic programs and in partnership with leading pharmaceutical companies to inform the discovery and development of novel therapeutics. A-Alpha Bio is based in Seattle and was founded in 2017 at the University of Washington's Institute for Protein Design and Center for Synthetic Biology. To learn more, please visit: https://www.aalphabio.com/

The remarkable specificity and safety of antibody drugs have been limited to blocking inactivators for the largest class of drug targets. Abalone Bio develops antibody drugs that activate, enabling us to turn on previously inaccessible biological activities like anti-cancer or anti-inflammatory actions.

Abiologics is pioneering a new class of supranatural and programmable biologics, called Synteins™. The Abiologics platform leverages cutting-edge generative artificial intelligence and high-throughput chemical protein synthesis to create Synteins with powerful, desirable pharmacological properties, redefining what therapeutics can achieve for patients across a range of disease areas. Abiologics was founded by Flagship Pioneering in 2021.

Absci is a generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to learn, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed antibodies to wet lab-validated candidates in as little as six weeks. Our vision is to deliver breakthrough therapeutics at the click of a button, for everyone.

Abterra Biosciences is reimagining antibody discovery and sequencing by harnessing the latest next-generation sequencing, mass spec, machine learning. Abterra Biosciences is enabling the next-generation of antibody therapeutics. Our technologies use the latest in next-generation sequencing.

Accel Diagnostics is medical diagnostic company developing proprietary point-of-care diagnostic assay for the diagnosis, monitoring and management of a wide variety of medical conditions. We are dedicated to making a difference in the quality of life of millions of patients through technology and innovation. AccelDx’s technology enables patients and healthcare providers to perform lab-quality medical diagnostic tests anytime and anywhere. The Company's patented platform technology transforms the patient blood testing paradigm, from lab-centered to near-patient. The technology bringing significant advantages in terms of simplicity, time to result, care delivery, and cost over current standard lab-based diagnostics. During COVID-19 pademic Accel Diagnostics began to operate the ADX Diagnostic Lab to provide high quality COVID testing in Houston, TX.

AcelaBio, wholly owned by The Alimentiv Health Trust, was incorporated in 2020 and aims to meet the growing clinical research demand for quality and efficiency in laboratory service. Our state-of-the-art facility, located in San Diego, California, is built on deep expertise in clinical and precision medicine research and our scientific and operational experts are dedicated to delivering reliable, high-quality data.

Acelot is treating functional protein misfolding diseases where the appropriate therapeutic mechanism is a restoration of the normal protein homeostasis. Functional misfolded proteins are found in various diseases such as ALS, FTD, Parkinson's, diabetes and cancer. Acelot's platform combines generative AI, molecular dynamics simulations and proprietary assays to discover small molecules that restore the homeostasis of misfolded proteins in various diseases. We have a pipeline of hit-to-lead discovery compounds across multiple indications, along with an IND-ready candidate for ALS. Our platform was invented by UCSB Computer Science Professor Dr. Ambuj Singh. Acelot's first development candidate, ACE-2223, is a first-in-class orally bioavailable small molecule that will undergo IND-enabling studies in 2024. ACE-2223 disrupts the misfolded forms of TDP43 and restores functional TDP43. It acts upon the misfolded conformations of TDP43 found across various patient populations, including ALS, FTD and Alzheimer's. ACE-2223 has excellent brain penetrance and ADME properties. Acelot also has a robust discovery pipeline.

Achira is building atomistic foundation simulation models to power the future of drug discovery.

At Activ Surgical, our mission is for every surgical imaging system to deliver intelligent information that reduces surgical complication rates, ushering in a new standard of patient care and safety. Having completed the world’s first autonomous robotic surgery of soft tissue in 2018, the company is focused on enhanced, real-time visualization capabilities for surgeons that combine advanced augmented reality (AR), artificial intelligence (AI), and machine learning (ML) technology. Our vision is to transform the collective surgical experience by leveraging emerging technologies and data into insights that make world-class surgery accessible for all.

AcuraStem (acurastem.com) is a near-to-clinic, patient-based, drug development company pioneering drug discovery and ultimately how treatments are developed for neurodegenerative diseases—including sporadic ALS and FTD. Enabled by our ground-breaking iNeuroRx® technology platform - AcuraStem has discovered and is now advancing drug candidates that promise to strongly impact disease progression for most patients, including those for whom the genetic cause of their disease is unknown (i.e. sporadic ALS and FTD patients). The causes of neurodegenerative diseases are complex, and genetically defined forms of disease (e.g. C9ORF72-ALS and FTD) only account for a small percentage of cases. Thus, many scientists didn’t believe it was possible to develop a single effective treatment that could work broadly for all patients. But AcuraStem has shown with its extremely promising therapeutic programs for ALS and FTD that it can be done.

Adaptive Clinical Systems, a global life sciences technology company, offers a simple, secure, validated, compliant and cost-effective solution for data interoperability as well as reporting and visualization for clinical trials. Adaptive Clinical offers the Adaptive eClinical Bus and Adaptive DataVIEW. The Adaptive eClinical Bus®, a cloud-based hosted service, will integrate with any EDC, eCOA, CTMS, ePRO/IWRS, Medical Imaging, IRT, Analytics, Data Acquisition Systems as well as RWD, EHR/EMR to reduce error and speed data management for any size study. With the Adaptive eClinical Bus, patient- centric clinical trials can ensure interoperability and full compliance from the many diverse eSources generated from the explosion of data from Digital Health Technologies (DHTs), such as wearables and remote patient monitoring (RPM) solutions. Key benefits of the Adaptive eClinical Bus include: ✔️ Fully-validated Platform with Detailed Audit Logs and Reports ✔️ Fully compliant with HHS 45 CFR Part 64, FDA 21 CFR Part 11, GxP and other regulatory guidelines ✔️ Standards-based for Interoperability ✔️ Easily Implement an eSource Data Capture Workflow ✔️ Adaptive Rules Engine offers Built-in Clinical Intelligence ✔️ Reusable components for Quick Installation ✔️ Full training and 24/7 support Adaptive DataVIEW provides a robust solution for visualizing and analyzing data from disparate sources quickly and efficiently. It provides real-time, bi-directional data from many disparate sources into comprehensive dashboards. Purpose built for clinical trial operational key performance indicators and dashboards. Reports can be created at the patient, site, study or program level, including across studies. Adaptive DataVIEW enables "single click-back" from any widget or dashlet to the data source regardless of eClinical tool.

Adaptive Phage Therapeutics (APT) is a clinical-stage company advancing therapies addressing multi-drug resistant infections. Prior antimicrobial therapeutic approaches have been “fixed,” while pathogens continue to evolve resistance to each of those therapeutics, causing those drug products to become rapidly less effective in commercial use as antimicrobial resistance (AMR) increases over time. APT’s PhageBank™ approach leverages an ever-expanding library of bacteriophage (phage) that collectively provide evergreen broad spectrum and polymicrobial coverage. PhageBank™ phages are matched through a proprietary phage susceptibility assay that APT has teamed with Mayo Clinic Laboratories to commercialize on a global scale. APT’s technology was originally developed by the biodefense program of U.S. Department of Defense. APT acquired the world-wide exclusive commercial rights in 2017. Under FDA emergency Investigational New Drug allowance, APT has provided investigational PhageBank™ therapy to treat more than 40 critically ill patients in which standard-of-care antibiotics had failed.

Develops a rapid leukocyte differential instrument is used to screen for infections, allergies, and blood-related cancers including leukemia.

Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. We're committed to staying at the cutting edge of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.

We are committed to the growth and development of companies and organizations using advanced therapeutic technologies to revolutionize medicine through specialized, bespoke advisory services. At Adjuvant Partners, we leverage our expertise, professional network, and pan-industry perspectives to provide unique, tailored solutions to our clients to best suit their needs. We believe in active participation with stakeholders throughout the industry, and in concert with our clientele work to foster continued growth, expansion, and implementation of advanced therapies across the healthcare spectrum.

Admetsys is a biomedical technology company specializing in critical care automation. The company's flagship PrecisionOne system is the first fully automated glycemic control system and continuous blood diagnostics platform for hospital care. The company was founded to commercialize the next generation of medical automation technology: continuous real-time biosensing, robotics, artificial intelligence and learning algorithms, intelligent therapeutic delivery, and advanced data telemetry.

AeroFarmsis an indoor vertical farming company. They usea patented aeroponic growing system to grow produce.

Aether's mission is to build a future of abundance for the human race. We believe that the machinery of nature can be reverse engineered to manufacture any arrangement of atoms desired, enabling the production of new products anywhere on earth.

Afecta Pharmaceuticals is an early clinical stage small molecule therapeutics company focused on developing precision medicines to treat chronic disorders and cancers more effectively. Afecta has a validated, proprietary Artificial Intelligence disease/drug targeting platform, PharmetRx®, to discover and optimize Multi-Target drug compounds and formulate them in NanoRx®, our tissue-specific drug delivery technology. Backed by an experienced management team, Afecta is currently advancing AFX-220, our clinically proven lead candidate that effectively treats the disruptive behaviors that occur in children and adolescents with several neurodevelopmental disorders such as Autism, AD/HD, and others. Please visit our website to learn more, register to access our Executive Summary, and receive our latest updates.

Affinia Therapeutics is an innovative gene therapy company focused on broadening the reach of gene therapy. Our proprietary Affinia Rationally-designed Therapies (ART) platform is created to address key limitations of conventional gene therapies, by developing novel capsids, novel promoters, and novel manufacturing approaches to developing gene therapies for rare and prevalent devastating diseases. We are backed by a strong syndicate of life science investors and have ambitious plans to have a dramatic impact on the lives of patients around the world.

AgBiomeis usingknowledge of the crop microbiome and an extensive network of field-sampling partners to build a proprietary microbial strain collection that is both diverse and large—larger, in fact, than the major public strain collections. Unlike many programs, which only use metagenomics surveys, the AgBiome platform is focused on true isolated microbial strains, which provideinsight into the genomic composition of crop-associated microbes. The company uses this collection as a resource for discovering new biologicals and trait genes.Existing microbial classification systems based on 16S rDNA sequences or other fingerprinting technologies are imprecise—microbes that are classified as ‘the same’ often differ by hundreds of genes. AgBiome uses proprietary algorithms based on whole genome sequence to classify organisms in their collection. This allows the company to measure the true diversity of plant-associated microbes at the gene level—and genes determine function and performance. The company has also applied our whole-genome methods to their straincollection.

We help entrepreneurs form new teams and build AI-first startups. Apply on our website for $500k investment, up to $1M in free AI compute, and network of AI founders and researchers. We bring together world-class engineers, researchers, and entrepreneurs to create new companies together from scratch. From ideation to execution, we help generate ideas, find co-founders, secure pilot customers, integrate cutting-edge AI, and more. Our hands-on support guides founders through building, scaling, and raising millions in venture funding. In 6 years, we've backed 40+ companies now valued at $1B+, raising $220M+ and creating 700+ jobs. Our startups are transforming industries: improving immigrant communication (Yoodli), accelerating cancer research (Ozette and Modulus), enhancing legal efficiency (Lexion, acquired by DocuSign), turning smartphones into medical devices (PreemptiveAI), and so much more. Any VC can write a check, but what truly sets us apart is our unparalleled technical and AI expertise. With our heritage at the Allen Institute for AI—founded by Microsoft co-founder Paul Allen—we’ve been singularly focused on commercializing AI long before it became a buzzword. AI2 has 200+ PhDs, researchers, engineers, professors, and support staff—and is well known for its contributions to the A.I. research community including 600+ papers, 20+ best paper awards, and numerous products/open-source offerings including SemanticScholar, AllenNLP, and more. Our core team includes pioneers like Oren Etzioni, a leader in AI for over three decades, and our deep technical expertise means we don’t just back you financially—we help you build breakthrough products, navigate complex challenges, and accelerate your company’s growth. We're soon launching AI House in Seattle, a central hub for AI innovation. In partnership with the Mayor of Seattle and supported by Washington state, this space will serve as a central hub for the region’s AI community.

A.I. Analysis, Inc. is a medical software company specializing in the application of artificial intelligence (AI) to radiology. A.I. Analysis, Inc.’s first product is the Change Detector for Brain Imaging, a machine-learning based system that compares serial MR imaging studies and presents changes in the form of a color overlay superimposed on the anatomical images. The Change Detector saves radiologists time at the beginning of their reading — perhaps up to 10 minutes for diseases such multiple sclerosis. The Change Detector highlights the locations of changes and degree of those changes, so the radiologist can more quickly reach clinical judgments. Using the Change Detector, it may be possible for radiologists to detect changes months earlier than is possible with manual inspection alone, with greater reproducibility.

Aiberry is an AI-powered multimodal platform that offers providers and care managers rapid, objective, and unbiased behavioral health assessments. Aiberry delivers evidence-based insights virtually (in telehealth scenarios) and at the point of care, offering unique outreach and scale opportunities.

Aigen is accelerating the transition to regenerative agriculture. We're launching the world's first AI-driven, network connected robotic fleet, powered entirely by the elements. Aigen is building a future with no harmful chemicals in our food. Backed by NEA, GFC, AgFunder, Regen.vc, and Bessemer Ventures

Ainnocence is a next-generation biotech company with a fast, self-evolving AI drug design platform. The company's third-generation AI system delivers lightning-fast virtual screening and multi-objective pharmacological profile optimization for small-molecule, antibody, and other complex therapeutic modalities. This platform provides a computational screening capacity of up to 10^10 protein sequences or chemical compounds within hours. The end results are a shortlist of candidates with a very high wet-lab hit rate, and a dramatically reduced discovery time and cost. To learn more, visit ainnocence.com.

Ainos Inc. is a diversified healthcare company focused on the development of novel point-of-care testing (POCT), low-dose VELDONA interferon therapeutics, women's health, pneumonia, Ainos Pen, AI Nose, and other medical technologies. The company was founded in 1984 and is engaged in developing innovative medical technologies for point-of-care testing and safe and effective treatments for various health conditions.

Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies.

We are creating a new category of medicines with the application of spatial biology and AI.

Improve yield, reduce deviations, and ensure product quality in GxP pharmaceutical manufacturing with real-time, practical Artificial Intelligence (AI)- powered software as a service solutions.

Alabama Agricultural and Mechanical University(AAMU) is a historic, student-friendly and community-focused institution of higher learning. Reflecting on its heritage as a historical black college and university (HBCU) and a traditional 1890 land-grant institution, AAMU functions as a teaching, research and public service institution, including extension.

Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. Alexion has over 3,000 talented colleagues dedicated to serving people living with rare diseases in more than 50 countries around the world. Our global headquarters are based in Boston, Massachusetts and our EMEA headquarters are in Zürich, Switzerland. We also have a Research Center of Excellence in New Haven, Connecticut, global supply chain and operations headquarters in Ireland, as well as local and regional operations in countries around the world. At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day.

Building a modern operating system for IVF, powered by artificial intelligence.

Aliri is committed to solving industry challenges by bringing innovative bioanalysis and spatial solutions to biotech and pharma, as the complexity of the drug development landscape continues to rise. Our mission is to support our customers with bringing life-saving therapies to market with speed and agility. We are focused on providing pharma and biotech companies with bioanalysis lab, spatial bioanalysis, and spatial biology solutions that will bring unique, comprehensive data to enable strategic decision making for lead optimization and strengthen regulatory submissions.

AliveCor, Inc. is transforming cardiological care using deep learning. The FDA-cleared KardiaMobile device is the most clinically-validated personal ECG solution in the world. KardiaMobile 6L provides instant detection of Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular Contractions, Sinus Rhythm with Wide QRS, and Normal Sinus Rhythm in an ECG. Kardia is the first AI-enabled platform to aid patients and clinicians in the efficient detection of atrial fibrillation, the most common arrhythmia and one associated with a highly-elevated risk of stroke. AliveCor's enterprise platform allows third-party providers to manage their patients' and customers' heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies. AliveCor protects its customers with stringent data security and compliance practices, achieving ISO 27001 Certification, SOC 2 Type 2 Certification and HIPAA compliance attestation. AliveCor is a privately-held company headquartered in Mountain View, Calif. "Consumer" or "Personal" ECGs are ECG devices available for direct sale to consumers. For more information, visit alivecor.com.

Alli Connect is a mental health care service for first responders that proactively promotes wellness and positive change in public safety.

Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna’s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.

Allurion was founded in 2009 with one mission: end obesity. The Allurion Program combines medical, digital, and nutritional approaches and engages an entire team to jumpstart weight loss and form lifelong healthy habits. Allurion has already helped thousands of people around the world lose weight, develop lifelong healthy habits, and transform their lives, with over 100,000 balloons placed, and over 1,000,000kg lost worldwide.

ATEC is a medical device company dedicated to revolutionizing the approach to spine surgery through innovation. ATEC’s Organic Innovation Machine™ is the greatest concentration of spine knowhow in the industry and committed to the creation of clinical distinction. Leveraging 100% spine focus and expertise, we seek to improve spine surgery by rethinking, redesigning and seamlessly integrating the technologies required from the ground up. The innovation that results from that process is being rapidly adopted because, like us, spine surgeons covet informatic and procedural sophistication that enables more predictable, more reproducible care. Our flagship technology, the Prone TransPsoas (PTPTM) Procedure, leveraged decades of experience to advance first-generation lateral surgery with a more familiar patient position and elevated neuromonitoring.   EOS imaging, the backbone of ATEC’s informatic ecosystem, provides radiographic imaging, enabling standing, full-body, global alignment assessments. We are further developing EOS technology to elevate spine care with unprecedented capabilities. Our vision is to be the standard bearer in spine. Visit our website for more information: www.atecspine.com

Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet. Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR), and artificial intelligence (AI). Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt.

Alto Neuroscience is a clinical-stage biopharmaceutical company that integrates the biology of the patient into drug development to improve the lives of people with mental health conditions. Through its AI-enabled biomarker platform, Alto Neuroscience combines rich sources of information on patients’ brain activity and behavior to rapidly develop

Aluna is designed to help you understand your chronic respiratory condition (such as asthma) and allow you to take control of your lung health. Using a combination of machine learning, our spirometer device and mobile app, you can now use the daily measurements to help you understand and manage your asthma.

Focusing on generating innovative biological respondents with a unique mode of action coupled with conditionally activated characteristics, we handle high-value disease targets with huge upside potential, which are otherwise intractable for traditional targeting approaches.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

Imagine a world in which devastating disease such as cancer is detected sooner; thus, providing doctors the ability to treat patients earlier with better outcomes. Amplified Sciences is a startup life science diagnostics company focused on accurately detecting and pre-empting the risks of debilitating diseases. The company leverages IP licensed from Purdue University and has developed a platform that can scale to point of care. The lead assay is an ultra-sensitive molecular sensing technology revolutionizing #pancreaticcancer. Enabling early detection of debilitating diseases across oncology and chronic kidney disease.

At Amsterdam UMC, more than 15,000 professionals strive to provide good and accessible care. For the generations of today and tomorrow. The two medical university centers in Amsterdam, AMC and VUmc, are working together towards a future in which we prevent illnesses and make the best treatment available to all patients. To this end, we develop new methods for diagnostics and treatment together with professionals from other renowned national and international institutions. We treat over 350,000 patients a year at both our sites - AMC and VUmc. Our main focus is on complex patient care and highly-specialized treatment of rare medical conditions. At Amsterdam UMC, we teach and train thousands of young people to become doctors, specialists or nurses. Our researchers are clustered in eight research centers so that we can achieve our ambition of executing international, cutting-edge research. At Amsterdam UMC, AMC and VUmc are working together on academic patient care, scientific research and teaching & training.

AngioInsight, Inc. is a digital health company based in Ann Arbor, Michigan, specializing in artificial intelligence for cardiovascular diagnostics. Founded in 2018, the company develops AI-driven solutions aimed at improving the accuracy and efficiency of diagnosing and managing coronary artery disease (CAD). The AngioAI+ platform is a key offering, designed for real-time assessment during angiography. It provides actionable insights by detecting microvascular dysfunction and quantifying stenosis severity. Additionally, AngioInsight offers fully automated angiogram analysis, which processes coronary angiogram videos to support clinicians in making informed treatment decisions. The company's technology integrates seamlessly into existing clinical workflows, enhancing resource allocation and patient outcomes. AngioInsight has received significant funding, including grants and investments, to support its innovative approach. The company is actively engaged in clinical studies to validate its platform's efficacy, particularly in addressing diagnostic gaps in cardiovascular care. Its solutions are targeted at cardiologists and healthcare institutions that perform millions of angiograms annually.

Anivive is focused on reshaping pet healthcare by bringing together experts in software development, veterinary medicine, and clinical research to accelerate the development of novel therapeutics. Anivive. Smarter for pet health.

Anumana™ is harnessing industry-leading AI and translational science to decode electrical signals from the heart as never before, empowering healthcare providers to transform patient care throughout the cardiac clinical pathway. Serious cardiovascular diseases affect millions of people worldwide, often going undiagnosed until symptoms advance and patients deteriorate. Unfortunately, these conditions can remain undiagnosed until the patient suffers a life-threatening event. Innovations enabling earlier diagnoses could address this unmet medical need and empower healthcare providers to intervene with life-saving treatments. Anumana recently acquired NeuTrace and is leveraging the power of novel ECG-EGM-EMR integration for clinically valuable, actionable insights. With nference's proprietary nSights real-world evidence generation platform, built on data from leading health systems, we combine unparalleled longitudinal structured and unstructured electronic medical record data with diagnostic and interventional ECGs and EGMs. By applying AI techniques to these electrical signals from the heart, the company has uncovered clinically critical electrical signatures and patterns unrecognizable to the human eye. The resulting software products can be integrated into routine clinical practice for earlier disease diagnosis and in-procedure decision-making. Anumana's 75+ peer-reviewed publications and ongoing research show significant promise to detect and diagnose otherwise hidden conditions earlier and uncover actionable insights for valuable patient interventions. The opportunity to offer clinical decision support tools for each unique patient throughout the cardiac care continuum paves the way for precision medicine. Anumana strives to introduce a new standard of care in cardiac clinical care supported by reimbursement.

Are you ready for a transformative leap in small bowel capsule endoscopy? Meet ProScan, our cutting-edge AI Assisted Reading Tool meticulously designed to revolutionize the diagnostic process for patients suspected of small bowel bleeding. ProScan leverages advanced artificial intelligence algorithms to significantly reduce the time required for reviewing capsule endoscopy studies, enabling quicker and more precise diagnoses. It is meticulously engineered to expedite the evaluation of capsule endoscopy images, enhancing the timeliness of a diagnosis and initiation of therapy. Headquartered in Plano, Texas, AnX Robotica brings versatility in development and integration of multi-discipline technologies such as precise magnetic, robotic control, in house ASIC design, artificial intelligence, micro-optical imaging, image processing, and wireless transmission. With more than 200 patents granted or applications pending, and dozens of clinical papers published in major international journals, AnX Robotica, together with its sister companies, have become the leading companies in robotic capsule technology.

Apertura is a biotechnology company opening opportunities in gene therapy for treating debilitating diseases with limited options. We are pioneering next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure in New York City.

AppHarvest is a sustainable food company in Appalachia developing and operating some of the world’s largest high-tech indoor farms with robotics and artificial intelligence to build a reliable, climate-resilient food system. AppHarvest’s farms are designed to grow produce using sunshine, rainwater and up to 90% less water than open-field growing, all while producing yields up to 30 times that of traditional agriculture and preventing pollution from agricultural runoff. AppHarvest currently operates its 60-acre flagship farm in Morehead, Ky., producing tomatoes, a 15-acre indoor farm for salad greens in Berea, Ky., a 30-acre farm for strawberries and cucumbers in Somerset, Ky., and a 60-acre farm in Richmond, Ky., for tomatoes. The four-farm network consists of 165 acres under glass. AppHarvest is a public benefit corporation and a Certified B Corp.

Applied Surgical Robotics is a MedTech company focused on developing robotic technology and SaaS software solutions to improve surgical precision.

Apriori is working to create a world where humanity is protected against viral threats. Our pioneering approach centers on a unique technology platform, which allows us to survey the entire landscape of existing and potential viral variants to design new vaccines and antibody drugs against the most threatening variants. Octavia can also inform public health policy in real time by predicting the impact of emerging variants. Apriori was founded in 2020 in Flagship Labs, a unit of Flagship Pioneering.

Aquavit Pharmaceuticals, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies. We focus on personalized medicine to improve patient health and to maximize the efficiency of the medical community. At Aquavit Pharmaceuticals, Inc., we combine this strategic focus with a modern, diverse approach that enables us to pursue new specialty areas with significant unmet needs. Science personalized. Healthcare modernized.

Arbor Bio is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines, with the most extensive toolbox of proprietary genomic editors in the industry. We have the unique ability to work backward from disease pathology and choose the optimal editors or combination of editors for the disease in question.

Archon is a biotechnology company developing computationally designed proteins to unlock powerful therapeutic targets that lie beyond the reach of existing modalities and to better treat disease. We directly apply generative protein design to create a new biologic class, Antibody Cages (AbCs), that integrates the industry-proven affinity and specificity of antibodies into self-assembling nanostructures. Precise control over AbC structure provides the ability to tune both how they distribute in the body and engage their cellular targets with high specificity and potency to establish a new gold-standard for biologic medicines.

Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.

Ardigen is a bioinformatics company that specializes in AI-driven solutions for drug discovery and precision medicine.

Argon AI is a platform that allows biopharmacy and life sciences experts to conduct complicated, data-driven operations. They help life sciences companies automate their data-intensive workflows with unprecedented AI.

Ariana Pharma is a leading Artificial Intelligence (AI) drug development company. Using its KEM® Artificial Intelligence (xAI) technology, Ariana helps its partners introduce personalized medicine clinical trial design into their protocols and optimize clinical endpoints, identify biomarkers of therapeutic response and potential synergistic therapies. Ariana routinely collects and combines clinical data with omic data, immunological readouts (such as Fluorescence-Activated Cell Sorting (FACS)), microbiota, Patient Reported Outcomes (PRO) as well as Real World Evidence (RWE) data. Combining advanced data analytics, drug development, and regulatory expertise, Ariana helps translate findings into innovative clinical development plans and regulatory approvals. With a growing number of successful therapeutic development programs, KEM® is an FDA-assessed technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for precision medicine. Ariana has developed Onco KEM®, the most advanced, clinically tested, oncology therapeutic decision support system. Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company operates a subsidiary in the United States since 2012.

ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced machine learning (ML) and imaging-based drug discovery platform enables a rapid and efficient identification of new drug classes with desired activity profiles and clinical utility, coupled with a deep understanding of mechanism of action at the outset of the discovery process.

Arrow Dx is combining Nanotechnology and Artificial Intelligence (AI) to create an inexpensive, sensitive test to screen early for non-alcoholic fatty liver disease (NAFLD). Our aim is to provide physicians with an alternative to liver biopsy which detects the disease too late. We are working to solve the lack of rapid, reliable, point-of-care, and inexpensive diagnostic devices by bring faster, inexpensive and mobile testing for many other applications that require a rapid response (e.g., epidemic/pandemics, public health crisis, early diagnosis for rising complex non-communicable diseases, testing in emergency rooms). Our technology makes it more affordable for smaller healthcare providers such as Physician Office Labs (~100,000 in the U.S.), independent physicians and public health workers to access diagnostics due to our significantly lower cost as well as our portable, small compact size. Finally, we are also working to create a test for COVID-19 as well as other viruses, initially quantifying the virus in wastewater to help public health authorities and later to detect it in biological samples from individuals and patients.

ArsenalBiosciences, Inc., is a privately held, clinical stage programmable cell therapy company focused on the realization of solid tumor cell therapy to defeat cancer. Our discovery engine comprises precise CRISPR-enabled genome editing, integrated circuits incorporating logic gates for improved tumor targeting, and therapeutic enhancements enabling multiple pharmaceutical functions. With our programmable and computationally driven approach, we aim for enhanced and broader efficacy, increased patient safety, reduced provider costs and expanded market access. Our team is engineering living medicines to attack cancer’s inherent multi-faceted nature and bring dramatic improvements to the lives of patients.

Artera is a SaaS digital health leader redefining patient communications. Artera is trusted by 700+ healthcare systems and federal agencies to facilitate approximately 2.2 billion messages annually, reaching 100+ million patients. The Artera platform integrates across a healthcare organization’s tech stack, EHRs and third-party vendors to unify, simplify and orchestrate digital communications into the patient’s preferred channel (texting, email, IVR, and webchat), in 109+ languages. The Artera impact: more efficient staff, more profitable organizations and a more harmonious patient experience. Founded in 2015, Artera is based in Santa Barbara, California and has been named a Deloitte Technology Fast 500 company (2021, 2022, 2023), and ranked on the Inc. 5000 list of fastest-growing private companies for four consecutive years. Artera is a two-time Best in KLAS winner in Patient Outreach.

Arterys was founded to facilitate the global advancement of medicine through data, artificial intelligence and technology. Because a significant proportion of the world's medical data resides in medical images, Arterys set out to tackle several issues around the space, including the enormous workloads radiologists face, the lack of accuracy with many of today's tools, and the need for increased consistency across practices. The company was the first to receive FDA clearance for a cloud-based product with Artificial Intelligence, and currently has 8 FDA clearances, and is active in 118 countries. Arterys continues to focus on solving some of radiology's most pressing needs. We deliver the most comprehensive set of clinical AI solutions in the industry, built off a single platform and user interface that focuses on users with seamless workflow integration and a unified and optimized UI for every one of our applications. By making imaging diagnostics quantitative, intelligent and available, we empower healthcare organizations to improve physicians' experience, patient outcomes, efficiency, and reduce costs with cloud and AI. Arterys has offices in San Francisco, Calgary and Paris. For more information, please visit www.arterys.com. Follow Arterys on Twitter at @ArterysInc at https://twitter.com/ArterysInc.

Artificial accelerates the pace of life science discoveries by making connecting and orchestrating labs easy with its cloud-based software platform, the Artificial Product Suite. As a vendor-agnostic platform, the Artificial connects with any native instruments, devices, databases, and informatics to provide a single, easy-to-use orchestration layer for the entire lab. Using Artificial, scientific labs can control and monitor their processes in real-time while capturing AI-ready data and keeping humans in the loop.

Artos helps clinical development and medical writing teams turn their data into regulatory submissions in days instead of weeks. Life sciences companies spend $13 billion and millions of man-hours each year on regulatory submissions for health agencies. At Artos, we build AI and software tools to shrink those timelines so that life-saving treatments can get to patients sooner.

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development. A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests. With more than 3,000 employees, ARUP offers in excess of 3,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays. ARUP is an Equal Opportunity Employer M/F/D/V and supports a drug-free environment. Scammers have been posing as ARUP recruiters to target jobseekers using fraudulent email addresses and social media accounts. ARUP recruiters will only contact you with legitimate offers by calling from 800-522-2787 or 801-583-2787 or emailing from an address ending in @aruplab.com. Read our full fraud statement on aruplab.com/careers

Arxspan provides cloud-based solutions to meet the scientific data management needs of leading life sciences, chemicals, and scientific companies globally. Arxspan offers ArxLab®, a suite of web-based scientific informatics applications, allowing scientists to record, manage, and share their research data​: * Notebook - Intuitive electronic laboratory notebook (ELN) optimized for collaborative models in current research environments * BioReg/ChemReg Registration - Configurable repository for registering unique chemical/biological entities and subsequent batches * Assay - Flexible system for registering assay protocol and result data * Inventory - Comprehensive tool for defining and managing chemical and biological compounds, reagents, equipment, and other items * Search - Robust decision support platform for querying, visualizing, and reporting data * Workflow - ArxLab Workflow allows users to create new work requests and to assign them to users and/or groups. The workflow management tool enables scientists to manage and prioritize all scientific projects, as well as to make procedure requests to internal colleagues and external partners. For more information, please visit our website at www.arxspan.com

Arzeda combines protein design, pathway design, HT screening and strain construction to create and improve designer fermentation strains for virtually any chemical. One example of their work is indeveloping new and improved enzymes to make rare sugars, natural sweeteners,and other oligosaccharides.

Ascertain, a healthcare technology company empowering care teams with AI, helps health systems, payers, and independent provider groups streamline operations and reduce administrative burden. Customers can either deploy Ascertain Automate, an enterprise software platform that uses agentic AI to automate high-volume administrative workflows, or engage Ascertain's tech-enabled services, outsourcing entire workflows to Ascertain's team, which operates the software on their behalf. From prior authorization and eligibility checks to discharge planning and patient scheduling, Ascertain's AI agents navigate complex systems, interpret unstructured data, and integrate across fragmented platforms — enabling faster throughput, lower costs, and more time for patient care. Ascertain was launched by Northwell Holdings, the for-profit investment arm of Northwell Health, and Aegis Ventures.

Asensus Surgical is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery™ by unlocking the Clinical Intelligence to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance® Surgical System powered by the Intelligent Surgical Unit™ (ISU™) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.Senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: https://www.senhance.com/indications.

Asimov's mission is to advance humanity's ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform from cells to software to design and manufacture next-generation therapeutics, including cell & gene therapies, through a combination of products, services, & collaborations. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million.

Aspen is developing induced-pluripotent stem cells (iPSCs) to address diseases with high unmet medical need, beginning with autologous neuron replacement for Parkinson’s disease (PD) and extending across the brain and affected organs.

Aspira Women’s Health Inc. is transforming women’s gynecological health with the discovery, development, and commercialization of innovative testing options for women of all races and ethnicities, starting with ovarian cancer. Our ovarian cancer risk assessment portfolio is marketed to healthcare providers as OvaSuite℠, which includes OvaWatch℠, a non-invasive, blood-based test intended for use in the initial clinical assessment of ovarian cancer risk in women with benign or indeterminate adnexal masses for which surgical intervention may be either premature or unnecessary. With a negative predictive value (NPV) of 99%, OvaWatch allows physicians to confidently rule out ovarian cancer malignancy and choose the appropriate clinical management for the right patient at the right time. Ova1Plus® combines our FDA-cleared products, Ova1® and Overa®, to detect risk of ovarian malignancy in women with adnexal masses planned for surgery. EndoCheck℠, Aspira’s first-of-its-kind non-invasive diagnostic test for endometriosis, is currently in development. Visit our website for more information at www.aspirawh.com.

Our vision is a world transformed by insect technology. Our mission is to harness the combined powers of technology and nature to pioneer the future of sustainable farming. We are creating tomorrow's traditions through breakthrough innovations that are in harmony with our largest stakeholder: our planet. We believe in technology that unleashes, rather than replaces, the incredible treasures of our natural world. We Aspire to a world that is abundant in planet-based nutrition that is better for people, pets and plants. Every company's culture is defined by its people and their actions. Who we are is the direct product of what we do and what we value. At Aspire, our culture is defined by the following attributes which spell the name of our company: • Audacity (we are competitive, innovative, and dream big) • Skill (we are competent, data-driven, and curious) • Passion (we are impact-centered, profit-minded, and market-driven) • Integrity (we are ethical, trusting, humble and candid) • Resilience (we face adversity and setbacks with fierce determination and collaboration) • Excellence (we aim to be world class in everything we do and believe generosity is a competitive advantage)

Develops a software solution, NICUtrition™, to improve thecare of preterm infants by providing quantitative data about gut health, allowing for personalized care and nutrition to optimize growth and outcomes.

Astellas Pharma US, Inc. is an affiliate of Tokyo-based Astellas Pharma Inc., a top 20 global pharmaceutical research company. Astellas is committed to turning innovative science into medical solutions that bring value and hope to patients and their families. Keeping our focus on addressing unmet medical needs and conducting our business with ethics and integrity enables us to improve the health of people throughout the Americas and around the world. All content developed by Astellas Pharma US, Inc. and intended for U.S. audiences.

At Asterra Labs, we are pharmaceutical scientists and industry veterans with a passion to innovate, develop, and manufacture a pharmaceutical-grade line of safe, beneficial wellness products and alternative medicines.

Ataraxis is an AI precision medicine company transforming cancer diagnostics and patient outcomes through the power of AI. We are addressing previously unsolvable problems in cancer prognosis and treatment selection through cutting-edge foundation models and multi-modal data. Our first clinically validated offering, Ataraxis Breast, is the world’s first AI-native prognostic/predictive test for breast cancer and provides greater accuracy than standard of care genomic assays. To learn more, visit ataraxis.ai.

At Athelas we're bringing simple, life-changing health care products and medical billing services to patients and providers around the globe. Athelas Revenue Cycle Management (RCM): Billing and reimbursement don't have to be painful. Athelas RCM delivers world-class service, maximizes reimbursements, and delivers actionable insights into the financial health of your practice. Athelas prides itself on end-to-end revenue cycle management. This means we cover all aspects of RCM besides simple submission - include denials, working A/R, research, and more as the backbone of your healthcare business. Athelas has powered revenue intelligence for hundreds of healthcare businesses, from small clinics to large health systems. Athelas Remote Patient Monitoring (RPM): We allow healthcare providers to monitor patient vitals like blood pressure, weight, and blood glucose without the patient ever having to enter a clinic, improving patient health and engagement, and reducing hospitalizations. We do this all through a beautifully integrated suite of devices and software tools that provides access to state-of-the-art technologies and groundbreaking AI powered analysis.

Athos Therapeutics Inc. is a clinical stage biotechnology company pioneering the development of artificial intelligence-based Precision Therapeutics for Inflammatory Bowel Diseases, lupus, and cancer. The company is focused on developing precision therapeutics for novel & specific subtypes of patients.

Atom Bioworks is a startup company that specializes in DNA nanostructures.

Developed a proprietary platform that holds the potential to discover novel structure targets across the transcriptome and for the design of RNA-targeted small molecules, RNA-based medicines and RNA tools.

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers

ATUM is an industry-leading provider of life science tools and solutions. Founded as DNA2.0 in 2003, we were a pioneer in the application of machine learning to synthetic biology and currently hold multiple patents covering several technologies, including our first-to-market Leap-In Transposase® platform. Our integrated offerings include Gene Design & Synthesis, Protein Production, Cell Line Development, and Master Cell Banking — all powered by our Leap-In Transposase® and machine learning platform. This means a streamlined path from sequence to Master Cell Bank (MCB) with just a click, ensuring efficiency, regulatory compliance, and innovative solutions tailored to our clients' needs. ATUM is privately held and is headquartered in Newark, CA.

Augmenta Bioworks discovers new therapeutics by harnessing the most powerful force in the fight against disease: natural human immunity. Our technology pinpoints the protective immune response of individuals and translates discoveries into therapies.

Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems toward killing tumor cells. Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors. The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.

Auron Therapeutics is a privately held patient-centered, platform-powered, product-driven oncology company. We are the leaders in identifying and targeting cell state to treat a range of solid tumors and hematological malignancies.

Auxilium Health is developing low-cost and smart biomaterials for hard-to-heal wounds. Our mission is to empower patients to take control of their healing journey by providing technology that actively heals and monitors wound infections, enabling faster recovery times and better quality of life for patients. We are providing a smarter way to heal wounds, one patient at a time.

Avellino turns genomic analytics into actionable healthcare insights, creating a healthier future for all. Powered by artificial intelligence and machine learning, its genetic discovery engine drives disruptive healthcare innovations. Avellino’s expertise spans a broad spectrum of healthcare specialties, including the impact of genetics in ophthalmology, oncology, pathogenomics and infectious diseases. As a global leader in leveraging artificial intelligence-powered algorithms, Avellino’s diagnostics provide eye care professionals with personalized genetic data to predict eye disease, prevent disease progression and ultimately preserve vision. Avellino has completed more than one million genetic eye tests since 2008, commercialized in the United States, South Korea and Japan. Its world class CLIA-certified laboratory in California has tested more than four million patients for COVID and RSV. Avellino’s research and development team has made groundbreaking discoveries leveraging genetic data, with programs in early detection of oncology, a polygenic risk analysis for glaucoma, and a siRNA gene-silencing therapeutic for the treatment of granular corneal dystrophy type II (currently in preclinical development). With a focus on health equity, Avellino prioritizes the inclusion of ethnically diverse populations in its studies to maximize the impact of its genomics breakthroughs for global healthcare. Avellino is headquartered in Silicon Valley, California, with operations in Korea, Japan, and the UK.

Avenue Biosciences is a biotechnology company dedicated to accelerating the discovery and development of protein biologics, so that no life-saving therapy goes unrealized because of production barriers. Headquartered in San Francisco, USA, and with laboratory operations in Helsinki, Finland, Avenue Biosciences has developed a protein engineering platform that combines organic biologics and machine learning to boost protein production. The proprietary method is based on years of scientific research from the University of Helsinki, Finland. Our goal is to drive significant progress in biotechnology by providing turnkey solutions that streamline production, improve quality, and unlock new therapeutic possibilities. We're a team of brilliant minds, each an expert in their field, united by a shared mission to make a real impact in a novel area of biotechnology. We are a highly experienced, entrepreneurial minded team with an impressive scientific background, that lives and breathes a casual, committed, and positive culture and spirit.

Avicenna Biosciences was founded to solve the intractable challenges that previously stopped drug candidates in their tracks. We have created an ML-driven medicinal chemistry platform that makes Lead Optimization faster, cheaper, and more successful – transforming sub-optimal development candidates into life-saving drugs. The platform has seen rapid success in discovering the first orally available, CNS-penetrant ROCK inhibitors for the treatment of neurodegenerative diseases, with IND-enabling studies initiated just one year since the program kicked off.

Axiom helps scientists eliminate molecular toxicity by providing the most accurate and affordable predictive models. Our proprietary dataset includes more than 100,000 molecules tested in pooled primary human liver cells, tens of thousands of molecules with pharmacokinetic measurements, and thousands of molecules with curated clinical outcome data. Axiom's AI models offer higher accuracy than advanced in vitro systems like 3d spheroids, deep mechanistic understanding which untangles mitochondrial toxicity, ER stress, ROS formation, cytotoxicity, and more, and precise risk assessment for any molecule at relevant clinical dosage and clinical exposure levels. Our models remove the need for costly physical experiments, giving more accurate and cheaper toxicity assessments, and empowering scientists to make better-informed decisions and bring safer drugs to the clinic.

AxoSim empowers advancements in human neuroscience by partnering with biopharma companies to facilitate breakthroughs in devastating neurological diseases and disorders. Their proprietary drug discovery platforms NerveSim®, BrainSim®, and microBrain™ deliver clinically-relevant data to select better lead candidates with phenotypically accurate assays. AxoSim's platforms have applications in peripheral neuropathy and neuropathic pain, disease modeling (such as ALS, MS, and CMT), and neurotoxicology.

Symphony Ayasdi is a FinTech company that specializes in AI-driven machine learning and data analytics solutions for financial services.

BAMF Health is the world's first vertically integrated platform for molecular imaging and radiopharmaceutical therapy. Using the most advanced imaging and therapy technologies, BAMF Health is dedicated to providing comprehensive and intelligent treatment options for patients with serious health issues such as cancer, heart disease, and stroke.

Purpose-built for organizations conducting clinical trials and observational studies, we leverage our AI-powered patient-matching platform and clinical expertise to optimize feasibility and speed up patient identification by extracting structured and unstructured data from electronic medical records (EMRs) that captures three times more trial criteria. Why: We believe sites are vital to the success of clinical trials. Empowering them to find the right patient for the right research at the right time is the focus of everything we do. What: We leverage our best-in-class technology and data expertise to detect more protocol-eligible candidates than traditional methods, so that site teams can focus on the parts of the job they actually love. How: We deliver an AI-powered software platform and support from clinical experts that enables our customers to find and match patients to available clinical research. With unbelievably fast and highly-accurate data extraction from electronic medical records (EMRs) we can capture three times more trial criteria - making trial participation more accessible and efficient.

BERGis aclinical-stage,AI-powered biotechnology company taking a bold ‘Back to Biology™, approach to healthcare. By leveraging a proprietary intelligence platform – Interrogative Biology®, their goal is to map disease and develop new treatments for patients.COVID-19: Testing their technology in reducing COVID-19 patient mortality.

BigHat’s mission is to improve human health by making it far easier to design advanced, next-generation antibody therapeutics. Our AI-enabled experimental platform integrates a high-speed characterization or “wet” lab with machine learning technologies to speed the antibody engineering process. When applied, these design capabilities have the potential to drive the development of new generations of safer and more effective treatments for patients suffering from today’s most challenging diseases. BigHat is backed by Section 32, ‍Andreessen Horowitz, 8VC, Amgen Ventures, Bristol Myers Squibb, Quadrille, Grids Capital, AME Cloud Ventures, Innovation Endeavors and Gaingels.

BillionToOne is a precision diagnostics company that quantifies biology to create powerful molecular diagnostics. They are focused on moving Prenatal Screening and Liquid Biopsy forward to improve disease detection.

BioAge is a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Our proprietary platform, which encompasses >65M molecular measurements spanning 45+ years of human aging, unlocks a universe of novel biological insights and druggable mechanisms for age-related disease. The company’s lead program, azelaprag, is a potential first-in-class oral APJ agonist entering Phase 2 trials in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to amplify weight loss and improve body composition in patients on obesity therapy with incretin drugs. BioAge’s preclinical programs address key pathways in metabolic aging, based on novel insights from its discovery platform built on human longevity data. BioAge offers a comprehensive compensation package, comprehensive health and wellness benefits (medical, dental, and vision insurance), childcare and fertility benefits, and a 401(k) retirement savings plan with matched employer contributions. We pride ourselves on giving employees many opportunities for career development, including a generous annual budget for continued learning and dedication to training and skill development. At BioAge, everyone matters, and we embrace diversity and differences while we learn from each other. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as the letter of all applicable laws and regulations.

At BioAI, we are developing world-leading machine learning technology to map the causal biology of disease, develop digital biomarkers, and identify novel drug targets, for the development of better medicine. BioAI’s PredictX Platform intakes your data and generates novel insights. PredictX is capable of ingesting a range of data types including: Digital Pathology, Multiomics, and Real-World Evidence. Using multimodal data and the most advanced AI methodologies, including In-silico phenotype projection and integrated deep learning, we can build predictive and prognostic models across a broad range of therapeutic areas. Founded by a group of friends who started by scribbling their ideas on a piece of paper, today we offer smart, innovative services to dozens of clients worldwide. Our team of experts has a proven track record in developing strategic partnerships with the Pharma industry and solving major challenges in R&D

We are commercializing a revolutionary new class of fieldable aerosol mass spectrometers and complementary products for protection from biological and low-volatility chemical threats.

Biofourmis brings the right care to every person, no matter where they are. The company’s AI-driven solution collects and analyzes over 120 biomarkers in real time and identifies shifts that require proactive interventions. This vital innovation enables Biofourmis to offer people everywhere connected access to hospital-level services, virtual provider networks for remote care, and life-changing clinical trials—all without leaving their homes. Trusted by leading health systems, payers, biopharma companies and patients alike, Biofourmis’ connected platform improves patient outcomes, prevents hospitalization readmissions, accelerates drug development, and closes critical gaps in care—with the goal of making science smarter, healthcare simpler, and patients healthier. Biofourmis is a global technology company enabling care delivery, with headquarters in Boston with key offices in Singapore and India. For more information, visit biofourmis.com and follow Biofourmis on LinkedIn, Twitter and YouTube.

BioGeometry is an AI-driven biotech dedicated to developing next-generation, programmable protein medicines. We aim to solve the high cost, long lead time, low success rate problems for traditional macromolecular theraputics through the combination of geometric deep learning, structural biology, immunology, and synthetic biology. We enjoy talents from renowned pharmaceutical companies, top-tier AI and bio labs worldwide.

BioLoomics is a preclinical stage biotechnology company leveraging directed evolution of antibodies in human cells to create ADCs with improved internalization and trafficking. Our proprietary tech combines single-cell bioassay engineering, robotics, and ML.

BioMap is an AI for life sciences company, unmasking nature’s rules to generate proteins for a wide range of therapeutic and industrial applications. We build super-scale Foundation models supported by access to unrivaled computational power through our strategic collaboration with Baidu, with whom we share our Founder and Chairman, Robin Li. We supplement our AI capabilities with a leading team of scientists, disease experts and cutting-edge high-throughput labs which generate large volumes of high quality proprietary data for our AI models. We partner with pharma, biotechs and industry to enable their discovery ambitions across a wide range of therapeutic and synthetic biology modalities through access to our AI technology platform, with a variety of flexible collaboration models. Our mission is to leverage AI to radically improve lives.

Biomeme's platform transforms your smartphone into a mobile lab for advanced DNA diagnostics and real-time disease surveillance. The system includes a docking station for real-time PCR, a mobile app to control the system and analyze results, and targeted test kits for preparing samples and identifying pathogens or diseases by their specific DNA or RNA signatures. The cutting edge platform performs to the gold standard used by the world's most advanced central labs but requires no lab equipment or special experience to use. The low-cost, user-friendly system enables mobile testing at the point-of-need for health care (mobile clinics, disease tracking, home use), agriculture (plant disease tracking, food safety), vector surveillance (Malaria, West Nile mosquitos), veterinary medicine, environmental monitoring (soil and water safety), and even education and citizen science.

BiomeSense is a pioneering life sciences startup focused on harnessing the power of the gut microbiome to revolutionize personalized medicine. With our breakthrough technologies GutLab and MetaBiome, we are setting new standards in microbiome data analysis and interpretation, enabling unprecedented insights to understand & leverage the microbiome for human health.

Biomonadic is an early stage techbio startup leveraging AI and IoT to resolve critical supply chain bottlenecks affecting the cell and gene therapy (CGT). They are creating a next generation AI empowered data platform for biotech manufacturing, leveraging reinforcement learning and LLMs to augment their capabilities.

BiomX (NYSE America: PHGE) is developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

BioPharm International® covers all aspects of biopharmaceutical development, analysis, processing, and packaging, as well as business strategies and regulatory issues. The print and digital editorial coverage provides technical and business insight and analysis for all biologic-based therapies including monoclonal antibodies, vaccines, biosimilars, protein therapeutics, cell therapies, gene therapies, antibody-drug conjugates, and other emerging therapies.

We provide services in genomics, statistics, and information technology. Our services include Bayesian analysis, bioinformatics, biomarker development, biostatistics, data management, data pipelines, data science, epigenomics, genetics, genome-wide association, imputation, microarray analysis, multiomics, next-generation sequencing analysis, pharmacogenomics, polygenic risk scores, predictive modeling, project management, proteomics, reproducibility, software development, statistical computing, statistical genetics, and statistical programming. We also developed the Smokescreen® Genotyping Array, advancing research into addiction and treatment approaches. Our highly-skilled transdisciplinary team of experts, carefully assembled from leading research universities and industry, has been solving our clients' research challenges for almost two decades. Extensive experience with a wide range of cutting-edge methods and technologies means we can help ensure your project's success, and provide high-quality deliverables on time and within budget. Whether you have a critical issue, need help with every aspect of a new project—including coordinating complex projects—or only one part of an ongoing project, we can work with you to develop the optimal solution to meet your goals and objectives. Our team can be an integral part of the collaboration, and provide full-service support for all the stages of your research journey. We follow all U.S. Department of Health & Human Services standards for the security of electronic protected health information (HIPAA-compliant). We believe in reproducible, reusable, transparent, and extensible research, and do everything we can to put those values into practice. We are prepared to use our internal computing environment, cloud-computing environments, or client-provided environments, if preferred.

We help scientists solve disease, develop drugs, and extend healthspan by building tools that simplify R&D, simulate biology, and untangle the complexity of life. Streamline computational analysis today. Discover drugs tomorrow.

Biostate.AI is a startup founded in 2023 with the mission of developing generative AI for predictive omics analytics in the healthcare sector. They offer services such as RNA sequencing, DNA sequencing, image sequencing, image data analysis, and more. The company aims to lower costs and increase the utility of RNA sequencing for research and drug discovery.

BioTherapeutics Inc (BTI) synergistically combines the power of advanced computational modeling, data analytics and artificial intelligence with translational experimentations to accelerate the development of innovative products for precision medicine and health. Our computational platform assembles biomedical and healthcare data from the molecular, cellular, tissue and population levels and leverages the latest innovations in technology to turn those data into answers to complex biological questions and solutions to healthcare's problems.

Biotia is a health tech company launched from Jacobs Technion-Cornell Institute at Cornell Tech in association with Weill Cornell Medicine, located in New York, NY, that leverages DNA sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Biotia is developing a next-generation sequencing-based test for COVID-19 that characterizes genetic variance across the whole viral genome.

BioTuring is an innovative bioinformatics company based in San Diego. Founded in 2016, the company has developed transformational bioinformatics platforms for sequencing data analysis, enabling scientists to gain valuable insights from biological data in an interactive, fast, and accurate approach. Its product portfolio now covers single-cell and spatial data analysis with BBrowserX, Talk2Data, Lens, BioVinci, and BioColab. BioTuring helps accelerate life sciences and nourishes computational minds.

Biovista is a biotechnology company located in Charlottesville, Virginia, founded in 2005 by CEO Andreas Persidis. The company specializes in AI-driven drug repositioning and development services, aiming to enhance the efficiency of bringing new treatments to market. Biovista offers services that include drug repositioning, which identifies new therapeutic uses for existing drugs, and drug de-risking, which assesses and mitigates potential risks in drug development. The company also conducts disease cohort analysis to better understand specific patient populations and treatment strategies. Biovista develops its own drug repositioning programs across various therapeutic areas, including central nervous system disorders, diabetes and obesity, eye disorders, and oncology. The company employs advanced AI technologies to analyze large datasets, facilitating the discovery of novel applications for existing drugs. Biovista is actively involved in R&D projects, reflecting its commitment to advancing drug discovery through innovative approaches.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence, or AI, to identify improved therapies in neuroscience and immuno-oncology.

Birch Biosciences uses Artificial Intelligence, bioinformatics, and high-throughput screening techniques to effectively engineer enzymes for recycling plastic.

BostonGene is pioneering the use of biomedical software for advanced patient analysis and personalized therapy decision making in the fight against cancer.

It is the mission of the College to engage students of uncommon promise in an intense full-time education of their minds, exploration of their creative faculties, and development of their social and leadership abilities in a four-year course of study and residence that concludes with a baccalaureate degree in the liberal arts.

BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.

Brightseed is a pioneer in biosciences and artificial intelligence (A.I.) that illuminates nature to restore human health. Brightseed’s proprietary A.I., Forager®, accelerates bioactive discovery, biological validation and ingredient formulation from years to months, rapidly revealing new connections between nature and humanity. Through Forager® and clinical evaluation, Brightseed partners with organizations across the consumer health continuum to offer insight into the world of bioactives and health solutions. Brightseed produces branded, proprietary, clinically proven bioactives that are sold to leading dietary supplement, food & beverage CPG, specialty nutrition and medical food companies for incorporation into health beneficial consumer products. Visit www.brightseedbio.com to learn more.

Buck Institute for Research on Aging is a biomedical research institute focused on studying the aging process and its effects on health.

BullFrog AI (NASDAQ: BFRG) is a technology-enabled life science company using advanced artificial intelligence (AI) to usher in the next generation of lifesaving therapies. With our leading-edge platform, bfLEAP™, we aid in accelerating and de-risking drug discovery and clinical development using one of the industry's most advanced graph analytic AI technologies. The Problem: The drug development landscape is littered with failed products and unrealized ROI — all while patients are desperately waiting for treatments that often don't come: • The cost of bringing a drug to market is $.8 to $2.8 billion • Almost 90% of drugs don't get there • The average time to market is 8.5 YEARS Our Solution: We're applying machine learning and AI in drug development to identify new potential therapeutic targets, optimize clinical trials, rescue and repurpose drugs for new indications, and discover new drug targets. By identifying hidden relationships in clinical data, we aim to mitigate risk and elevate the trajectory of precision medicine. Our Technology: The bfLEAP™ platform delivers in a way that neural network models cannot: Explainable AI. We use network models in an interactive graph machine learning format to display and explain your data insights with confidence. Say goodbye to "black box" processing and say hello to AI outputs you can explore and understand. Join Us in Our Mission: With our platform's superior capabilities, a high-powered team of industry experts, and a pipeline of exclusive in-licensed assets for clinical development, BullFrog AI is pushing the boundaries of AI-assisted drug development. Make BullFrog AI an extension of your organization and clear your analytical barriers. Leap into the next generation of drug development with BullFrog AI.

Bullseye Biosciences is a therapeutics discovery company revolutionizing drug development through robotics and evolution. Our platform operationalizes cutting-edge directed evolution technology by incorporating automation and Next Generation Sequencing. By targeting challenging drivers of human disease, we are creating life-saving medicines for cardiometabolic, inflammation, and oncology patients with the highest needs.

Butterfly’s mission is to create access to valuable clinical insights using innovative ultrasound technology, made simple with artificial intelligence, to benefit all patients worldwide. Through the delivery of high-quality, affordable, easy-to-use, intelligently connected ultrasound, Butterfly Network enables better clinical decisions through better information and insight at the point of care. With Butterfly, seeing is knowing – in the hospital, community, or home.

Clinical Assay Innovation (CAI) Biosciences is a consulting firm focused on providing expertise and guidance in the development of Laboratory Developed Test (LDT) and In Vitro Diagnostic (IVD) assays in the areas of Next Generation Sequencing (NGS), Real-Time Polymerase Chain Reaction (qPCR), Immunochemistry, and Clinical Chemistry. Our mission is to provide our clients with best in class assay development services and to insure successful implementations of their projects.

At CAMP4 Therapeutics, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of diseases affecting millions of patients. Join us at the forefront.

Capra Biosciences is developing a new technology that will make the manufacturing of chemicals using biology cost-competitive with petroleum-based products. Significant advances in synthetic biology have been made over the past 20 years, enabling a multitude of products with lower environmental impact and potentially better performance than their petrochemical counterparts. However, cost-competitive large-scale manufacturing of these products remains a significant bottleneck to their adaptation. Our technology tackles this bottleneck through an innovative bioreactor design that promises to significantly reduce end-to-end manufacturing costs.

Caption Health has been acquired by GE HealthCare. Follow us at @GEHealthCare and @CaptionCare for the latest updates and healthcare news.

CaraVan Biologix is a biotechnology company focused on expanding the life-saving benefits of CAR-T cell therapeutics to the broader cancer patient population by addressing their limitations. Our underlying and core novel technologies enable the development of allogenic treatments for a spectrum of human diseases, including solid tumors and hard-to-treat cancers. Our therapeutic agents are expected to show superior safety profiles, including a low risk for cytokine release syndrome. Importantly, our technology will greatly reduce the complexities of manufacturing that are associated with whole-cell therapies, thereby minimizing the time, cost, and variability risk to facilitate greater access for patients in need.

Delivering cutting-edge cardiac medical devices to clinicians since 1994. CardioCommand Inc., headquartered in Tampa, Florida, is a pioneering medical technology company dedicated to revolutionizing cardiac care. Established in 1994, CardioCommand has established itself as a leading innovator in the field of cardiovascular health, leveraging cutting-edge advancements in medical technology to enhance patient outcomes and streamline medical procedures. At CardioCommand, our mission is to empower healthcare professionals with state-of-the-art cardiac monitoring solutions, ensuring timely and accurate diagnoses while prioritizing patient comfort and well-being. We are committed to advancing the standard of care in cardiovascular medicine through innovation, integrity, and excellence.

Cardio Diagnostics is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The Company was formed to further develop and commercialize a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic EngineTM ("Core Technology") for cardiovascular disease to become one of the leading medical technology companies for enabling improved prevention, early detection, and assists in the treatment of cardiovascular disease.

Contact: contact@cardiosense.com Cardiosense is building a physiological waveform data platform that leverages novel multi-modal sensors and industry-leading AI to develop predictive biomarkers for pre-symptomatic disease detection and enable personalized therapy.

CardioWise's non-invasive Cardiac Computed Tomography (cCT) analysis software produces an easy-to-understand 3D image model of the human heart.

At Caresyntax, we are dedicated to making surgery safer and smarter. Our mission is to converge AI-powered software, devices, and clinical services to help our customers improve surgical outcomes. Our platform, an enterprise-grade surgical intelligence system, is vendor-neutral and equipped with proprietary software, hardware, and advanced AI capabilities. It can ingest and analyze data throughout the surgical workflow, including EMR, video, audio, image, device data, financial and outcomes data, and clinical and operational metrics to capture a complete picture of the surgical pathway. The platform generates insights across the entire continuum of care—before the procedure with surgical workflow optimization, during surgery with real-time clinically relevant support tools, and post procedure with clinical safety modules. The platform also produces data analytics and insights for medical device companies, insurers, and other ecosystem players to innovate and drive the future of healthcare delivery. Headquartered in the US in San Francisco and internationally in Berlin, Caresyntax software is used in over 3,000 ORs globally and aids surgical teams in over 3 million procedures annually. To learn more about how we're transforming surgical care, visit us at www.caresyntax.com.

Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra's high throughput LSA, LSA-XT, and Ultra platforms for monoclonal antibody (mAb) and small molecule screening and characterization combine patented microfluidics technology with real-time High-Throughput Surface Plasmon Resonance (HT-SPR) and industry-leading analysis and visualization software. These systems deliver up to 100 times the throughput in 10% of the time while using only 1% of the sample compared to existing label-free platforms. The LSA-XT and Ultra instruments introduce enhancements to Carterra’s flagship product, the LSA, increasing sensitivity and enabling new applications in biotherapeutic discovery and small molecule analysis. Carterra, Inc. is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. For additional information, please visit www.carterra-bio.com.

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. The Company’s innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. Castle currently markets six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, Barrett’s esophagus, mental health and uveal melanoma. DecisionDx®-Melanoma, Castle’s test for invasive cutaneous melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. DecisionDx®-SCC is the Company’s GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. MyPath® Melanoma provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. IDgenetix is Castle's pharmacogenomic (PGx) test for depression, anxiety and other mental health conditions designed to analyze a patient’s genetic make-up to guide timely and evidence-based decisions on the optimal drug for each patient. DecisionDx®-UM, the standard of care in uveal melanoma staging, is Castle's GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. Castle Biosciences is based in Friendswood, TX, (a suburb of Houston) and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

CD ComputaBio is a professional computational biology service company. Our service spans across different areas in computational biology, providing access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. We are committed to providing high-quality data and customer service to various industrial and academic customers.

Cancer diagnostic

Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas including those in metabolic disease, hematology, and immuno-oncology.

CellChorus conducts dynamic single-cell analysis at scale. Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) uses visual AI to evaluate how cells exist in motion. CellChorus is a single-cell, visual AI company that is the leader in visual AI for single-cell analysis.

Celldom is developing next generation, high throughput single cell analysis technology to advance research, drug discovery, and drug development by illuminating diversity in cell populations. The company's cloneXplorer and proprietary nanowell plates uniquely integrates both phenotypic and genomic data at massive scale (up to 100,000s of cells per experiment) to identify and characterize rare cells that play critical roles in biological pathways and disease. Celldom is developing initial applications of the platform in the areas of oncology, immunology and stem cell biology. Learn more at www.celldom.com and follow the company's growth @celldominc on Twitter.

Cellibre is a best-in-class manufacturing technology company.. Employing an organism-agnostic approach, we turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Our world-class scientific team has led programs from napkin to commercial, pioneering revolutionary breakthroughs in energy, ingredients, medicines and more. Member: BioMade, Defense Industrial Base Consortium (DIBC)

Cellinfinitybio is a biotechnology company that pioneers massive directed evolution to unlock the infinite potential of cell therapy.

Cellino is building a scalable, automated biomanufacturing system for potentially curative personalized cell therapies. Cellino’s vision is to enable healthier lives worldwide with personalized treatments derived from induced pluripotent stem cells (iPSCs), which can serve as the basis for therapies for a host of chronic degenerative diseases, including vision loss and Parkinson's disease.

Cell X is pioneering a revolution in cell processing. At the core of this revolution lies our transformative Celligent platform – an innovative bundling of automation, imaging, data analytics, and machine learning that enables therapeutic researchers to develop consistent, reproducible, and scalable GMP-compliant processes for stem cells and bio-fabrication. Celligent enables the development of safe and effective products by executing the necessary process development and cell manufacturing procedures in a fully documented, compliant way. Successful cellular therapies demand starting with optimized cell sources; and intrinsic variability and heterogeneity among cell sources presents a major challenge. This critical first step of control over starting materials demands the use of quantitative and reproducible standards for cell and clone selection and process management based on critical process parameters (CPPs) in order to achieve products with defined critical quality attributes (CQAs). Backed by a highly experienced team, Cell X automates cell processing in diverse cell culture applications spanning mesenchymal stromal/stem cells (MSCs) and exosomes, induced pluripotent stem cells (iPSCs), hematopoietic stem cells (HSCs), connective tissue progenitor cells (CTPs) and tumor-infiltrating lymphocytes (TILs) as well as other progenitor cell types. We are dedicated to advancing the promise of cellular therapies for innovators and patients alike, ultimately making cell therapies more accessible to millions of patients worldwide. 

Centaur Labs is the modern data labeling solution for AI innovators across the healthcare landscape. With an expert crowd of 50k+ labelers and a gamified app to incentivize and quality-control them, our scaleable labeling methodology ensures high-quality labels in as little as 24 hours.

Cercle is an AI technology company with the mission to advance healthcare for all women. With AI, we harness anonymized, diverse and reliable biomedical and genomics data from around the world to deliver unprecedented and secure healthcare insights. The Cercle™ Biomedical Graph is a first-of-its-kind knowledge graph. It uses AI to analyze billions of anonymized data points securely drawn from hospitals, clinics and research labs from all over the globe. We're turning raw, unstructured and disconnected biomedical and genomics data into clear insights for doctors, hospitals, research centers, pharmaceutical companies, labs and clinics so they can treat patients more effectively. That's how we support innovation and advancements in treatments and healthcare outcomes across the entire healthcare ecosystem. Women's health is the most underserved healthcare market, which is why Cercle's first focus will be fertility and IVF. We're proud to beta launch Luce, a fertility companion for women and doctors that analyzes data from thousands of treatment cycles to help people make more informed decisions for their fertility journeys. Cercle's suite of products includes: — Data access tools: Researchers and lab directors can query and visualize structured biomedical and genomics data to accelerate health innovation. — Modeling and insights products: Advanced modeling tools help healthcare providers with financial and operational strategies. — Tools for clinicians: Doctors get personalized care insights and predictive treatment outcomes based on Real World Data and Real World Evidence. — Patient companions: Patients get clear, data-driven insights that make it easier to understand their health and make informed decisions with their doctors. Cercle is built by medical professionals, molecular biologists, data scientists, engineers and business entrepreneurs dedicated to unlocking a world where everyone feels informed, empowered, and in control of their own health.

At CereHealth, our mission is to revolutionize healthcare through the power of artificial intelligence. We are committed to improving patient outcomes and enhancing the efficiency of clinical practices by providing cutting-edge AI-driven Clinical Decision Support Solutions (CDSS). Our purpose is to bridge the gap between data and insights, enabling healthcare professionals to make informed and precise decisions at every critical juncture. By harnessing the potential of AI, we aim to empower medical experts with real-time, evidence-based recommendations that promote accurate diagnoses, personalized treatment plans, and optimize patient care. Driven by our dedication to innovation and integrity, we envision a future where healthcare providers can seamlessly integrate AI into their workflows. Through continuous research, collaboration, and advancements in AI technology, we strive to be at the forefront of CDSS, setting new standards for excellence in healthcare decision-making. We are unwavering in our commitment to privacy and security, ensuring that patient data is treated with the utmost confidentiality and adhering to the highest standards of compliance. Our solutions are designed not only to support medical professionals but also to engender trust among patients, knowing that their well-being remains at the heart of every AI-driven recommendation. By working hand in hand with the medical community, we aim to foster a healthcare landscape where AI augments human expertise, leading to faster, more accurate diagnoses, reduced medical errors, and ultimately, improved patient outcomes. At CereHealth, we are dedicated to shaping a healthier tomorrow through the synergy of AI and medical wisdom.

Transformation. It's a word we hear a lot—the moment when a discovery leads to an innovation that fundamentally changes our world. There's a backstory to transformation—one that takes place in labs and research facilities by people who work tirelessly for years to reach that a-ha moment. Cerillo understands the passion, tenacity and investment that come before transformation. Our technology is laser-focused on helping you achieve greater efficiency and agility in your research. But more than that, it's designed to illuminate possibility by letting you view the same problem from new angles. Stratus, our portable plate reader, is helping scientists anticipate and creatively solve human challenges from the palm of their hand, giving them the freedom to take their work out into the world. And that's just the beginning. Our team is committed to constant innovation in our lab to make discovery in your lab easier. Think of us as the proactive lab partner you didn't know you needed, clearing the way for you to reach that transformational moment that changes the world for good.

Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors. Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett's esophagus, and mental health. https://castletestinfo.com Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient's tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. http://bit.ly/DDx-Melanoma DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM Our comprehensive diagnostic offering — myPath® Melanoma and DiffDx®-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx TissueCypher® Barrett's Esophagus is the world's first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett's esophagus. https://tissuecypher.com Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.

Certis Oncology is a life science technology company committed to realizing the promise of precision oncology. Certis was founded in 2016 with a singular purpose: to bring certainty to the fight against cancer. Their science delivers clinically relevant, predictive data and they are located in the heart of San Diego's Life Sciences center, Sorrento Valley.

ChemDiv, a fully Integrated Target-to-Market Contract Research Organization (CRO) headquartered in San Diego, CA USA. ChemDiv provides integrated drug discovery and early clinical development deliverables by extracting added value from potential therapeutic candidates via rapid, streamlined outcomes and effective use of capital. - 25 years experience and 2500 customers worldwide - Premium R&D CRO based in USA with global reach - Seasoned project managers - Extensive Academic partnerships - Flexible business models - Competitive pricing options - Industry's largest ever-greening stock compound inventory - Ongoing investments in novel proprietary chemistry and discovery platforms One of the oldest CROs in the industry, ChemDiv provides Integrated Discovery outSource™ solutions that cover the complete range of disciplines needed to bring new drugs for treatment of CNS, oncology, inflammation, metabolic and infectious diseases from target to candidate and through clinical Proof of Concept to the market. ChemDiv champions collaborative development models with co-investors to rescue under-exploited R&D assets for pharmaceutical and biotech partners. #pharma #biotech #chemistry #screening_Libraries #drug_discovery_services

Circle Pharma initiated operations in June 2014 with seed funding from Pfizer, Inc. and Mission Bay Capital, LLP; we received additional seed funding from ShangPharma Investment Group Limited in November 2015. They recently raised Series B and Series C financing from The Column Group and NextTech Invest. Circle Pharma design and develop bioavailable macrocyclic peptide therapeutics against important clinical targets. They do this by applying a computational structure-based design approach that combines physics (conformational modeling), chemistry (innovative molecular components) and biology (protein target structure and function). They have selected intracellular protein-protein interactions that play key roles in cancer as the initial target group for our internal pipeline development. Circle is taking a new approach to the development of macrocylic peptide therapeutics that is based on the pioneering work of its founders to understand and computationally predict drug-like properties of macrocycles. Circle is advancing this understanding to design novel, inherently permeable macrocyclic peptide drug candidates against Circle’s internal targets and those of our collaboration partners. Circle Pharma workflow includes the use of proprietary algorithms to design large, conformationally diverse, virtual libraries of cell permeable macrocyclic scaffolds that incorporate natural and non-natural backbone components. They deploy these virtual scaffold libraries in subsequent design steps that include the incorporation of functional side chains selected for both target binding and maintenance of permeability. Candidate compounds are synthesized and tested for both permeability and target affinity and the results are used to inform subsequent design cycles.

CircNova, Inc. is a biotechnology company that leverages our unique AI NovaEngine™ to generate, analyze and identify circular RNA for therapeutic development.

Citeline powers a full suite of complementary business intelligence offerings to meet the evolving needs of health care professionals to accelerate the connection of treatments to patients and patients to treatments. These patient-focused solutions and services deliver and analyze data used to drive clinical, commercial and regulatory-related decisions and create real-world opportunities for growth. Our global teams of analysts, journalists and consultants keep their fingers on the pulse of the pharmaceutical, biomedical and medtech industries, covering it all with expert insights: key diseases, clinical trials, drug R&D and approvals, market forecasts and more.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

Citrine empowers product experts with vanguard AI technologies. With no background in data science, product experts apply Citrine to deliver next generation products faster than any other time in history. Citrine’s software learns easily from the knowledge of its users and their idiosyncratic data to enhance all aspects of the product lifecycle across all industries with a physical product. Citrine’s users increase supply chain efficiency, rapidly improve product quality, enhance customer experience, expand product reach and increase the velocity of product delivery. With Citrine, product experts unlock the capability to solve our society’s greatest environmental and productivity challenges. Citrine's customers include Eastman, Panasonic, Grace, LyondellBasell, LANXESS, Morrow Batteries and some of the biggest and most respected names in the materials and chemicals and CPG industries in Asia, North America, and Europe. For more information visit our website at https://citrine.io.

Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

Clarapath is a medical robotics company automating the laboratory. Our first product is focused on automating the microtomy station in pathology. Our vision is to innovate, standardize, and digitally transform anatomic pathology through higher quality lab medicine, more robust safety standards, increased lab throughput, while lowering laboratory costs and labor related delays.

Clarity Genomics provides consulting services for microbiome-metabolome data insights in clinical research. Using our global network of specialists and regional cloud storage and computing, we provide expertise in collection and preparation of microbiome and metabolome samples, data processing and analysis. We work closely with our clients to offer biological insights that empower the development of new microbiome products and therapies. Partnerships with leading research institutions ensure that your project receives relevant information utilizing technologies and techniques on the forefront of innovation.

Clear Guide Medical is a leader in next-gen medical imaging fusion and navigation technology. Our vision-based approach has been introduced in a family of clinical guidance products, including the CLEAR GUIDE SCENERGY for instrument guidance and SCENERGY FUSION for ultrasound and CT/MRI image fusion. Our products make minimally-invasive interventions like biopsies, ablations, pain injections, and peripheral nerve blocks efficient and cost-effective. The company is a privately-held spinout of the Johns Hopkins Medical Institutions and The Johns Hopkins University based in Baltimore, Maryland.

Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, we deliver accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Our treatments are defined by our commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. We are continuously expanding and refining our shared platform technologies with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning. Digital therapeutics under development on our platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, cardiology and immunology. Consistently named a best place to work, we foster an inclusive, diverse workforce of innovators, clinicians, scientists, researchers, designers, technologists, engineers and more, united in our mission to provide patients everywhere access to safe and effective prescription digital therapeutics. NOTE: Fake job advertisements and offers are increasingly appearing on the internet. If you have encountered a job posting or have been approached with a job offer that you suspect may be fraudulent, we strongly recommend you do not respond and report it to the Federal Trade Commission and to recruitment@clicktherapeutics.com. Other than your email address or telephone number, which you may provide via a job application portal, Click Therapeutics will never ask you to provide personally identifiable information about yourself (such as a Social Security Number or Driver’s License Number) via a messaging application.

Clinion is a leading global clinical trial company renowned for its award-winning solutions that drive innovation and excellence in the field of clinical research. We implement cutting edge technologies like AI/ML and GenAI to accelerate clinical trials for better outcomes. Our unparalleled expertise empower pharmaceutical, biotechnology, and medical device companies to conduct clinical trials more efficiently and effectively. Join us in revolutionizing the future of clinical trials and making a lasting impact on global healthcare. Facebook : https://www.facebook.com/clinion Twitter : https://twitter.com/clinion YouTube : https://www.youtube.com/c/Clinion Instagram : https://www.instagram.com/clinion_ai/

Cloudbyz is focused on building cloud-based products and solutions for life sciences customers, and help them innovate drug development and research to bring therapies faster to market which improve patient health and saves lives. Our innovative digital solutions for Pharmaceuticals, Contract Research Organizations (CRO) and Medical Devices companies helps to digitize research, drug and device development and commercialization. Our suite of products include: 1. Cloudbyz CTMS 2. Cloudbyz CTBM 3. Cloudbyz eTMF 4. Cloudbyz EDC, ePRO & eCOA 5. Patient Recruitment 6. Cloudbyz Safety & PV 7. ClinicalWave.ai (AI based platform for Life sciences organizations) Cloudbyz CTMS, eTMF, EDC, and Safety & Pharmacovigilance are built 100% native on Salesforce cloud platform for sponsors, clinical research organizations (CRO), and Clinical Sites. Cloudbyz Clinical Research Solutions are flexible and scalable to enable to manage and collaboration on clinical trial operations while the intuitive, straightforward design allows rapid deployment with a very intuitive and easy-to-use cloud-based solution. Cloudbyz ITPM offers 360° view and real-time visibility across IT planning, execution, and operations and helps organizations to achieve agility, velocity, innovation, and collaboration across IT and business. Cloudbyz ITPM helps CIO, PMO, and IT leaders to visualize the IT landscape, capability mapping, investment, and operational health in real-time and better align IT initiatives with business.

We're a dedicated team of engineers, data scientists, doctors, innovators, and creative thinkers from across the globe. We're united in our drive to use technology to simplify healthcare and make it work better for everyone involved. We unify all data sources and other systems together for a complete picture. We automate for efficiency throughout. Clinical, operations, and financial results are collected and coordinated like never before.

Cloud Pharmaceuticals is a pharmaceutical company that specializes in in silico therapeutics, revolutionizing drug discovery and development processes.

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications.

Cognoa innovates solutions for child developmental health. We build breakthrough products like Canvas Dx, the first and only FDA authorized autism diagnostic for children ages 1.5 to 6 years that uses responsible AI to empower doctors to quickly, accurately, and fairly diagnose developmental risk without bias. Our digital solutions are child centric and designed to find, assess, and treat developmental concerns early, within the time windows that will yield the optimal outcomes. Our proprietary "whole child" approach to AI fuels our pipeline of diagnostic and therapeutic products for autism, speech and language, ADHD, childhood anxiety, and more. For more information, visit www.cognoa.com.

Cognos Therapeutics Inc. (Cognos) is an advanced medical device company focused on creating unique technologies to radically advance the diagnosis and treatment of neuropathic diseases including tumor-based brain and spinal cancers, degenerative cognition disorders (such as Alzheimer’s and Parkinson’s disease), cerebral trauma occurrences (such as epilepsy and stroke) as well as other Central Nervous System afflictions.

Collaborations Pharmaceuticals, Inc. works on drug discovery for rare and neglected diseases. We develop and license our AI software as well as provide fee for services for pharmaceutical and consumer product services. To date we have won with collaborators $23.5M in grants since 2016.

Collaborative Drug Discovery's CDD VAULT is a hosted biological and chemical database that securely manages your private and external data. It lets you intuitively organize chemical structures and biological study data, and collaborate with internal or external partners through an easy-to-use web interface. The available modules within CDD Vault include Activity, Registration, Visualization, Assays, AI, Automation, Curves, Inventory, and Electronic Lab Notebook (ELN). Each module is designed to optimize various aspects of research and data management, enhancing the overall efficiency and productivity of scientific workflows. CDD Vault is a system your entire team can actually use! Engineered for Ease of Use CDD Vault allows you to enjoy the benefits of large enterprise systems without the administrative burden or expense. Modern Cloud Solution Saves Money CDD Vault is affordable to academic laboratories, research foundations, and small companies. Beats Juggling Spreadsheets of Screening Data! Eliminates the Risk of Data Loss CDD Vault provides a secure environment to collect all your compound and screening data. Get Better Results from Unified Data CDD Vault consolidates all your compound and screening data in one place. This makes analysis easier, more consistent, yielding results more quickly. Securely Store Experimental Data in a Private Hosted Vault Data Migration is a Snap CDD Vault can provide easier access and better management of your existing data too. Safely Share Data CDD Vault allows you to selectively share data in real time with your designated researchers in your own lab or across the globe. Security is Built-In - CDD Vault is protected with SSAE 16 Type II certified cloud storage on locked and guarded hardware. https://www.collaborativedrug.com/pages/benefits CDD VAULT from Collaborative Drug Discovery https://www.collaborativedrug.com

Genetic testing, direct to consumerCOVID-19: EUA (05/2020) for their LAMP (Loop-mediated amplification) and uses three SARS-CoV-2-specific primer sets targeting the SARS-CoV-2 nucleocapsid gene (N), the envelope gene (E), and the ORF1a region.

The science of genetics. The business of discovery. Colossal is a breakthrough bioscience and genetic engineering company that builds radical new technologies to advance the field of genomics. Colossal creates disruptive technologies for extinct species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. The company is the first to apply CRISPR technology for the purposes of species de-extinction, beginning with the woolly mammoth. Colossal is accepting humanity's duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies.

Conceivable has developed the world’s first fully automated IVF lab. Our end-to-end reinvention of today’s largely manual, artisanal labs delivers new levels of precision, quality, and scalability. Simultaneously, Conceivable brings the innovation of modern cell therapies to IVF. We are already exceeding the clinical benchmarks of today’s best IVF labs. Worldwide 95% of the infertile population–and 80% in the United States–don’t have access to IVF. Conceivable exists to change this. By automating the IVF lab we will vastly broaden the availability of this Nobel Prize winning therapy, improve results, and meet the demands of millions of infertile people wishing to achieve the dream of becoming parents.

Their mission is to accelerate insights and outcomes for patients through leading real-world data, AI technologies, and scientific expertise in partnership with the leading biomedical innovators, healthcare providers, and medical societies.

Science has a problem. There are many suppliers and many scientists. Finding the right supply at the right price is hard, and if you're a life science company, you want to be able to get your customers the best product. We are creating a better vision for scientists to conduct science and make new discoveries. Located between two of the most prominent universities in the world, Harvard University and Massachusetts Institute of Technology, our startup has access to some of the most talented biotechnology, life sciences, and medical/health professionals in the world. https://linktr.ee/conduct_science

Consegna Pharma Inc. is a specialty pharmaceutical company with a mission to create best-in-class long-acting medications.

MAVEvidence is the premier functional evidence resource for the clinical genetics community. MAVEvidence delivers increased productivity and time savings through comprehensive curation, rigorous analysis, and clear presentation of functional evidence derived from high-throughput studies of genetic variants. The MAVEvidence platform contains more than 187,000 pieces of evidence across 125,000 genetic variants, and is continually updated with data from the latest functional studies.

Conversio Health is an innovative chronic condition management company focused on COPD and Asthma Disease Management. They aim to improve outcomes, prevent hospitalizations, and reduce the total cost of care for chronic respiratory conditions.

CoraVie Medical's implantable, continuous blood pressure monitor informs treatment decisions to improve lives. The end to end solution improves patient compliance to monitoring and improves blood pressure reliability and actionability. By monitoring trends over day and night, CoraVie enables timely notification of changing health status.

Cortechs.ai develops and markets cutting-edge imaging solutions that are used by radiologists, neurologists, and oncologists in hundreds of clinics and research centers around the world. The Cortechs.ai team includes scientists, engineers, business professionals, and clinical specialists working towards the common goal of improving the diagnosis and treatment of patients with neurodegenerative disorders and cancers. Cortechs.ai's​ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician's desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer's disease, multiple sclerosis, epilepsy and traumatic brain injury.

Cortex aims to transform the diagnosis and treatment of atrial arrhythmias by providing insight into each individual patient's disease pathophysiology. The OptiMap™ System is a 510k cleared, electrographic flow mapping solution designed with AI, enabling physicians to See What Matters.

Reinventing drug development from the ground up and making on-demand oligonucleotide therapeutics possible.

Cyclarity Therapeutics, Inc. is pursuing a mission to treat, cure, and reverse atherosclerosis. The company aims to deliver simple and affordable therapies for cardiovascular disease and other chronic diseases of aging. Cyclarity is continuing to develop technology to treat the underlying causes of age-related diseases.

Cyrus Biotechnology is a biotechnology company that specializes in protein engineering and drug discovery through computational biology.

Cytonus is reinventing drug-discovery and drug-delivery by questioning the principled approaches of pharmacodynamics (physiological effects of drugs) that has failed patients since the start of medicine. With a revolutionary platform technology called the Cargocyte, we believe the days of flooding the body with medicines with a hope and prayer to effect disease is not only antiquated, it is scientifically flawed. With a combination of precision drug delivery and in-vivo drug production the Cargocyte platform enables science and medicines to new level of effectiveness without compromising safety for patients.

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful. Follow us on Twitter: twitter.com/cytovale

Cytovia Therapeutics aims to accelerate patient access to transformational cell therapies and immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on harnessing the innate immune system by developing complementary and disruptive Flex-NK™ bispecific antibody and iPSC-derived, TALEN® gene-edited NK-cell platforms. FLEX-NK™ bispecific antibodies are built on a quadrivalent multifunctional antibody platform designed to engage natural killer cells by targeting NKp46 using Cytovia's proprietary Flex-NK™ technology. The company is also developing three types of iPSC-derived NK (or iNK) cells: unedited iNK cells, TALEN® gene-edited iNK cells with improved function and persistence, and TALEN® gene-edited iNK cells with chimeric antigen receptors (CAR-iNKs) to improve tumor-specific targeting. ​ These two technology platforms are being used to develop treatment of patients with solid tumors such as hepatocellular carcinoma (HCC) and glioblastoma as well as hematological malignancies such as relapsed multiple myeloma. Clinical studies are expected to initiate in 2023.

Dandelion Science is a US-Swiss Generative Neuromodulation™ company, committed to advancing precision therapies for vision and brain disorders. Led by a world-class team, Dandelion's mission is to enhance the lives of people affected by these conditions through the integration of advanced generative technologies and deep scientific expertise. The company boasts extensive intellectual property and has received prestigious funding from the US National Institutes of Health and the Swiss Innovation Agency.

Darmiyan is a pioneering brain technology (deep-tech) company based in San Francisco, California, focused on developing innovative and rapidly scalable products for brain health screening and monitoring. The company's mission is to enhance brain health, equipping physicians with tools for precise, personalized patient care, thereby optimizing health outcomes. Darmiyan's first product, BrainSee, is FDA-approved and available to physicians to aid in prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI).

The BIOVIA portfolio integrates the diversity of science, experimental processes and information requirements, end-to-end, across research, development, QA/QC and manufacturing. Capabilities include Scientific Informatics, Molecular Modeling/Simulation, Data Science, Laboratory Informatics, Formulation Design, BioPharma Quality & Compliance and Manufacturing Analytics.Subsidiaries: Accelrys Ltd, Synomics Ltd, VelQuest Corporation, others.

DayTwo is leading the charge in personalized nutrition through cutting-edge microbiome analysis. Our mission is to empower individuals to take control of their health by understanding and optimizing their unique gut microbiome. About Us: We specialize in precision health through microbiome-based insights that drive personalized dietary recommendations. We decode the intricacies of the microbiome and translate it into practical solutions. Services: -Microbiome analysis for personalized nutrition optimization. -Predictive dietary recommendations based on individual microbiome composition. Why Choose Us: -Advanced technology: State-of-the-art sequencing methods (full shotgun) and proprietary algorithms -Supported by science: Microbiome insights combined with 25 years of diverse patient data, bolstered by research published in prestigious journals such as Nature, Cell, JAMA, and Diabetes Care -Largest collection of data: World's largest high-resolution sequenced data set of over 90,000 samples -Personalized approach: Recommendations based on each unique microbiome profile Join us on the journey to better health and unlock the potential of your microbiome with DayTwo. Connect with us to learn more!

The future of infectious disease diagnostics starts at Day Zero. By using whole-genome sequencing (WGS) and our proprietary enabling technologies, Day Zero is creating a new class of sequencing-based in-vitro diagnostics that generates clinically actionable data at scale. Our technologies include novel sample preparation methods enabling unprecedented ultra-high enrichment of pathogen DNA for sequencing directly from clinical samples, machine learning algorithms that provide clinically actionable diagnostic results, and a world-class database of WGS and drug efficacy profiles. Day Zero Diagnostics is on a mission to transform the way infectious disease diagnostics are performed by generating the stream of real-time sequencing data required to change how we track, manage and combat infectious diseases. With an enormous unmet clinical and economic need, we are targeting bloodstream infections and sepsis for our first application. The life expectancy of a patient with septic shock is 24 hours without fast effective antibiotic treatment. However, even when successful, current diagnostics take 2-5 days to identify the pathogen AND provide its antibiotic susceptibility profile. The lack of rapid, accurate, and comprehensive diagnostics, forces physicians to “carpet bomb” patients with severe infections with powerful, yet toxic, broad-spectrum antibiotics, which is not only ineffective in many cases but can also lead to significant morbidity and mortality. Day Zero delivers a complete diagnosis, including both the species and antibiotic resistance profile, in hours vs. days, enabling the physician to use a targeted treatment on day zero of hospital admission and resulting in better patient outcomes and cost savings.

D&D is a clinical-stage global biotech company that focuses on development and commercialization of revolutionary medicines with the potential to change the lives of patients with unmet medical needs. Our success is built on a product pipeline originating from top research centers.

Deep 6 AI is a clinical trials software company based in Pasadena, California, founded in 2016. The company focuses on accelerating patient recruitment and enhancing clinical research through AI-powered analysis of real-world clinical data. In March 2025, Deep 6 AI was acquired by Tempus, further integrating its capabilities into Tempus' healthcare ecosystem. The company specializes in AI-powered patient matching, which analyzes both structured and unstructured electronic medical record data to identify eligible patients for clinical trials. Its platform connects healthcare organizations, researchers, and life sciences companies, streamlining trial workflows. Deep 6 AI also generates real-world evidence to support rapid clinical trial feasibility analysis and data-driven protocol design, utilizing natural language processing and machine learning to process data from over 25 major healthcare organizations.

Deep Apple Therapeutics is writing a new playbook for drug discovery, leveraging a powerful combination of cryo-EM enabled structural biology, AI-powered pocket extraction, and more. The company is advancing multiple programs focused on GPCR modulators, a proven target class with applications in metabolic disorders.

DeepCure is transforming the field of small-molecule drug discovery, by delivering better drugs in a faster and cheaper way. The company was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists. DeepCure does not use AI to simply generate a profile of the target candidate profile (TCP), but instead re-engineers drug discovery to deliver transformative results.

DeepHealth is RadNet's AI-powered health informatics subsidiary, created to empower breakthroughs in care delivery. The heart of its portfolio of solutions, the DeepHealth OS, is a cloud-native operating system that orchestrates all data to drive value across the enterprise. DeepHealth aims to elevate the role of the radiologist, beyond radiology and across the entire care pathway. It empowers all users across the care continuum with personalized workflows to make work easier and more meaningful. DeepHealth leverages advanced AI technologies in breast, lung, prostate, and brain health, as well as operational efficiencies to create end-to-end efficiency across the enterprise.

Deep Lens is a digital healthcare company focused on enabling faster recruitment of the best-suited cancer patients for clinical trials at the time of diagnosis using VIPER. Deep Lens' AI-driven cloud platform gives care teams, trial coordinators and oncologists visibility into all available trials and the ability to collaborate on groundbreaking cancer research across all cancer types.

DELFI uses artificial intelligence and whole genome sequencing to sensitively detect unique patterns of DNA fragmentation in the blood of patients with cancer.

Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Headquartered in Novi, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Called SoftVue™, and featuring proprietary TriAD™ (triple acoustic detection) technology, the system captures reflection echoes from all directions around the breast and gathers transmitted signals coming through the breast. This is something no other ultrasound system, currently available, can do. SoftVue has received 510(k) clearance from the U.S. Food and Drug Administration for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Formed in 2010 as a spin-out of Karmanos Cancer Institute in Detroit, MI, Delphinus is committed to creating improved imaging methods that assist medical professionals better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, and without concern of radiation or discomfort.

Now cleared by the U.S. Food and Drug Administration (FDA), DermaSensor equips physicians with immediate, accurate, and objective results that improve skin cancer detection through data-driven breakthrough technologies.

Detect builds tools that empower people to understand their health and make informed, timely decisions. Led by Founder Dr. Jonathan Rothberg, the Detect team is redesigning the future of healthcare with the power of technology. Detect wants to make fast, accurate diagnostic testing as routine as taking your temperature and as accessible as telemedicine.

Dewpoint is the first company to apply an emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Novo Nordisk, Evotec and Chemify. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable. 

We are the first gut microbiome, genetics-based virtual care platform for people struggling with polychronic mental & physical illness associated with weight and gut. We use AI to harness clinical, genetic, gut microbiome, food and behavioral signals to target the root cause of illness. We deliver tailored whole-person care, including remote monitoring, food-as-medicine, pharma reduction, behavioral coaching support, and care coordination. We use AI to harness food information, clinical, genetic, gut microbiome, and behavioral signals, to deliver tailored holistic care, including food as medicine, behavioral coaching support, remote monitoring, and care coordination, to target the root cause of illness. Our customers love us because we acknowledge their unique physiology, lifestyle, food habits and deliver data-driven personalized care supported by specialist coaches that puts the customer in charge.

Digital Diagnostics is an Iowa-based AI diagnostic platform that offers solutions such as image analysis and EMR integration for the healthcare industry.

Diagnostic testing for patients across all rare genetic diseases, including Cystic fibrosis, Fabry disease, Epilepsy, Hemophilia, all types of hereditary cancers, and cell and gene therapy.

Develop artificial intelligence that is utilized to aid and augment certified genetic counselors and pharmacists, during pre-test, post-test and support services.

As a nonprofit engineering innovation company, Draper serves our nation's interests and security needs; advances technologies at the intersection of government, academia, and industry; cultivates the next generation of innovators; and solves the most complex challenges. Multidisciplinary teams drawn from a broad and deep talent pool of 1,200 engineers and scientists collaborate to develop first-of-a-kind solutions. Our unbiased approach enables us to focus on our customers' needs and to deliver new capabilities to them.

DynoSense Corp. is a medical technology founded by successful high tech veteran, with a mission to “innovate best in class products and services for better, longer, and healthy life that are integrated, accurate, secure, elegant, and simple to use”. We call it “Innovation For Life”.

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy.Using machine learning and quantitative high-throughput in vivo experimentation, they are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

EchoNous creates transformative handheld point-of-care ultrasound solutions by infusing premium ultrasound performance with industry-leading AI educational tools providing more clinicians with increased information faster. Visit our website at https://www.echonous.com/ Explore a directory of our most popular content https://linktr.ee/echonous.kosmos

EDDA Technology, Inc. is an innovative leader in the rapidly growing field of imaging-guided cancer treatment. By adopting a fully quantitative, real-time interactive approach to imaging analysis, simulation and guidance, our next generation computer-assisted radiology and surgery solutions go well beyond advanced 3D image visualization. The award-winning IQQA® platform supports a patient-specific, disease-targeted, and multi-disciplinary approach to cancer treatment. With exceptional ease-of-use and clinical versatility, it facilitates efficiency and precision in treatment planning, guidance, monitoring, and follow-up. The IQQA® platform provides targeted solutions to assist physicians in advanced clinical applications including: fast 3D quantitative analysis and visualization, highly automated volumetric organ/lesion segmentation & quantification, pre– & post–operative assessment, treatment planning & simulation, procedural guidance and monitoring, and Computer-Aided Detection (CAD).

Edeniq, Inc. is a leading biotechnology company specializing in innovative, analytical solutions for the biofuels industry. With a focus on the analysis of fiber and cellulosic ethanol, Edeniq helps its customers quantify and qualify increased yield value and reduced carbon intensity, and optimize plant operations. Founded in 2008, Edeniq’s experienced team and strong customer focus have established the company as the top analytical testing service provider for ethanol producers across North America. Learn more at www.edeniq.com.

Founded in 2006, eHealth Technologies is the industry-leading provider of clinically informed referral services. We serve more than half of the nationÕs top 100 hospitals, including 16 of the top 20 U.S. News & World Report Honor Roll Hospitals for 2016-2017, and leading health information exchanges (HIEs) across the United States. The companyÕs eHealth Connect¨ solution enhances patient and physician satisfaction by streamlining referrals and intelligently aggregating patientsÕ clinical records. This assures physicians have the right healthcare information to care for their patients, right when they need it. As a critical adjunct to HIEs, eHealth Connect¨ Image Exchange enables the automated access to all types of medical images in the context of the aggregated patient record, in full diagnostic quality, and supports the ability of providers to meet Meaningful Use Stage 2 requirements.

Eigen Therapeutics is a biotechnology company developing therapies that make cancer easier to find and eliminate. Eigen is focused on the development of 'priming' therapies that improve efficacy while reducing the toxicity of small molecule therapies.

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery. They are pioneering a new method of drug discovery based on tracking and measuring movement of molecules within living cells. The company leverages superior engineering and high-performance computing to analyze single molecules and discover innovative medicines.

We are a skincare startup founded in 2018 in San Francisco. We combat the rise of skin conditions and sensitive skin by building a world in which beauty and science work together to produce optimal health. We develop clean, science-backed products that respect our skin's natural ecosystem. Discover our B2B microbiome tech platform @hellobiome. Our founder, Elsa Jungman, has a Ph.D. with strong expertise in dermatology, microbiome and clean beauty. She is a UCSF, L'Oréal and AOBiome alumna.

Elucid is a Boston-based medical technology company using histology-validated software to provide physicians with a cost-effective means to optimize treatment decisions for patients with cardiovascular disease. Advanced clinical insight from Elucid's CTA analysis equips physicians with critical information designed to enable precision medicine. Elucid is the first non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. The company has published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall. Elucid's unique information informs improved treatment decisions by physicians leading to better patient outcomes, improved quality of care, and reduced healthcare costs.

CompuGroup Medical is a leading provider of healthy solutions for healthy patients and healthy providers. We offer integrated electronic health records, practice management software, revenue cycle management solutions, and credentialing services for physician practices and enterprises. Founded by physicians, the company is an industry leader for usable, connected software that enables physician productivity and a superior clinical experience. eMDs software has received top rankings in physician and industry surveys including those conducted by the American Academy of Family Physicians’ Family Practice Management, AmericanEHR™ Partners, MedScape®, and Black Book®. For more information, please visit http://www.emds.com.

Emerald Cloud Lab® (ECL®) provides researchers from various disciplines with access to state-of-the-art scientific labs from anywhere on earth, 24 hours a day, 365 days per year. With ECL researchers utilize a single software interface to securely design, run, and analyze experiments, allowing researchers to spend more time designing protocols and analyzing data, and less time on mundane time-intensive activities in the lab. With ECL every researcher utilizing the platform becomes more productive, and more efficient while reducing operational costs and the impact on the environment.

Empire Genomics is a leading biotechnology company focused on the development of advanced molecular diagnostics and genomic products. Our mission is to accelerate precision medicine by providing tools that empower researchers, clinicians, and pharmaceutical companies to better understand, diagnose, and treat complex diseases, particularly in oncology. We offer an extensive portfolio of FISH (Fluorescence In Situ Hybridization) probes, ancillary reagents, and custom assay development services. These products are essential for detecting genetic abnormalities, such as gene amplifications, deletions, and rearrangements, critical for diagnosing and monitoring various cancers and genetic disorders. Committed to quality and innovation, our products are rigorously tested to meet the highest industry standards, ensuring reliable results. Selling products globally through a network of distributors, Empire Genomics continues to advance personalized medicine, enabling healthcare providers worldwide to deliver more targeted and effective treatments to patients.

At EnClear Therapies, we are combining Bioscience & Med-tech expertise to develop solutions that improve and extend the lives of patients with CNS disease. The team at EnClear is developing systems and medical interventions that Access, Recirculate & Modify CSF for: › Targeted removal of toxicity from CSF correlated to neurodegenerative disease progression. › Continuous localized delivery of therapeutics & monitoring of CSF to ensure effective and personalized therapy.

Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. Our proprietary and patented technologies oriented around deciphering the complexity of biology networks include both high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. In January 2018, we announced the closing of a US$10M seed round from notable biotech and tech institutional investors and are expanding the team.

Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.

Enthought specializes in digital transformation of science-driven companies in the materials science, chemistry, semiconductor, life science, and energy industries. In today's competitive global business environment, it's imperative that R&D organizations move from the traditional human-centric model to a digital, compute-centric infrastructure. Enthought is expert in this transition. We have been providing technical consultation and implementation services for scientific R&D for over 20 years.

Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.

At Epistemic AI we are building the next generation of tools to accelerate biomedical research with AI and NLP. We are a group of senior scientists and engineers from the likes of Google, New York University, Stanford and more. We are dedicated to enabling advances in biomedical research and practice with AI and NLP.

Epitel is a digital health company modernizing brain health solutions to improve seizure monitoring and detection.

Our mission at Erasca is embedded in our name: To erase cancer. Energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. We have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals. In addition to our initial programs for undisclosed cancer targets, we seek to expand our pipeline through partnerships with academic scientists and biopharmaceutical companies who have revealed potential new mechanisms for precision oncology. Importantly, Erasca isn’t tied to one form of drug or any singular approach to treating cancer. By keeping an open mind about what is possible, we believe we will achieve the greatest results for patients everywhere.

Essenlix Corporation is a fast-growing startup company in Princeton that develops a new easy-to-use, ultrasensitive, fast, assay platform for life science, diagnostics, and personal health.

埃格林医药是一家高速发展的国际化生物医药公司，以“关注临床迫切需求，惠及全球广大患者”为使命，致力于在全球范围内的临床研发与商业化推广

Everlum Bio is pioneering a novel approach to drug development for rare diseases. As opposed to working on a single disease we are doing "Drug Development as a Service". We are relentlessly focused on innovating the drug development process. Ultimately we believe this approach will usher in a personalized/precision medicine revolution.

Every Cure is a nonprofit initiative on a mission to unlock the full potential of existing medicines to treat every disease and every patient they possibly can.

Evia Bio™ is a life science innovation company enabling the growing cell therapy market. We provide new non-DMSO cryopreservation solutions developed by world-leading cryobiologist, Allison Hubel, PhD. We partner with cell therapy companies looking to advance their products to clinical trials and commercialization. Our solutions unlock the full potential of emerging life-saving therapies through the use of all-natural organic compounds to protect the integrity of cells during cryopreservation and patient safety at the point of care. Please visit www.eviabio.com.

Evidation creates new ways to measure and improve health in everyday life—making proactive, personalized, and truly human-centered healthcare possible. By connecting directly with millions of individuals, Evidation harnesses real-world data to deeply understand health experiences, rapidly and at scale. Evidation’s privacy-centric digital health measurement and engagement platform uses data science and machine learning to translate these everyday insights into high-impact health guidance, treatments, and tools. Founded in 2012, Evidation is headquartered in California with employees working around the globe.

EvolutionaryScale is a biotech startup focused on AI research in the field of biology. The company has developed a database of over 2 billion protein sequences to train its AI model, offering technology that can provide insights into biological processes. EvolutionaryScale has raised significant funding, including a $142 million seed round, and is known for its ESM3 Generative AI Model for biology.

Evozyne designs novel protein therapeutics to solve previously unaddressable patient needs.

Exagen Inc. is a Patient Focused, Discovery Driven, CLIA-certified, CAP-accredited laboratory with a growing menu of proprietary, internally developed tests focusing in the area of Rheumatology and Autoimmune diseases. Committed to Personalized Medicine, our AVISE tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.

Exai Bio is a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ultimately cured. The company's proprietary RNA and artificial intelligence-based liquid biopsy platform delivers clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer. Exai Bio was founded with technology from the UCSF laboratory of Dr. Hani Goodarzi, and consists of veteran leaders in the RNA biology, liquid biopsy, and artificial intelligence/machine learning fields from both academia (UCSF, Stanford, MIT) and industry (Bluestar, CareDx, Evidation, Google, 23andMe, Deep Genomics). Exai Bio is supported by leading life sciences and tech investors including Section 32, Casdin Capital, and Two Sigma Ventures, who have been integral to advancing cancer diagnostics, and artificial intelligence and machine learning technologies. We know that people are our greatest asset and we are rapidly building a rock-star team of talent. Our people are driven by the mission, inspired by the vision of the future, and are committed to living our core values (integrity, openness, teamwork, exploration, and kindness) that connect us to our work and to one another. What We Value Our core values represent what we stand for as a team. This is what we believe in. Everyday, we strive to align our behaviors to these core values in everything we do. Integrity – Our thoughts and actions are true to science and to people. We do the right thing. Openness – We recognize and respect our differences – and embrace learning from them. Teamwork – We are team players who trust and respect each other. Exploration – We are explorers, putting curiosity into action. Kindness – We are kind whenever possible – and we believe it's always possible.

Discover how Excelra, a leader in biopharma data and analytics, uniquely blends scientific understanding with technological expertise. This dual mastery empowers innovative drug discovery and development, transforming research data into actionable insights for groundbreaking discovery. 𝗘𝗺𝗽𝗼𝘄𝗲𝗿𝗶𝗻𝗴 𝗗𝗲𝗰𝗶𝘀𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝗘𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 Excelra's interdisciplinary approach combines life science expertise with cutting-edge technology. This leads to confident, data-centric decisions, simplifying your data-driven drug discovery journey and accelerating your research. 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝘃𝗲 𝗦𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀 𝗳𝗼𝗿 𝗘𝗻𝗵𝗮𝗻𝗰𝗲𝗱 𝗖𝗮𝗽𝗮𝗯𝗶𝗹𝗶𝘁𝗶𝗲𝘀 At Excelra, collaboration is key. By co-creating solutions, we amplify your team's capabilities, blending scientific insight and technological acumen for more valuable discoveries and greater project control. 𝗙𝗿𝗼𝗺 𝗖𝗵𝗮𝗼𝘀 𝘁𝗼 𝗖𝗹𝗮𝗿𝗶𝘁𝘆: 𝗦𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗶𝗻𝗴 𝗗𝗮𝘁𝗮 We navigate the complexities of drug discovery, enhancing your success by structuring chaotic data into actionable insights, leveraging our scientific and technological prowess. 𝗖𝗼𝗺𝗺𝗶𝘁𝘁𝗲𝗱 𝘁𝗼 𝗬𝗼𝘂𝗿 𝗚𝗼𝗮𝗹𝘀 Your goals of faster drug development and better patient outcomes are central to our mission. Committed to delivering insights and tangible progress, we ensure each data point contributes to your innovation journey, helping you 'Excelrate' towards success. 𝗥𝗲𝗱𝗲𝗳𝗶𝗻𝗶𝗻𝗴 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗧𝗼𝗴𝗲𝘁𝗵𝗲𝗿 Join us in redefining drug development. Our services span across the life science value chain, from molecule to market. At Excelra, each data point is a step towards a healthier future. Discover how partnering with us can 'Excelrate' your healthcare innovations.

We are a specialty CDMO for LV vector manufacture & use. Our three platforms: Expression Cassette Optimization (ECO), LentET (3rd gen system), & LentET Express (cGMP mfg.) enable GMP LV manufacture 10 months from sequence submittal. ECO increases expression up to 8 fold. LentET plasmids are ECO optimized, have improved safety, produce potent LVs & may be available royalty/licensing free depending upon the specifics. With full CMC & regulatory support, Expression is your preferred CDMO of choice.

Fable Therapeutics Inc. was founded with a conviction to revolutionize drug discovery through the purposeful integration of AI techniques. ‍ Our cross-functional team of ML scientists and drug hunters collaborate to design novel medicines with expanded therapeutic potential. ‍ With this passion and vision, we’re designing the future of drug discovery.

FAR Biotech is a preclinical, computational drug discovery company that focuses on hard-to-drug targets that have high scientific and commercial value. Founded by Dr Martin Martinov after 25 years in academia and industry -- and named after the Bulgarian word “far” that translates into “lighthouse” or “beacon” -- FAR seeks to shine a light on drug discovery in areas of high unmet clinical need. FAR's proprietary technology can more rapidly identify novel, structurally diverse, optimized, lead molecules that other approaches would not look for, let alone find. The key differentiator is FAR's complete and rigorous quantum mechanical representation of drug-target interactions -- which embeds the advantages of quantum similarity and multi-property optimization for hit and lead identification -- augmented by AI / machine learning & big data. FAR's quantum biomodelling platform has been validated preclinically across a number of therapeutic areas, including neurodegeneration, oncology and infectious diseases.

Fauna Bio is inspired by the untapped potential of non-model organism biology. We leverage insights from extraordinary mammalian phenotypes to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans.

FDNA uses facial analysis, deep learning and artificial intelligence to transform big data into actionable genomic intelligence to improve diagnostics and therapeutics.

Fibronostics is a healthcare technology company providing algorithm-based solutions in a variety of diagnostic testing areas, focusing on assessing liver disease existence/progression, but also other chronic areas such as coronary heart disease, stroke, diabetes, and obstructive sleep apnea. Fibronostics'​ LIVERFASt products provide early detection and monitoring for patients with NAFLD & NASH when a diagnosis is often missed due to limited screening with low-sensitivity tools. The current standard for diagnosis is risky and costly with mounting evidence calling for an efficacious and cost-effective non-invasive diagnostic tool. Fibronostics'​ HealthFACTR tool employes technology to predict risk, providing results for risks of coronary heart disease, stroke, diabetes and fatty liver disease. HealthFACTR enables action-oriented recommendations which allow healthcare professions to determine patients'​ risk levels and drive better patient care.

Welcome to the future of neurological assessments with Firefly Neuroscience’s FDA-cleared Brain Network Analytics (BNA™). Utilizing ADVANCED AI and an extensive proprietary EEG database, BNA™ combines the automatic analysis of Event-Related Potentials (ERPs), spectral EEG, and behavioral performance data for a comprehensive and objective data-driven brain health evaluation.

For patients whose cancer has returned, First Ascent Biomedical provides new ways to fight by combining functional drug testing, genomics, and artificial intelligence to design an individualized treatment plan in a week for each patient. Our technology rapidly grows tumor bulk, more importantly chemo-resistant cells enabling the testing 100s of FDA-approved drugs to measure the cellular response of both cell populations. This is the key dataset for the AI engine, supported by genomics data to identify every cancer weakness and identify which drugs work.

Flagship Biosciences is a leader in spatial biology and biomarker analysis, bringing innovative approaches to clinical research and drug development. The company delivers the most accurate and informative data available in the field of spatial biology and biomarker services.

Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple transformative human health and sustainability products. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures. The current Flagship ecosystem comprises over 40 companies, including Denali Therapeutics, Foghorn Therapeutics, Generate:Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.

FluoroFinder is developing innovative cloud-based research tools for the search of fluorescent reagents and the design of medical experiments: accelerating the research initiatives aimed at curing Cancer, HIV, Multiple Sclerosis, in addition to other infectious diseases. Simplifying the complexity of managing the life-cycle of reagent selection, FluoroFinder's technology solutions offers unparalleled support and resources to core facilities and labs. Members receive additional benefits and support to drive efficiencies and resource savings. FluoroFinder's technologies save thousands of days - and millions of dollars - for research institutions every year! Please contact us at info@fluorofinder.com to request a demo.

Forever Oceans is pioneering a new way to produce delicious, natural seafood that's good for people and the planet. We combine our expertise in off-shore aquaculture with unique innovations to ocean-raise fish that are always delicious, healthy, and sustainable.

Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.

Form empowers scientists to harness the data, computing power and collaboration that drive how today's breakthroughs are made.

Freenome is a private biotech company focused on developing blood tests to detect cancer early and make screening accessible for everyone.

Frontier Medicines, located in South San Francisco, CA and Boston, MA, is a precision medicine company that has pioneered a powerful discovery and development platform designed to generate medicines against disease-causing proteins previously considered undruggable. We are deploying our technologies in chemoproteomics, covalent drug discovery, and machine learning to develop a pipeline of groundbreaking medicines against the most important drivers of disease. Our lead program targets both the activated and inactive forms of KRAS G12C, a validated driver in a number of cancers that until recently has been undruggable. Our pipeline embodies our vision of bolding advancing science to defeat disease, starting with cancer.

Gain Therapeutics, Inc., a development stage biotechnology company, develops various therapeutics to treat diseases caused by protein misfolding. It focuses on lysosomal storage disorders, such as rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding treating the underlying disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

We are building the largest longitudinal cohort in the Americas to power precision health at scale for all. Our goal is to improve diagnostic testing and accelerate drug discovery in diverse underserved populations. We are focused on Latin America and our diaspora populations throughout the world including founder populations in the Americas, those who identify as Hispanic/Latino, Black or African American, Asian American, American Indian/Alaska Native, First Nations, and Native Hawaiian/Pacific Islander as well as people who self identify as belonging to two or more of these groups. Core to our mission is building trust with the communities we serve and long term partnerships with communities, researchers, clinicians, and most of all patients and their families. This is your biobank and for the benefit of all. If we build it, we can decide how the data are used. And no one is going to do it for us, so let’s roll up our sleeves and “time to build.” Join us! Este biobanco es tuyo y para todo el continente porque si lo construimos juntos podemos decidir cómo se usan los datos y con que fines. Nadie lo va a hacer por nosotros así que bienvenido a nuestro esfuerzo. Unete!

GATC Health Corp is a technology company revolutionizing drug discovery and development through its transformative AI platform and approach, which accelerates therapeutic development with accuracy, efficiency and speed never before achieved in medical science. The company’s validated and proprietary Multiomics Advanced Technology™ (MAT) platform simulates human biochemistry’s billions of interactions for accurate and rapid novel target identification/verification, and drug discovery/development. GATC Health envisions the future of medicine now, where disease is reversed safely so everone can live their best lives.

GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases. The core technology of GCTx was conceived, invented and perfected in Professor George Church's lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.

Geisinger Medical Laboratories, a medical reference laboratory in Pennslyvania (PA). Dedicated to caring, laboratory excellence, patient safety, quality assurance, and service excellence.

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. They develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. GEn1E is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities—creating novel therapeutics at an unprecedented pace. Their AI platform has enabled them to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Their AI platform enables tremendous pace and capital efficiency as demonstrated by their progress in ~2 years with seed capital—a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. GEn1E’s team has decades of experience in drug development and machine learning, and they graduated from YCombinator and Stanford-StartX in late 2019. GEn1E is based in Palo Alto, CA.

Genemod helps scientists maximize productivity in their research to drive the next generation of medicines. Genemod helps solve problems of data sharing and data archiving for research labs by providing inventory, experiment management, applications, and data, all in one collaborative workspace.

The company offers products and services in:advanced probiotics and feed additivesgenetically engineered probioticsassays and screens of probiotics, andcustom probiotic fermentation.

Generate:Biomedicines is a new kind of therapeutics company—existing at the intersection of machine learning, biological engineering, and medicine—pioneering generative biology to create breakthrough medicines. Through The Generate Platform, we are able to expand the breadth of technical possibilities in order to fundamentally change the way medicines are made.

Genesis Drug Discovery and Development (GD3), a member of Genesis Global Group, is a contract research organization focused on providing services to support preclinical drug development programs from discovery to candidate selection. Our diversified portfolio of services covers all the areas of preclinical drug discovery/development including Discovery Biology, Chemistry, DMPK/in-vivo pharmacology and Toxicology. The portfolio spans a wide range of therapeutic areas include oncology, ocular, inflammation, metabolic diseases, ​and microbiome.

Genesis Therapeutics – headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego – is unifying AI and biotechnology to discover novel and breakthrough treatments for patients with severe and devastating conditions. We are using a proprietary state-of-the-art generative and predictive AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery. The GEMS platform integrates deep learning-based predictive models, molecular simulations, and molecular generative AI. GEMS accelerates hit ID through lead optimization and candidate selection by generating promising molecules for synthesis and experimental testing, and iterating this process through multiple cycles of AI-enabled discovery and optimization. We have leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has two AI platform collaborations across a range of therapeutic areas: Eli Lilly (signed in 2022) and Genentech (signed in 2020). Genesis has raised over $280M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures. We are rapidly growing our team with a variety of openings on our machine learning, computational chemistry, and software teams (primarily located in the Bay Area) and our chemistry, biology, and clinical teams (primarily located in San Diego). To learn more about Genesis Therapeutics, or current employment opportunities, please visit our website.

Geneyx offers best-in-class practices harnessing #geneticdata available to guide digital insights for rare and #germline disorders and diseases. We aim to enrich disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and #pharmaceutical organizations.

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC). Today, GENFIT has a diversified R&D pipeline covering several therapeutic areas: five programs in acute on chronic liver failure (ACLF) are in clinical stages (Phase 2) and pre-clinical stages, including hepatic encephalopathy (HE), one of the main complications of ACLF; a Phase 2 clinical program targeting cholangiocarcinoma; and a preclinical program targeting urea cycle disorders (UCD) and organic acidemias (OA). GENFIT’s pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) and ammonia. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital.

Genomenon is a leading genomic intelligence company dedicated to improving the quality of patients’ lives by uncovering the genomic drivers of genetic disease and cancer. Blending the power of AI with genomic expertise, Genomenon simplifies complex genetic data into actionable insights for patient diagnosis and precision medicine development. The company’s solutions include software, data, and services. Genomenon offers advanced genomic software solutions designed to streamline and enhance genetic research and clinical decision-making. Our flagship product, the Mastermind® Genomic Intelligence Platform, provides comprehensive genomic data integration and analysis, offering researchers and clinicians a powerful tool to interpret genetic variants and their clinical relevance. Complementing this is the Clinical Knowledgebase (CKB), which focuses specifically on the landscape of somatic mutations, offering curated, actionable insights to support oncology research and personalized cancer treatment. Together, these platforms aim to accelerate discoveries and improve patient outcomes through sophisticated data analysis and knowledge integration.

GenomOncology enables real-time clinical decision-making at the point-of-care for Molecular Pathologists, Clinical Oncologists and Cancer Informaticists in their research of cancer treatments and therapies for cancer patients.

A One-Stop-Shop Gene to Antibody Partner Genovac is a contract research and manufacturing organization committed to positioning our clients for the successful development of new transformative drugs and diagnostics. Genovac specializes in antibody discovery and production against challenging targets. Our unique combination of genetic immunization, multiple host species, multiple single B cell platforms, and state-of-the-art production facilities enables us to serve as your one-stop-shop Gene to Antibody partner.

Founded in 2002 and listed on the Hong Kong Stock Exchange in 2015, GenScript has an established global presence across Greater China, North America, the EU, and Asia Pacific. Today, over 200,000 customers from over 100+ countries and regions worldwide have used GenScript's premier, convenient, and reliable products and services. GenScript has over 6,900 employees globally, with about 10% R&D personnel. In addition, GenScript has a number of leading commercial technologies developed in the fields of synthetic biology, immunotherapy, antibody design, chemical synthesis, and bioinformatics, including more than 300 patents and about 900 patent applications. As of December 31, 2023, GenScript's products and services have been cited by 87,745 scientific papers worldwide. GenScript is committed to striving toward its vision of being the most reliable biotech company in the world to make humans and nature healthier through biotechnology.

Based in Sudbury, MA., Gentuity is a commercial-stage medical technology firm dedicated to developing next-generation intravascular imaging devices capitalizing on today's best-in-class technologies. Gentuity was founded on the principles of advancing patient care, improving outcomes, and expanding the utility of intravascular procedural guidance tools in the realm of cardiovascular disease. The Gentuity High-Frequency OCT Imaging System is the first commercially available OCT imaging system to deliver Total Vessel Imaging with the first 1.8F micro-imaging catheter. Gentuity and its' next-generation platform are paving the way for transformation in the intravascular imaging world. Designed to support the growing needs of the imaging industry, the platform incorporates AI and machine learning with the intention of creating "collaborative intelligence" to enhance ease of use and procedural success.

Gestalt transforms pathology through an intelligent, configurable, and vendor-neutral, AI-driven, digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow® solution is a cloud-based digital pathology enterprise platform that can easily be customized based on your specific preferences. This platform consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing their invaluable experience where it matters most. *Research Use Only (RUO) unless following CAP guidelines for LDT.

Gilgamesh is a clinical-stage biotech whose vision is to reshape how mental illnesses are treated by shifting away from symptom management to a focus on rapid-acting and durable therapies targeting the fundamental drivers of disease. We do this by designing best-in-class new chemical entities (NCEs) acting through proven mechanisms, which are optimized for safety, efficacy, and patient access

At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more. We know our unique experiences, ideas, and perspectives are essential to our success and enable us to make biology easier to engineer and ensure equitable distribution of the benefits of our platform. As such, we seek to ensure that DEI is in our DNA, continuing to grow an inclusive culture and diverse workforce. Let's make biology easier to engineer and join our team.

Our mission is to use visionary science and technology to overcome major unsolved diseases.

Glytec's industry leading SaaS platform, trusted by 350+ hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing readmissions, and streamlining workflows while delivering a 6-8x ROI. The first-ever FDA-cleared cloud-based insulin management software is EMR-integrated, easy to set up, and validated by 106 patents and over 100 publications. The Glytec Glucommander® solution, with clinical decision support, workflow alerts, patient monitoring, at-risk patient identification, and AI-driven analytics, is supported by a mission-driven team dedicated to helping healthcare leaders, clinicians and patients promote health equity and improve diabetes outcomes from hospital to home. We are on a mission, join us. For more information, follow Glytec on X (@Glytec) or visit www.Glytec.com.

GNS Healthcare is a healthcare analytics company that specializes in precision medicine and biomedical research through advanced health data analysis.

Meet your business challenges head on with cloud computing services from Google, including data management, hybrid & multi-cloud, and AI & ML.

Process, analyze, and annotate genomics and biomedical data at scale using containerized workflows.

Discover the limitless potential of human induced pluripotent stem cells (iPSCs) for groundbreaking research at Greenstone, a leading Bay Area biotech company. We combine cutting-edge technology with AI, computational biology, and pharmacogenomics to accelerate drug discovery and development, transforming the future of therapeutics. Our vision is to transform drug discovery from a slow, sequential, and high-failure process into a rapid, integrated, and novel computational platform. By harnessing the power of iPSCs and our advanced technologies, we revolutionize the traditional drug discovery paradigm, paving the way for a faster, more efficient approach. With our curated and diverse collection of iPSCs, sourced from both healthy individuals and those affected by various diseases, we offer a comprehensive platform for disease modeling, uncovering novel mechanisms, and advancing drug discovery. Our high-quality iPSCs provide researchers with patient-specific and disease-specific cells, enabling the development of personalized treatment strategies. At Greenstone, collaboration and innovation are at the core of our values. We proudly offer our iPSCs to academic investigators free of cost, fostering an environment of shared knowledge and progress. Together, we can unlock new insights, accelerate drug discovery, and shape the future of personalized medicine. Join us on the frontier of biomedical research and tap into the immense potential of iPSCs. Together, let's transform drug discovery into a rapid, integrated, and computational platform that propels us towards groundbreaking therapeutics. #Biotech #iPSCs #DrugDiscovery #BiomedicalResearch #PersonalizedMedicine #Innovation

Gritstone Oncology, Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/2 clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

Automate and scale your participant recruitment and engagement with the Grove AI Assistant and PRM™. Our AI assistant is available 24/7 and adapts to every trial, ensuring the right participants are connected to the best clinical trials.

Grove Biopharma is a preclinical biotechnology startup, pioneering the discovery and development of a new class of synthetic biologic drug modality to access challenging drug targets. Our Precision-Linked Proteomimetic therapeutic platform has the potential to address significant unmet medical needs in oncology, neurodegenerative disease, and other rare diseases.

In April 2024, Deloitte acquired substantially all of the assets of Gryphon Scientific LLC. The team, comprised of life scientists and health researchers who apply rigorous scientific analysis to problems of global health and homeland security, is now part of the Deloitte GPS Federal Health sector. Our projects drive policy changes in security, preparedness, and science policy at the highest levels of US government.

Guided is a Georgia-based medical technology company that develops and commercializes non-invasive medical devices for early detection of cancer.

At Harbinger Health, our mission is to change the cancer paradigm by taking a proactive approach to cancer detection and prevention. We envision a future where cancer is no longer a life-altering event, but a routine health problem that can be addressed with early intervention. To achieve this, we have developed proprietary solutions for cancer pre-emption, starting with blood-based tests that can detect cancer before it even becomes visible. By identifying biological programs that are the root cause of cancer, we can enable early-stage and pre-disease identification, leading to truly personalized and effective cancer care for everyone. With Harbinger Health leading the way, we believe that a cancer-free future is not only possible but within reach, for everyone.

Harter Secrest & Emery LLP is a full-service business law firm providing legal services to clients ranging from individuals and family-owned businesses to Fortune 100 companies and major regional institutions. With offices in Buffalo, Rochester, Albany, Corning, and New York City, New York, the firm is a recognized leader in litigation, corporate, employee benefits, environmental and land use, health care, higher education, immigration, intellectual property, labor and employment, real estate, and trusts and estates law. The firm and its attorneys are consistently recognized by the industry's leading law firm and attorney ranking programs, including Chambers and Partners, Best Law Firms® and The Best Lawyers in America®.

hc1 + Accumen, together, unlock the vast potential of actionable lab data to transform labs into a strategic asset. Health system executives often face challenges in improving patient care and financial performance. By partnering with hc1 + Accumen, health systems can gain profitable new growth and improve patient outcomes. Our solutions use advanced data management, analytics, and workflow automation powered by AI to uncover actionable insights and hidden risk signals, delivering innovation, operational and clinical excellence, and revenue growth across the entire care continuum. With over a decade of experience and thousands of health systems and labs leveraging our technology and consultative services to care for nearly 100 million patients, we provide the expertise needed to unlock the strategic value of your lab data, improving patient outcomes and boosting financial performance. Healthcare Progress Starts Here.™ With hc1 + Accumen.

HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming cardiac care by providing powerful insights wherever the patient is. The Company is creating the first ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions.

HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With our HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease--the number one killer of men and women worldwide. HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide. Cleared for use in the United States, Canada, Europe and Japan and with offices in Redwood City, Austin, London and Japan, HeartFlow's footprint is growing rapidly. HeartFlow has received more than $240 million dollars in funding in a recent Series E financing round, is pre-IPO and leverages the latest technology including deep learning and computational fluid dynamics. We try to embody the best of both technology and healthcare companies and hire people who are passionate about living our mission to save lives, improve the patient experience and reduce the overall cost of care. For more information, visit www.heartflow.com.

Vista.ai is harnessing the power of artificial intelligence (AI) to offer clinicians an easy, cost-effective and stress-free way to conduct MRI studies. The company's FDA 510(k) cleared MRI CoPilot™ software-only solution automates and dramatically simplifies a CMR exam, enabling any MRI tech to perform a CMR in a standard mixed-use scanner time slot. Available for use on Siemens Healthineers and GE Healthcare MRI scanners, MRI CoPilot™ • Eliminates the need for specialized CMR technologist • Allows CMRs to fit into your mixed-use scanner standard time slot • Makes scans less stressful for the technologist • Gives patients greater comfort and convenience Vista.ai is funded by Khosla Ventures, and the National Institute of Health's Small Business Innovation Research program.

HelixNano is building the world's most advanced mRNA platform to enable previously impossible applications across human and non-human biology

Hengrui Therapeutics, Inc. (HTI), located in Princeton, NJ, is a biotech focused on early-stage clinical development of innovative therapeutics in areas of major unmet medical needs, such as oncology, metabolic and autoimmune disorders.

Hepion Pharmaceuticals (Nasdaq: HEPA) is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offer benefits to address these multiple complex pathologies. CRV431 targets multiple biochemical pathways involved in the progression of liver disease. Preclinical studies with CRV431 in NASH models demonstrated consistent reductions in liver inflammation, fibrosis, and cancerous tumors. Additionally, CRV431 shows antiviral activity towards hepatitis B, C, and D viruses which also trigger liver disease. The multiple mechanisms of action of CRV431 equate to many therapeutic opportunities for alleviating the life-threatening risks of liver disease. CRV431 has been tested in Phase 1 human clinical trials. Our drug candidate demonstrated good safety and tolerability in oral doses ranging from 75 mg to 525 mg. As expected, the pharmacokinetics of CRV431 showed increasing maximal blood concentrations as doses increased. Systemic blood exposures demonstrated good linearity up to 375 mg, which we anticipate will be more than sufficient for efficacy, based on our preclinical testing. The half-life of CRV431 was long and supports once daily oral administration. Data from our preclinical program and our phase 1 clinical trial support the further advancement of CRV431 in liver disease.

Imagine your drug’s effect lasting for months, after one single dose, and with fewer side effects—Hera Health Solutions is turning this vision into reality. Pharma companies can rapidly turn their promising APIs into long-acting, precise, and profitable therapeutics. How? Through our proprietary, cutting-edge nanotechnology-based drug delivery platform. The best part? The platform is: ♻️ Biodegradable: Resorbs into the body. 💊 Versatile: Delivers your API through implants, pellets, patches, and more. ⏳ Long-acting: Lasting up to 48 months! We are focused on significant healthcare and industry challenges. Our mission is to revolutionize drug delivery and transform patient care. 💭 Send the direct message “Long-acting” to Hera’s LinkedIn inbox to explore your API’s potential. Or visit: https://www.herahealthsolutions.com/contact

Hexagon Bio is a biopharmaceutical company pioneering the discovering novel payloads for antibody-drug conjugates (ADCs) to address critical unmet needs in oncology. Leveraging a proprietary platform, the company mines cytotoxic small molecules from microbial genomes for use as ADC payloads. Advances in DNA sequencing have enabled the identification of both existing ADC payloads—such as topoisomerase and tubulin inhibitors—and novel payload mechanisms targeting essential cancer pathways such as protein translation. Hexagon Bio is advancing a pipeline of next-generation ADC candidates with novel payloads designed to treat a wide range of solid tumors and hematological malignancies.

HiFiBiO Therapeutics is an emerging multinational biotherapeutics company mobilizing the human immune system to combat disease. The company integrates deep-rooted biological expertise with our comprehensive single-cell profiling technologies to rapidly discover and advance a pipeline of antibody drugs to treat cancer and autoimmune disorders. In addition, HiFiBiO Therapeutics aspires to benefit patients through open-innovation partnerships with industry and academia. For more information, please visit www.hifibio.com.

Hippocratic AI’s mission is to develop the first safety-focused Large Language Model (LLM) for healthcare. The company believes that a safe LLM can dramatically improve healthcare accessibility and health outcomes in the world by bringing deep healthcare expertise to every human. No other technology has the potential to have this level of global impact on health. The company was co-founded by CEO Munjal Shah, alongside a group of physicians, hospital administrators, healthcare professionals, and artificial intelligence researchers from El Camino Health, Johns Hopkins, Washington University in St. Louis, Stanford, Google, Microsoft, Meta and NVIDIA. Hippocratic AI has received a total of $137 million in funding and is backed by leading investors, including General Catalyst, Andreessen Horowitz, Premji Invest, SV Angel, NVentures (Nvidia Venture Capital), and Greycroft.

We’re an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While we discover and develop groundbreaking products and services that benefit everyone, we are especially passionate about those that advance women’s health and well-being. This allows us to be a company that prospers, grows and empowers women to experience healthier lives. None of this would be possible without the talent, skills and aspirations of our employees. Their expertise and dedication to developing and sharing more robust, science-based certainty drives our increasingly global presence, as well as a pipeline that responds to the unmet health and wellness needs of women, families and communities. What powers our growth across Breast & Skeletal Health, Diagnostic Solutions, and GYN Surgical Solutions is also what differentiates us: the exceptional and clinically proven ability of our products to detect, diagnose and treat illnesses and other health conditions earlier and better. This clinical superiority creates high expectations, which we fulfill by always challenging ourselves to improve health through better technology, education and market access. Our goal is to minimize doubt and maximize the confidence our customers and their patients have in their decisions and diagnoses. We work toward this goal every day, always aware that in an increasingly complex and competitive global environment, we must continually earn the trust of our customers and their patients. By focusing on women’s health while still delivering health benefits to everyone, we are setting a new standard of excellence that is strengthened by purpose, driven by passion and brought to life by our promise of more certain early detection and better health outcomes. To view our community guidelines, visit: www.hologic.com/social-media

Honeywell is a Fortune 500 company that invents and manufactures technologies to address tough challenges linked to global macrotrends such as safety, security, and energy. With approximately 110,000 employees worldwide, including more than 19,000 engineers and scientists, we have an unrelenting focus on quality, delivery, value, and technology in everything we make and do. For additional information on how Honeywell processes your personal information please visit https://www.honeywell.com/privacy-statement.

The Future of Microsurgery is Robotics and AI. Horizon Surgical Systems, founded in 2021 by experts in ophthalmology and medical robotics, is at the forefront of innovation in microsurgery. Our groundbreaking product, Polaris, leverages state-of-the-art robotics, advanced medical imaging, and AI to extend the capabilities of surgeons beyond their current limitations. With a foundation rooted in academic excellence and a vision for the future, Horizon is committed to revolutionize global healthcare through technological innovation, bringing a new era of precision, enhanced outcomes, and safety to eye care.

Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties.

The Swoop® system brings MR brain imaging within reach. Our mission is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging and data solutions. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking medical technology company that has redefined brain imaging with the Swoop® system—the world's first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of care. The Swoop® system received initial U.S. Food and Drug Administration (FDA) clearance in 2020. It is a portable ultra-low field magnetic resonance imaging device for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis.

Iambic Therapeutics is disrupting the therapeutics landscape with its unique AI-driven drug-discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and experienced drug hunters with strong track records of success in delivering clinically validated therapeutics. The Iambic platform has been demonstrated to deliver high-quality, differentiated therapeutics to clinic with unprecedented speed and across multiple target classes and mechanisms of action. The Iambic team is advancing an internal pipeline of clinical assets to address urgent unmet patient needs. Learn more about the Iambic team, platform, and pipeline at iambic.ai.

iBio is an innovator biologics company developing therapeutics and vaccines for the betterment of human and animal health with pipeline candidates targeting systemic sceleroderma (IBIO-100), COVID-19 (IBIO-200 and IBIO-201), and classical swine fever (IBIO-400). iBio’s subsidiary, iBio CDMO is a global leader in plant-based manufacturing.

At iCAD, we believe that is possible to create a world where cancer can't hide. Leveraging the power of artificial intellegence (AI), we empower healthcare providers to more accurately, reliably, and quickly detect disease and improve outcomes. The ProFound Breast Health Suite offers a comprehensive portfolio of clinically proven AI technologies for breast cancer detection, automated breast density assessment, and short-term personalized risk evaluation providing certainty and peace of mind - Optimizing every patient's opportunity to live better, longer lives! To learn more, visit www.icadmed.com.

ICON works to accelerate the development of live-saving drugs and devices by providing a wide range of consulting, development, and commercialization services.

Welcome to the cutting edge of spatial biology and translational research! We're a specialized Contract Research Organization (CRO) and a CLIA High Complexity-certified, CAP-accredited clinical diagnostic laboratory, dedicated to empowering your scientific pursuits! Our focus lies in the field of spatial biology, spatial phenotyping, tumor micro-environment mapping, multiplex immunofluorescence (mIF), IHC, histology, digital pathology, digital and quantitative PCR (dPCR and qPCR), as well as next-generation sequencing (NGS). We use cutting-edge equipment to provide next-generation tissue pathology services, including high-resolution imaging and comprehensive analysis of tissue samples. Our collaborators include scientific teams across the drug development pipeline. Whether you're trying to identify predictive biomarkers or stratify patients, we can help you study the intricate interplay between cells and their surroundings, unlock insights into disease mechanisms, and uncover novel targets. Our team of experts can provide you with end-to-end support including method development and validation, sample testing, regulatory compliance, and clinical trial logistics.

Ikonopedia is a next-generation breast radiology reporting and patient tracking system. Our closed-loop system is automated to track and monitor patients to full resolution of all clinical concerns. Clinical reports are clear, consistent, and 100% compliant with the ACR BI-RADS® Atlas 5th Edition. Ikonopedia is MQSA-compliant and offers screening and diagnostic modalities that will improve patient safety and save valuable time for the radiologist and staff.

AI-powered fertility care

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.

Immune IQ has developed, in collaboration with Honeywell, the Immune Reveal platform. It reads disease information from a patient's immune system in 5 minutes to rapidly identify critical diseases, many not detectable today. Our powerful diagnostic approach has a much lower cost-per-test, a greater range of disease identification, and a shorter time to results than other cellular- and mRNA-based approaches. Immune IQ's initial focus is sepsis, one of the world's greatest healthcare challenges.

ImmunoMind is a UC Berkeley SkyDeck alumnus company, focused on understanding drug-human interactions to create more effective immunotherapies for underserved populations.

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry's most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome. 1. ROOTS 2022: Antibody Discovery Services and Platforms Market (Industry Trends and Global Forecast, 4th Edition), 2021-2035​; p.118

ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic. To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.

INanoBio’s mission is to develop high-accuracy early stage disease diagnostics using transformative nano-biotechnology platforms and machine learning. Extract systems scale information from complex disease biology, identify and detect disease specific molecular biomarkers, signatures at prodromal or pre-symptomatic stages. We believe most diseases can be detected early, enabling early personalized therapeutic intervention to preempt full development of diseases, ushering in preemptive medicine.

Inari is the SEEDesign™ company, using new breeding technology to push the boundaries of what is possible by designing nature-positive seeds for a more sustainable global food system. A combination of AI-powered predictive design and a pioneered multiplex gene editing toolbox enables us to unlock the full potential of seed and advance critical solutions with broad applications for growing more food with fewer resources.

Biological Software is one or more synthetic molecules that execute complex functions, specified from a program, in a biological system. We are creating tools to develop increasingly powerful biological software for the rational design of novel, broadly accessible medicines and biotechnologies previously out of reach. Our antedisciplinary team of scientists, machine learning researchers, engineers and entrepreneurs is growing. If you are excited to learn, teach, discover, and create together in pursuit of learning life's languages to improve the lives of billions of people around the world, please visit our website.

Indiana University is a Higher Education institution that provides academic programs and conducts research.

Indica Labs is a digital pathology company that specializes in advanced software solutions for medical imaging and analysis in the field of healthcare technology.

Inductive Bio is a biotechnology company based in San Francisco, California, founded in 2022. The company specializes in using advanced machine learning and data analytics to enhance the compound optimization process in small molecule drug discovery. With a seed funding of $4.3 million, Inductive Bio aims to address challenges in Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) during drug development. The company's core offering is a proprietary dataset combined with sophisticated machine learning models. This platform enables scientists to efficiently optimize initial compounds into viable leads and development candidates, providing real-time predictions and insights throughout the drug design process. Inductive Bio collaborates with pharmaceutical companies, biotech firms, and research institutions, including a partnership with Nested Therapeutics focused on precision medicine for challenging cancers.

InduPro is a biotechnology company that brings proteins on the cell surface closer together, manipulating their interactions and opening new possibilities for treating various conditions.

IndyGeneUS AI is a Black-Owned & Service-Disabled Veteran-Owned Small Business (SDVOSB) genomics company creating the world’s largest block-chain encrypted repository of indigenous and diasporic African clinical and multi-omics data for disease prevention/detection, drug discovery and development, clinical disease management, and precision health equity.

Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions. *Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.

InfoBionic.Ai's MoMe® ARC system empowers physicians with control to transform the efficiency with which they manage cardiac arrhythmia detection and monitoring processes for their patients. Leveraging a comprehensive, Cloud-based remote patient monitoring platform – the first and only of its kind – we deliver on-demand, actionable monitoring data and analytics directly to the physicians themselves. The MoMe® Kardia 3-in-1 device streams continuous ECG, respiration, and motion data to the Cloud for analysis, and delivers automated reporting to an iPad and or a web-based portal where physicians can access and interact with the data they need, in the detail they want – anytime, anywhere.

INNOVIMMUNE is a specialty Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule NME immunomodulatory drugs for the treatment of Autoimmune, Inflammatory and Oncologic Diseases. Follow us on Twitter: @Innovimmune

Insamo is a global biotechnology company pioneering the discovery of membrane-permeable and orally available cyclic-peptides with antibody-like binding.

Inscripta® is a life science technology company committed to creating a cleaner, healthier, and more sustainable world through biomanufacturing. A global leader in genome engineering, our innovations are designed to unlock the full potential of the bioeconomy. We are committed to the continued development of critical technologies that enable scientists to bolster and expand domestic biomanufacturing, and spur new, safe, and secure biotech innovations. Inscripta supports customers around the world from facilities in Pleasanton and Burlingame, California. To learn more, visit Inscripta.com and follow @InscriptaInc.

Buys life science software companies.

InsightRX empowers life science and provider healthcare organizations to individualize treatment from clinical development to the point of care.

Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.

insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We’re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes. This cannot be done without great people. We are bringing together an outstanding team of people whose expertise spans multiple disciplines - life sciences, machine learning, human genetics, engineering, and drug discovery - and building a unique culture where people from diverse backgrounds work as a single team towards a common goal. We offer opportunities to collaborative people with expertise in life science and computational science. Join us to help bring better health to more people, faster and cheaper.

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients in the United States. It also develops INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug for the treatment of rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

We combine synthetic biology and machine learning to control cellular stress responses for next-generation therapeutics.

Integro Theranostics is a clinical stage company developing fluorescent imaging agents and associated medical devices that enable surgeons to readily see and remove cancerous tissue. This accurate, real-time visualization of cancer tissue facilitates a more complete removal of cancer during surgery. Integro Theranostics was born out of a collaboration between Kingdom Capital (values based private investment company) and Washington University School of Medicine. We are combining the clinical infrastructure of a top research medical center, the technology of a world renowned scientist, and the resources of Kingdom Capital to commercialize this transformative technology and improve surgical outcomes for cancer patients.

Inteliquet, an IQVIA business, Inteliquet is a leading provider of innovative technology and comprehensive support services for cancer clinical researchers. We bridge sponsors, patients and cancer centers nationwide for the ultimate purpose of increasing patient access to cancer trial treatment options. From trial selection to patient matching, Inteliquet enables a streamlined and more accurate journey to patient enrollment. To learn more about Inteliquet, visit https://inteliquet.com/

InterVenn was co-founded by Nobel Laureate Dr. Carolyn Bertozzi, world-class scientist, and distinguished professor Dr. Carlito Lebrilla and leading AI/ML expert Aldo Carrascoso on the belief that no one should ever be blindsided by disease. We are focused on decoding the glycoproteome as a rich source of biological insight. Thanks to the use of artificial intelligence (AI), we have pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology at a clinically meaningful scale. GlycoVision is capable of producing a robust pipeline of powerful clinical applications, ranging from early disease screening to diagnostics and potentially therapeutics. The GlycoVision platform is accessible to industry partners seeking to discover novel biomarkers from as little as 50 µL of serum or plasma.

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.

InveniAI is pioneering AI and machine learning to map and identify breakthrough innovation across industries. Our platform, AlphaMeld, is an Artificial Intelligence (AI) based system that monitors millions of data points every day to identify signals for breakthrough events and provides a first mover advantage in detecting early signals of innovation. It combines human ingenuity and experience, with ceaseless, comprehensive and efficient machine learning that ensures no data point is missed in the pursuit of Alpha signals. AlphaMeld monitors developments daily across industries and rank orders them on their breakthrough potential. Visit www.inveniai.com for more details. Connect with us on Twitter: @Inveni_AI Careers: We are always on the lookout for talent to join our team at our US headquarters in Guilford, CT USA. We are not hiring at present. Please check back or contact us at +1 203 643 8002. Important Note on Our Hiring Process at InveniAI (inveniai) At InveniAI, we are committed to upholding the highest standards of transparency and integrity in everything we do. As part of our dedication to providing a fair and genuine hiring process, we would like to address a crucial matter. It has come to our attention that some individuals may be receiving fraudulent claims requesting money or personal information under the guise of being associated with InveniAI's hiring process. These unauthorized and fraudulent individuals are sending emails from domain names which are similar to our official domain name ‘inveniai.com’. When the recipient clicks on the domain name provided by the fraudulent individuals, they may be redirected to our website (www.inveniai.com). All individuals are requested not to communicate with any email id other than our official email id(s) that end with ‘@inveniai.com’. We want to make it clear that this is not how we operate, and we take this matter very seriously. Our Policy: No Course Registration: We want to emphasize that

Invenio Imaging is a medical device start-up based in Santa Clara, CA dedicated to advancing the care of cancer patients by combining intraoperative histologic imaging with artificial intelligence. Our technology, the NIO® Laser Imaging System has been used in over 2500 cancer treatment procedures at major cancer centers both in the US and in Europe. In 2021 Invenio received a Medical Design Excellence Award, was selected to be a Rosenman Innovator and received CE Mark to commercialize in Europe.

Invicro is a company in the medical imaging and biotechnology industry that specializes in imaging services for pharmaceutical and life sciences companies.

INVI MindHealth was founded at the University of Oxford and leverages learnings from the Health Pillar of The SEAL Future Foundation, a 501(c)3 co-founded by Jonathan. INVI combines the power of biometrics, deep learning analytics, and human networks to provide personalized mental health support.

ioGenetics

Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis. With MIBI technology and the expertise of world class pathology and data science teams, Ionpath provides actionable insights to translational and clinical researchers at leading pharma, biotech, and research organizations in immuno-oncology, immunology, neuroscience and infectious disease research.

IPA is a progressive, scientific Contract Research Organization (CRO) recently ranked by one of the pharmaceutical industry's most trusted, independent market research sources with the highest competitive score, for its antibody service portfolio.1 The company represents a HUB of biotherapeutic intelligence that includes a hybrid of experts and technologies, in the science and business of bioplatform-based discovery. We provide highly specialized full-continuum therapeutic antibody discovery, development, and out-licensing services [Talem] —with advanced omics and complex intelligence technology [LENSai] that provide greater efficiency and accuracy than ever before. Our mission is to provide our pharmaceutical customers with a HUB of the most advanced intelligence and technology to treat disease, bar none. Our goal — is to improve the specificity of biotherapeutics by unlocking the language of the genome. 1. ROOTS 2022: Antibody Discovery Services and Platforms Market (Industry Trends and Global Forecast, 4th Edition), 2021-2035​; p.118

IQVIA applies data science to the continuous advancement of human science to make health care decisions more precise, relevant, and even creative.

FUJIFILM Irvine Scientific is a worldwide leader in the innovation and manufacture of cell culture media, reagents, and medical devices for researchers and clinicians. The company provides unrivalled service and quality to scientists working in cell therapy and regenerative medicine, assisted reproductive technology and cytogenetics, and industrial cell culture for the large-scale production of biotherapeutics and vaccines. FUJIFILM Irvine Scientific adheres to both ISO and FDA regulations and operates dual cGMP manufacturing facilities in California, USA and Tokyo, Japan. The company's consultative philosophy combined with expertise in cell culture and compliance provides customers with unique capabilities and support. For over 50 years FUJIFILM Irvine Scientific has remained uniquely flexible and focused on media while becoming a strategic global leader in media products and services.

The iSono Health has developed the world’s first AI-driven platform with an automated, portable, and wearable ultrasound to empower women and their physicians with early breast cancer detection and monitoring. Our patented compact ultrasound scanner captures 3D images by automatically scanning the whole breast volume in 2 minutes. The device connects to a smartphone/tablet/laptop. The data is transferred to a secure cloud for image processing and storage. Our machine-learning algorithm uses acoustic biomarkers to identify abnormal masses. Our platform’s automated operation and software expand ultrasound use in point-of-care diagnostics and monitoring of breast health at radiology centers, walk-in, and mobile clinics. iSono Health offers women and healthcare providers : Safety: No Radiation Actionable Feedback with AI Fast: 2min Scan Easy to Use

IUPUI is a Higher Education institution that offers a wide range of academic programs and research opportunities.

We are on a mission to create the next century’s worth of impact on human health, starting with early detection. Since our founding in 2018, we have been operating at the convergence of artificial intelligence, transcriptomics and liquid biopsy — applying the most advanced compute to the most fundamental language of the human cell to create the world’s most advanced early detection blood tests. Our disease-agnostic platform is revolutionizing healthcare diagnostics, providing a reliable and scalable approach to solving real-world problems for pandemic diseases, from oncology to metabolic health. To date, our brain trust of visionary entrepreneurs and world-class scientists and technologists have conceived, created and scaled three pioneering early detection companies — @mammogen, @liquidlung & @hepgene — leveraging our novel end-to-end AI-powered platform to usher in a new era of clinical assays capable of detecting early-stage disease with unprecedented accuracy, affordability and accessibility. To learn more about us visit IVBH.studio or send us a note at info@IVBH.studio.

JADBio’s purpose-built AutoML platform provides leading-edge AI tools and automation capabilities enabling life-science professionals to build and deploy accurate and interpretable predictive models with speed and ease, even if they have no data science expertise. For life-science professionals, knowledge discovery is fundamental and sets the requirements apart when it comes to data analysis. JADBio can analyze small sample sizes or very large feature sets, focusing on feature selection and interpretation of the predictive model.

Jan Medical is a medical device start-up company dedicated to providing physicians critical data for accelerating and expanding therapy while improving the diagnostic experience for patients with brain disorders. Its proprietary platform technology, BrainPulse, uses accelerometers on a non-invasive headset to detect skull motion resulting from pulsatile blood flow into the brain. The BrainPulse system is an FDA cleared device for cranial motion measurement currently under research for a variety of neurological conditions. Jan Medical has developed clinical experience and collected valuable clinical data with the BrainPulse device in a variety of indications such as concussion, stroke, aneurysm, AVM, and vasospasm detection. Visit us at www.janmedical.com to better understand our company, our technology and our people.

At Janssen, we never stop working toward a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, and you can count on us to keep working tirelessly to make that future a reality for patients everywhere, by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Arterial Hypertension. Visit us: www.janssen.com Follow us: @JanssenGlobal on Twitter and Instagram Watch our videos on our YouTube channel: http://bit.ly/1LY2xQ5

Javelin Biotech makes predictive drug discovery platforms that merge human biology with computational biology to improve the speed and predictive power of preclinical testing. The Javelin platform combines human tissue chips, also known as organs-on-chip, with translational software to provide predictive solutions for drug discovery.

Jeeva Clinical Trials Inc. specializes in decentralized clinical trial solutions, offering a unified SaaS platform that enhances global patient engagement and streamlines trial operations. The company utilizes AI-powered tools and modular technology to support efficient trial management, allowing sponsors and medical centers to conduct studies under a single login. Their services include decentralized and hybrid trial solutions, patient recruitment and retention tools, and comprehensive clinical data management. Jeeva's platform features a next-generation Clinical Trial Management System (CTMS) for real-time oversight and protocol adjustments. The company prioritizes security and compliance, adhering to HIPAA, GDPR, and other regulatory standards. Jeeva has successfully implemented its solutions in oncology trials, achieving significant improvements in patient enrollment and data accuracy. They also support academic research, reducing costs and administrative burdens for campus-based studies. With a focus on scalability and workflow standardization, Jeeva provides a patient-centric approach to modern clinical trials.

JOGO Health uses wearable sensors and AI to treat chronic pain, migraine, post-stroke, and pelvic floor disorders using the foundational science of digital therapeutics.

Johns Hopkins University is a higher education institution known for its research initiatives and academic programs.

✨ Journey Biosciences is on a mission to shift the future of care. 🧬 Our flagship solution blends the precision of NaviDKD®, a clinically-validated predictive screening, with the AI-driven insights of Compass™, to offer up to 12 years of advanced diabetes-related kidney disease (DKD) detection, plus tailored intervention strategies to slow or prevent progression. 🎯 This approach improves patient outcomes, optimizes resource allocation, and reduces costs. 🔍 Discover more about our transformative approach at journeybio.life.

JuneBrain is an early start-up company based in the Washington, DC area. Our mission is to develop a telehealth eye-scanning system that allows clinicians to monitor patients with eye and brain disease outside of the traditional clinical setting, leading to earlier detection of new disease and improved monitoring of treatment efficacy. Though our mission begins in the eye care community, our long-term goal is to extend the use of our device into the broader neurological disease population, thus creating a pathway towards more frequent, widely accessible monitoring of eye and brain health.

Junevity is a biotech rewinding complex metabolic disease. Based on 6 years of breakthrough research at UCSF, Junevity's REWIND platform identifies high-level regulators of metabolic disease with known pharmacological pathways. Junevity is advancing multiple therapeutic programs towards a new era of medicines.

Juvena Therapeutics is a biopharmaceutical company that focuses on developing innovative therapies for various medical conditions.

Kailera Therapeutics (Kailera) (previously Hercules CM NewCo) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health.

Kailos Genetics provides consumers access to affordable physician-ordered genetic tests. It is our mission to help people take control of their health and make more informed decisions. The Kailos test is an easily accessible genetic test catered to your lifestyle.

Karius sees a world where infectious disease is no longer a major threat to human health. The Karius Test uses genomics and AI to map a patient’s microbial landscape from a single blood sample to enable clinicians to make rapid treatment decisions.

Kerna Labs is unlocking the full potential of mRNA as the universal toolkit for genetic medicine.

Kernal creates mRNA therapies to cure severe diseases including cancer. Our mRNA therapies instruct specific cells on how to make their own drugs. With roots at MIT, Harvard and Big Pharma, our team previously built a successful Biotech company and has deep expertise in mRNA space.

Kimia Therapeutics is generating a chemical atlas for treating human disease. Kimia's ATLAS is the key to druggable space, unlocking the potential of generative chemistry. The company is focused on drug discovery and developing disease-modifying therapies for metabolic diseases.

KiraGen Bio is pioneering the next wave of cancer treatment through AI-driven, multiplex gene-edited CAR-T cell therapies, targeting the challenging realm of solid tumors. Despite the transformative success of cell therapies in hematologic cancers, solid tumors — which constitute the majority of cancer cases — have remained elusive to current treatments due to their complex tumor microenvironment (TME). Our mission is to breach this final frontier, leveraging our proprietary AI platform and combinatorial gene editing to design CAR-T cells capable of overcoming the immunosuppressive barriers of the TME. Founded on the belief that every cancer patient deserves a chance at a cure, KiraGen Bio combines the latest in biotechnology and computational science to bring innovative therapies from the lab to the clinic. Our team, comprised of experts in oncology, immunology, gene editing, and artificial intelligence, is dedicated to creating effective, durable treatments for solid tumors. KiraGen Bio stands at the intersection of innovation and hope, where cutting-edge science meets the urgent need for more effective cancer treatments. Our integrated approach spans from discovery through clinical development, embodying a commitment to excellence, patient-centricity, and the relentless pursuit of curing cancer. Join us as we work to transform the landscape of cancer therapy and bring new hope to millions of patients worldwide.

Kiromic BioPharma is an allogeneic Gamma Delta T-cell therapy company featuring unique, proprietary, end-to-end bioinformatic, AI targeting, and manufacturing technologies to address solid tumors. We are a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic’s DIAMOND® AI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.

Kleiner Device Labs - Advancing Minimally Invasive Spinal Surgery™ During 25 years of active spinal surgical practice and over 6,000 surgeries, Dr. Jeffrey Kleiner became increasingly aware that instrument design and quality played a significant role in the clinical outcome of spinal surgery. He recognized key gaps in the instrumentation available to spinal surgeons and this led him to develop a series of innovative solutions. In 2013, Dr. Kleiner established Kleiner Device Labs to build and sell innovative spinal surgical products. These novel and advanced tools deliver improvements in efficiency and safety for patients and enable surgeons to perform more effective and less complicated fusion surgery. Kleiner Device Lab's first product, a Bi-Directional Graft Funnel (KG™1), works with any flowable biologic graft material, provides a more efficient and safer delivery vehicle for bone graft extenders, facilitates grafting in front of or alongside all types of interbody cages and can eliminate or reduce surgeon dependency on BMP. Building on the underlying philosophy behind the KG™1, Kleiner Device Labs developed the KG™2 Surge™ Flow-Thru Interbody Implant in 2021. No other device integrates implant positioning and graft delivery like the KG™2 Surge™. The system not only maximizes successful outcomes for patients (while simplifying the procedure for surgeons) but reduces costs for healthcare providers and insurers as well. Kleiner Device Labs has a broad patent portfolio and a runway of innovative minimally invasive spinal surgical products. These strategies are equally effective in open theater surgical technique as well.

Koidra is an intelligent automation company, dedicated to modernizing the automation of manufacturing facilities, with the high-tech greenhouse industry being the core market. Our tiered products deliver a comprehensive solution that enhances industrial efficiency.

Koios DS™ is a Smart Ultrasound™ solution for radiologists diagnosing cancer. Using AI algorithms trained on tens of thousands of images combined with data from pathology results, Koios DS™ is clinical decision support for a new era of diagnostic excellence. Smart Ultrasound™ redefines what radiology professionals can discern in the radiology suite. Our proprietary technology and patented methods provide an invaluable “second opinion” that is already being adopted by leading healthcare institutions to improve diagnostic accuracy, speed clinical decision making, and elevate the quality of care. Our software is FDA cleared for use in the USA. Koios DS. We put the AI in ultrasound.

Koliber Biosciences is a biotechnology company that accelerates biomedical discoveries using machine learning and artificial intelligence.

Koning Corporation develops and manufactures advanced medical imaging systems for breast cancer detection using cone-beam computed tomography technology. This revolutionary technology provides true 3D images for early breast cancer detection, providing a significantly more accurate and effective test than mammography and tomosynthesis. Koning's vision is to fundamentally change breast cancer is detected and diagnosed, with earlier detection, increased patient comfort and lower costs. We believe our Koning Breast CT will dramatically improve the way clinicians visualize and evaluate breast tissue. We believe that the power, versatility and lower cost of Koning Breast CT will serve as a viable substitute for many traditional imaging applications. Our hope is to be able to improve survival rates and outcomes for millions of patients. Koning Corporation's core technologies are protected by over 80 patents globally, and has received regulatory approval in the US (FDA), Europe (CE-Mark), China (CFDA), Australia (TPG), and Canada (Health Canada). Koning has been the beneficiary of over $17 M in venture funding and over $20 M in government grants to bring this exciting technology to market. Future versions of our technology are expected to optimize early disease detection, diagnosis, intervention and treatment in numerous areas of the body.

Korro Bio was founded to turn extraordinary scientific insights into life-altering new treatments for patients. We harness the body’s natural RNA editing machinery to make precise, single-base RNA edits to modulate protein function, addressing the medical needs of patients. Our mission is to rewrite the future for patients living with debilitating disease by repairing the underlying genetic cause.

Küleon is a drug discovery company leveraging proprietary, AI-based technology to identify novel serotonergic drugs for the targeted treatment of various neuropsychiatric diseases and disorders. We’ve created a proprietary portfolio of serotonin receptor ligands designed to target neurocircuit abnormalities in the brain that are responsible for difficult-to-treat disorders such as schizophrenia and depression. We have successfully identified several preclinical leads that have significantly improved agonism characteristics such as low-to-no hallucinogenic or cardiotoxic liability, as well as modified PK/PD profiles when compared to other known atypical antipsychotics and serotonergic drugs. Serotonergic drugs have the potential to address multiple indications affecting large population groups that make up extremely sizable markets. This is because many of the current SSRIs and non-selective serotonin receptor agonists were not designed with an eye towards functional selectivity. Our novel compounds are designed for functional selectivity via biased signalling mechanisms, potentially enhancing their therapeutic effect and reducing unwanted side effects. Our proprietary molecular scaffolds and compounds are novel and patentable, providing us with a tremendous strategic foothold in the market as companies continue to explore novel mechanisms of action for targeting neuropsychiatric diseases and disorders. We are collaborating with some of the world’s leading academic researchers and key opinion leaders in the serotonergic and atypical antipsychotic drug development space. Please reach out if you would like learn more about the work we are doing with our collaborators!

We are building next-generation products to transform how food testing is done, providing fast, accurate, and affordable testing solutions for consumers and businesses so they can test anytime and anywhere. At its core, Labby is an AI-powered spectrometer. It is portable and super versatile. It combines the power of optical sensing and machine learning so it can be used in many industrial applications beyond food.

Headquartered in Somerset, NJ with offices around the world, LabVantage Solutions, Inc. provides laboratories with a comprehensive portfolio of informatics products and services, including LIMS (Laboratory Information Management System), integrated electronic laboratory notebook (ELN) and business intelligence. Our industry-leading solutions and services are the result of 35+ years of experience in laboratory informatics. We leverage that knowledge with state-of-the-art technology to help organizations redefine and optimize the way their laboratories conduct business. LabVantage has a solid track record of delivering return on investment to laboratories of all sizes. Our capabilities extend to legacy system migration, global laboratory harmonization, and laboratory business intelligence derived from disparate sites and systems. LabVantage delivers the best technical and domain expertise available to help you drive the success of your business. To find out more, visit us at: http://www.labvantage.com.

Lantern Pharma Inc., a clinical stage oncology biotechnology company, focuses on the development of precision oncology therapeutics using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer. The company also develops LP-300 as a combination therapy for female non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers and is from the fulvene class of compounds. The company was incorporated in 2013 and is based in Dallas, Texas.

Lattice Automation provides complete solutions to fundamentally change the way that biological designs are conceived, designed, physically created, and managed. Our technology builds upon state-of-the-art techniques in computer science, electrical engineering, and bioengineering. We're hiring!

Layer Health is a healthcare AI company spun out of MIT and backed by GV (Google Ventures), General Catalyst, MultiCare Health System and Froedtert Health. We are solving the information problem in healthcare.

Laza Medical is a healthcare technology company based in California, founded in 2020. As a portfolio company of Shifamed, it focuses on developing innovative solutions for cardiovascular interventions. The company specializes in AI-powered robotic assistance technology, which enhances medical imaging and procedures. Laza Medical's main offering is an advanced imaging solution that supports cardiovascular interventions. This solution utilizes AI and robotic technology to provide navigation tools for structural heart and electrophysiology procedures in cath labs. The company aims to improve the precision and efficiency of these medical procedures through its technology. In December 2023, Laza Medical raised $36 million in a Series A funding round, led by The Capital Partnership, with participation from investors like Unorthodox Ventures and GE Healthcare Financial Services. With its innovative approach and strong funding support, Laza Medical is positioned to make a notable impact in the medical technology field.

Leash Bio is a biotechnology company that is transforming drug design with a rich dataset built by screening millions of compounds against thousands of proteins to generate billions of data. They are pioneering AI-driven medicinal chemistry and unleashing machine learning to solve medicinal chemistry.

Leica Biosystems is proud to be part of Danaher. Danaher's science and technology leadership puts Leica Biosystems' solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day. -- Leica Biosystems Privacy Policy can be found at: https://www.leicabiosystems.com/about/privacy-policy/ The collection, storage, use, disclosure, retention and destruction of data on this page, including any personal data, are all subject, as applicable, to Leica Biosystems' Terms of Use and Privacy Policy. We do not endorse or approve user generated content to promote any other use of our products and will remove any comments or references to such off-label use. We reserve the right to remove a topic or comment at our discretion. By accessing the content, you expressly acknowledge and agree: (1) the content is provided only as a convenience to you and you are accessing the content for your personal educational purposes only; (2) the content may be from a variety of sources over which Leica Biosystems has no control, and should therefore not be interpreted as representing the opinions of, or an endorsement by, Leica Biosystems or its associates; (3) the content is provided to you AS IS, and you release Leica Biosystems of any responsibility or damages you may suffer as a result of the content, including without limitation, any damages resulting from the inaccuracy or unsuitability of the content.

Leica Microsystems develops and manufactures microscopes and scientific instruments for the analysis of microstructures and nanostructures. Ever since the company started as a family business in the nineteenth century, its instruments have been widely recognized for their optical precision and innovative technology. It is one of the market leaders in compound and stereo microscopy, digital microscopy, confocal laser scanning microscopy with related imaging systems, electron microscopy sample preparation, and surgical microscopes. Leica Microsystems has seven major plants and product development sites around the world. The company is represented in over 100 countries, has sales and service organizations in 20 countries, and an international network of distribution partners. Its headquarters are located in Wetzlar, Germany. Leica Microsystems is proud to be part of Danaher Danaher's science and technology leadership puts solutions from Leica Microsystems at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher's other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.

Leuko is developing the first non-invasive white blood cell device. White blood cell assessment is a first-line indicator for various medically-relevant situations, ranging from chemotherapy management to the detection of life threatening infections worldwide. This test is currently invasive and not readily accessible - it requires patient travel, blood draws and laboratory infrastructure. Based on MIT research, Leuko is re-imagining the way to perform these tests without extracting blood and in a portable device.

LifeAdapt is at the forefront of AI technologies that promote healthy living.

SVBio is now LIfecode, Inc. We are focused on the genetic basis of human disease. With an initial focus in oncology, Lifecode is committed to improving the lives of patients through molecular information that is concise, accurate and actionable. The long-term vision of Lifecode is to revolutionize the world of genomic medicine.

LifeMap Sciences offers a leading integrated biomedical knowledgebase for empowered life sciences research and precision medicine, and a powerful advertising products for research reagents. Our products are used by more than 5 million researchers from both academia and the biopharma industry. GeneCards (www.genecards.org) is a searchable, integrative database that provides comprehensive, user-friendly information on all annotated and predicted human genes. The knowledgebase automatically integrates gene-centric data from ~150 web sources, including genomic, transcriptomic, proteomic, genetic, clinical and functional information. MalaCards (www.malacards.org) is an integrated database of human maladies and their annotations, modelled on the architecture and richness of the popular GeneCards database of human genes. Today, it offers information about 22,060 disease entries, consolidated from 74 sources

LifeNome's AI algorithm looks at 9000+ genetic variations holistically (rather than other companies that look at single gene associations)to assess your overall predispositions for nutrition, fitness, skin care and many more wellness traits.​

Ligandal is a genetic medicine company that uses nanotechnology to develop targeted and personalised therapies. As a regenerative medicine biotechnology company, Ligandal develops ultra-rapid therapeutics and vaccines for outbreaks and pandemics, in addition to its work in immuno-oncology and rare genetic diseases. Our current focus is on delivering a peptide-based cure to the COVID-19 pandemic (SARS-CoV-2 coronavirus), as part of a broader mission of enabling personalized medicine on a global scale through the power of nanomedicine and gene therapies. Given that increasingly complex disease states require precise and custom-tailored medicine, much of our technology development has focused on combining gene therapy with targeting peptides to enable completely new paradigms in evolutionary medicine. Currently, we are utilizing a peptide nanoscaffold based approach for treating COVID-19 without a gene therapy component, with the goal of creating a combined antidote-vaccine. My expertise lies in targeted gene delivery, nano- and biomaterials, computational modeling of peptides, binding simulations, immunoengineering, as well as CRISPR and TALEN based gene editing. At Ligandal, we have demonstrated peptide-based delivery of CRISPR, RNA, DNA, siRNA, and a range of genes or proteins to virtually any cell type.

Lila is a technology company pioneering the application of artificial intelligence to transform every aspect of the scientific method.

Lindus Health is an anti-CRO running radically faster, more reliable clinical trials for life science pioneers – bringing ground-breaking treatments to patients more quickly. This is achieved through a commercial model that aligns incentives (fixed-priced quotes per study, with milestone-based payments), a world-class clinical operations team with its unique software platform, and access to over 40 million Electronic Health Records. Clinical trials are the biggest bottleneck to advances in healthcare. Lindus Health removes this constraint through end-to-end execution of clinical studies driven by technology and forward-thinking approaches to clinical operations.To date, Lindus Health has delivered clinical trials across the US, UK and Europe to tackle a range of conditions, including diabetes, asthma, acne, social anxiety, major depressive disorder, hypertension, chronic fatigue syndrome and insomnia. The company has raised over $80M from investors including Peter Thiel, Balderton, Creandum, Firstminute Capital, and Seedcamp.

Livongo is now a part of Teladoc Health. Teladoc Health is transforming the healthcare experience and empowering people everywhere to live healthier lives. Recognized as the world leader in whole person virtual care, Teladoc Health uses proprietary health signals and personalized interactions to drive better health outcomes across the full continuum of care, at every stage in a person's health journey. In more than 175 countries and ranked Best in KLAS for Virtual Care Platforms in 2020, Teladoc Health leverages more than a decade of expertise and data-driven insights to meet the growing virtual care needs of consumers and healthcare professionals. For more information, please visit www.teladochealth.com or follow @TeladocHealth on Twitter.

We connect customers with integrated solutions & predictive technologies to ensure they stay ahead of emerging threats. Headquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.

Next generation CRISPR technology for programmed cell death. Focused on developing therapies for infectious disease and the microbiome. Locus Biosciences’ novel approach to precision antimicrobials works by taking advantage of a part of an immune system present in many bacteria called the CRISPR-Cas system. The CRISPR-Cas system protects bacteria from invaders such as viruses by creating small strands of RNA called CRISPR RNAs, which match DNA sequences specific to a given invader. When the CRISPR RNAs find a match, they activate Cas proteins that cut the DNA.

LTZ Therapeutics is an immunotherapy-focused global biotech company pursuing innovative therapies in oncology and autoimmune diseases. Pioneering a novel myeloid engager platform that is guided by reverse translational science, emerging disease biology, and leveraging the power of myeloid cell subsets, particularly macrophages, which offer tremendous potential as an effective therapy to improve the lives of patients with the bold aim to one day eliminate cancer.

LungLife is a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence. The Company's diagnostic solutions are designed to make a significant impact in the early detection of lung cancer. The Company's technology is a combination of the recovery of rare cells and blood-based biomarkers shown to be altered in lung cancer. The Company employs machine learning to improve biomarker detection, and intends to build a deep, novel pool of lung cancer-related data for AI-enabled applications designed to improve its diagnostic solutions over time. The Company's core technologies are integrated in the LungLB® test, which is intended to be used as a tool to provide physicians with additional information to help in the decision-making process for people with indeterminate lung nodules that may be lung cancer following a CT scan. There are estimated to be over 1.5 million individuals with indeterminate lung nodules diagnosed each year in the United States. The LungLB® test may have additional utilities, the most significant of which is likely to be in monitoring individuals for recurrence following surgical removal of cancerous lung nodules. The Company has completed a 149 subject pilot study to evaluate the LungLB® test, which showed a well-balanced performance and a Positive Predictive Value of 89 per cent. The Company is now gearing up to proceed to a larger, multi-centre validation study to garner regulatory and reimbursement support and facilitate commercialisation.

For organizations committed to providing the best behavioral health, human services, or wellness care, Lyssn's AI is the modern evidence-based quality improvement and training solution that provides visibility into human interactions and integrates expert-developed best practices so organizations can measure, train, and improve evidence-based practice at scale while meeting regulatory requirements. And, Lyssn requires dramatically less labor than current approaches with superior results at lower cost.

Mammoth Biosciences is a biotechnology company focused on leveraging its proprietary ultracompact CRISPR systems to develop long-term curative therapies, as well as other applications such as decentralized precision diagnostics. Founded by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington, the company’s ultracompact proteins are designed to enable in vivo gene editing in difficult to reach tissues utilizing both nuclease applications and new editing modalities beyond double stranded breaks, including base editing, gene writing, and epigenetic editing. The company is building out its pipeline of potential in vivo gene editing therapeutics and capabilities and has partnerships with leading pharmaceutical and biotechnology companies to broaden the reach of its innovative and proprietary technology. Mammoth’s deep science and industry experience, along with a robust and differentiated intellectual property portfolio, have enabled the company to further its mission to transform the lives of patients and deliver on the full promise of CRISPR technologies.

Mana.bio is an AI based drug delivery startup, creating a platform for Lipid Nanoparticle (LNP) development for oligonucleotide therapies including mRNA-based therapeutics, vaccines and gene therapy.

Manas AI is a full-stack, AI-driven drug discovery company. By harnessing the power of proprietary AI models and leveraging extensive computational infrastructure, the company aims to dramatically reduce drug discovery timelines. Co-founded by Dr. Siddhartha Mukherjee and Reid Hoffman, and a world-class interdisciplinary team that spans AI, computational chemistry, biology, and clinical research, Manas AI is on a mission to bring life-saving treatments to patients faster than ever before.

Manifold Bio is a therapeutics company with an unprecedented advantage in engineering precision biologics. We have developed the world’s first high-throughput in vivo drug design platform, enabled by a novel protein barcoding technology and other innovations at the interface of molecular biology and compute. Our mission is to make the best life-saving drugs available to patients as quickly as possible. We’ve brought together a team with unique expertise in library-guided protein engineering combining DNA synthesis, sequencing, and advanced bioinformatics and machine learning. We’re growing and we’re looking for those who are excited about the potential of our novel approach to engineering biology.

Guided by the needs of our patients and their families, Massachusetts General Hospital aims to deliver the very best health care in a safe, compassionate environment; to advance that care through innovative research and education; and, to improve the health and well-being of the diverse communities we serve. Visit our careers page! http://www.mghcareers.org

Massive Bio collects and curates the latest scientific knowledge in genomics of cancer, connects with clinical information incorporate all new discoveries in treatment plans.

Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.

Mateon Therapeutics is developing OXi4503 for the treatment of acute myeloid leukemia. OXi4503 has a unique dual mechanism of action which causes the release of leukemic stem cells from the bone marrow and enables their destruction.The company is also using artificial intelligence to develop treatments for coronavirus.

Developing novel serpin-based therapies for the treatment of fibrosis and fibroproliferative disorders.

MedCognetics provides an advanced AI software platform which integrates into the radiology workflow. The AI platform is trained on a diverse global patient dataset to mitigate data biasing. The future of AI in healthcare is unbiased services and MedCognetics is at the forefront of creating more predictable medical outcomes and ultimately saving lives. Founded in 2020, the company is based in Dallas, Texas. For more information, please visit our website at www.medcognetics.com.

Medeloop accelerates breakthrough discoveries through novel deep AI model explainability techniques built on top of a comprehensive data linkage infrastructure. Medeloop is a one of a kind platform that seamlessly links, harmonizes, and analyzes massive amounts of health data. We are pioneering AI techniques that find biomarkers for clinical researchers, helping break down barriers to save lives. For Researchers: Our platform shortens the clinical research process using advanced AI techniques that provide research hypotheses for even the most understudied diseases. All of your data, all in one place. Cleaned, organized and analyzed. Medeloop transforms the research approach, enabling researchers to publish more and publish faster. For Research Participants: Our patient-facing app encourages the public to take control of their health and contribute to life-changing medical research. You always have access to view your health information and how it is being utilized.

Mednet is a leading healthcare technology company specializing in eClinical solutions designed for the global life sciences community. Pharmaceutical, medical device, biotechnology, academic institutions, and Contract Research Organizations (CROs) around the world have trusted Mednet for over 23 years to deliver the technology innovation, experience and reliability they need for success. Mednet's comprehensive, EDC-centric eClinical platform, iMednet, optimizes clinical studies of all types and sizes – accelerating research with exceptional flexibility, ease-of-use, robust functionality, affordability, and stellar support. iMednet is feature-rich and uniquely designed to help sponsors and CROs get studies up and running quickly and to see them through with a full suite of native capabilities, including: randomization, trial supply management, adjudication, ePRO, payments, DICOM Imaging, and eConsent. All backed by a highly tenured and experienced support team, ensuring quality, compliance and easy onboarding of the entire research team and clinical trials sites. For more information, visit mednetsolutions.com. Mednet Solutions, Inc.

Patient populations and their medications are continuously moving. MedTek21 ensures your entire patient base is continuously monitored for potential drug/gene interaction risks, allowing you to focus your care.

Medtronic plc is an Irish medical device company. The company's operational and executive headquarters are in Minneapolis, Minnesota, and its legal headquarters are in Dublin, Ireland. Medtronic operates in more than 140 countries and employs over 90,000 people worldwide. The company is the world's largest standalone medical technology development company.

Melio is developing a clinically actionable fast and comprehensive test for all common infections

MeMed is a leading med tech and bio-convergence company, having developed innovative diagnostic host immune response testing methods that address complex clinical dilemmas and improve patient outcomes. Our mission is to translate the complex signals of the immune system into simple diagnostic insights that transform the way we treat infectious diseases and inflammatory disorders – at the right place and the right time.

MemVerge is a pioneering developer of software for Big Memory Computing. In the cloud or on-premises, data-intensive workloads run faster, cost less, and recover automatically with the company’s award-winning Memory Machine™ products. Memory Machine X is poised to revolutionize how CXL® memory will be used in the future, while Memory Machine Cloud stands out with its ability to continuously right size cloud cost and performance. Learn more about MemVerge and its Memory Machine software at www.memverge.com.

Mendel AI is the only clinical AI platform that performs clinical reasoning to supercharge clinical data workflows. Powered by coupling large language models with a clinical Hypergraph, Mendel's AI copilots, known as Hypercubes, offer clinically trustworthy and explainable insights, streamlining tasks like cohort building, chart review, and data discovery. Mendel's solutions cater to biopharma, providers, and diagnostics, integrating seamlessly with existing tools and delivering proven results We strive for excellency, to be authentic and original, and to make a difference by greeting our challenges head on. Please visit our website, mendel.ai, to learn more about our company, goals, and values.

Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.

The METiS platform (AiTEM) combines state-of-the-art AI data-driven algorithms, mechanism- driven quantum mechanics and molecular dynamics simulations to calculate Active Pharmaceutical Ingredient (API) properties, elucidate API-target and API-excipient interactions, and predict chemical, physical and pharmacokinetic properties of small molecule and nucleic acid therapeutics in specific microenvironments. This enables efficient lead optimization, candidate selection and formulation design. Founded by a team of MIT researchers, serial entrepreneurs and biotech industry veterans, METiS develops and in-licenses novel assets with high therapeutic potential that could benefit from its data-driven platform.

Microsoft is a technology company that offers a wide range of software, cloud computing services, hardware, and artificial intelligence solutions.

Micro Systems Engineering, Inc. (MSEI), with its main office in Lake Oswego, Oregon, is is a pioneer in developing innovative implantable medical device technologies and devices that save and enhance the quality of life for millions of patients across the globe. With more than 40 years of experience in design and manufacturing active implantable medical devices, our continuing success is based on our company's core values – innovation, quality, reliability, integrity, teamwork, and undisputed expertise – thus enabling us to inspire confidence and trust in physicians and patients worldwide. MSEI has two main divisions, Operations and System Design & Development. With over 400 technical staff including physicists, electrical, software, biomedical and materials engineers, MSEI employs an elite team of the brightest minds in the medical technology industry. The Operations division is a specialist in medical microelectronics manufacturing including development, design, testing, supply chain and system integration for medical technology, in particular for active implants in the area of CRM (cardiac rhythm management) and other medical applications. The Operations division is dedicated to the innovative design and quality construction of electronic modules used in implantable medical devices. System Design & Development is the innovation center for next generation class III active implants. This includes full system design, clinical research, hardware and software, as well as the design and test of application-specific integrated circuits (ASICs). The resulting products deliver life-saving therapies to patients accurately and reliably across the globe.

Mid-Atlantic BioTherapeutics (MABT) was founded in 2011 with the mission of eradicating terrible infectious diseases using a novel, patented technology platform called IMT504. IMT504 harnesses the body’s own immune response to fight off infections that would otherwise be difficult or impossible to treat. IMT504 has shown impressive results in animal safety and efficacy models, and in humans. IMT504 is a truly revolutionary, proprietary molecule with an impressive safety and immunostimulatory profile in humans and multiple primate models. The immune system-based therapy that IMT504 uses is called “immunotherapy”. Our focus on immunotherapy offers partnering and collaboration opportunities in the area of Infectious Disease applications. Fundamentally, we are a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases (eg, Tamiflu alternative for influenza), emerging infectious diseases and biodefense. In addition, MABT is the first company to have received a valuable regulatory incentive called Orphan Drug Designation for late-stage rabies disease. Orphan Drug Designation offers a unique opportunity for ensuring a more rapid, efficient pathway to FDA approval and extended market exclusivity. Since the company’s inception, the founders have been responsible for funding the development of the IMT504 technology platform, investing over $23M to date. They continue to invest in this promising new therapy to develop therapies to impact disease with innovative treatments.

Focus on women's heatlh

Mindera Health™ is commercializing scalable extraction technology and data analysis to report a patient’s individual transcriptomic data. Mindera’s technology creates Dermal Intelligence™, actionable information for payers, providers and patients. The company’s flagship test, Mind.Px, uses both a dermal biomarker patch and Machine Learning to determine a patient’s receptivity to very expensive psoriasis biologics. This information is valuable to payers, who can save thousands of dollars per biologic patient using Mind.Px at the outset of prescription. Mind.Px is the first test in a large planned product pipeline, including psoriatic arthritis and eczema biologic receptivity.

Mirador Therapeutics is a next-generation precision medicine company focused on immunology and inflammation. The company's Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to accelerate the next generation of precision medicines for immune-mediated diseases.

We're Mirai Bio, biotech's first open end-to-end development platform company for co-creation of optimized #GeneticMedicines. Learn more at MiraiBio.com.

The Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts. MIT is devoted to the advancement of knowledge and education of students in areas that contribute to or prosper in an environment of science and technology.

Model Medicines is an AI-driven, human health company using AI to model all of chemistry and human biology, to accelerate the creation of life-changing drugs. The company was founded in 2019 to deliver on the promise of AI-Drug discovery. With more than 182 compounds for 26 targets, they are delivering on the promise of AI-drug discovery. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. The company is based in La Jolla, CA.

Modicus Prime's Self-Service software places cutting-edge AI where it belongs: in the hands of biotechnology experts. Our computer vision solution, mpVision, provides intelligent image analysis to monitor biologics at any scale. mpVision has been tested by scientists in a Top 10 Pharma company supporting our mission to eliminate contamination from the pharmaceutical industry. These contaminations cost 100’s of millions of dollars per incident as illustrated by the recent Covid vaccine 60 M incident experienced by J&J/AstraZeneca/Emergent. Such unmet needs of the Life Sciences industry, including real-time product quality assurance, full agency compliance, faster go-to-market, and reduced operating costs, are being met with Modicus Prime’s Self-Service AI solution.

Modulo Bio simulates the neuroimmune system to find medication candidates that target microglia cells. The organization's proprietary neuroimmune system mapping platform is designed to identify potential treatments for neurodegenerative diseases such as ALS and FTD.

We are a tech-centered, animal diagnostics company on a mission to help veterinarians lengthen the lives of their patients by applying deep learning to the diagnostics they use daily.

MOMA Therapeutics is a clinical-stage, next-generation precision medicine company dedicated to targeting highly dynamic proteins that underlie human disease via a small molecule approach, utilizing its proprietary KNOMATIC platform. The platform was designed to exploit key vulnerabilities inherent to all dynamic proteins, namely their dependence on well-coordinated, stepwise changes in protein conformation. By focusing on genetically validated targets with high translation potential MOMA is rapidly advancing its pipeline toward responses in the clinic. In January 2024, MOMA announced a five-year discovery collaboration with Roche focused on critical cancer dependencies. We are unapologetically scientific, and we know this will help us achieve our mission to get new medicines to people in need. We’ve removed the bureaucracy and believe having a teammate’s back is critical to our success. You see, MOMA isn’t your typical biotech company. We are drug discovery professionals, industry specialists and scientific experts. More importantly, we’re collectively unstoppable.

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn’s disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.

Moonwalk Biosciences is an early-stage therapeutics company co-founded by Dr. Feng Zhang and leading experts in cell state epigenetics including Alex Aravanis, the former CTO of Illumina. The company has developed a differentiated approach to mapping the epigenome of cellular states at the whole genome, single cell resolution level, as well as proprietary strategies for precise epigenetic engineering. The combination enables both a novel discovery platform and a path to developing therapeutics that include both epigenetic engineering and other traditional modalities.

Morgridge Institute for Research is a scientific research institution that focuses on biomedical research and innovation.

Morphoceuticals is pioneering the bioelectric reprogramming of biology. They are focused on organogenesis and organ regeneration without transplantation. The company has successfully achieved limb regeneration in adult frogs using a novel drug combination.

The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care. WHO WE ARE We are compassionate collaborators—38,000 strong—working to heal, teach, and advance medicine in New York City and throughout the world. WHAT WE BELIEVE We believe in challenging the status quo. Forging a new pathway in clinical excellence is only possible by putting the patient at the center of the experience. WHY WORK WITH US Here, innovation is valued and collaboration is integral. Mount Sinai is full of friendly, helpful people who share a common devotion to delivering exceptional patient care. Yet we’re as diverse as the city we call home—culturally, ethnically, in outlook and lifestyle. When you join us, you become part of Mount Sinai’s unrivaled record of achievement, education, and advancement as we revolutionize healthcare together.

We develop AI and wet-lab technologies that enable the rational design of developable, selective, and functional drugs against previously undruggable targets. To maximize the patient impact of our platform, we collaborate with leading pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb and Takeda, to expand their pipelines with high-quality drug candidates. If successful we could double the number of disease-relevant drug targets the industry advances for drug development. Since launching in 2021 we have raised $37 million with the backing of leading investors, including Radical Ventures, Khosla Ventures and Zetta Venture Partners. Our technical team is based in Cambridge, Massachusetts and continues to recruit top machine learning and synthetic biology talent. For more information check out the Careers section of our website at www.nabla.bio.

Nanite is a next-generation non-viral gene delivery company developing a new class of programmable polymer nanoparticles for a range of modalities and indications. The company’s AI-driven platform, SAYER, combines cutting-edge high-throughput experimental and computational methods to design fit-for-purpose delivery vehicles delivering a broad range of genetic cargoes with tissue specificity.

National Institute of Standards and Technology is a government agency that sets standards, conducts research, and promotes innovation in technology and measurement.

Nephrogen is a therapeutics company developing transformative medicines for kidney disease. Their initial focus is on gene therapy for autosomal dominant polycystic kidney disease (ADPKD).

Nereid starts with approaches to see and measure the biomolecular forces driving phase separation, amplifying insights with machine learning, and accelerating translation with cell biology and medicinal chemistry. Nereid’s platform uses physics to discover therapeutics that can modify the phase behavior of livingcells.

We are Nested Therapeutics, a biotech company inspired by service and driven by a desire to make a meaningful impact. We are creative innovators who challenge our own assumptions as we strive to find new, overlooked areas of opportunity to design therapeutics for a perfect fit. We embrace diverse perspectives and experiences in a space for everyone to add value and be valued in return, with the purpose of building solutions together while having fun doing it. United through our common vision for the future of precision medicine and our shared values of service, humility, impact, invention, and connection, we’re determined to dramatically expand the reach of precision medicine and make first- and best-in-class precision oncology treatments available to a larger population.

While our healthcare system has increasingly embraced virtual health in many areas to accelerate access to care, in-person care for patients with cognitive conditions remains the status quo - but Neuroglee Health is making virtual cognitive care a reality. We partner with medical groups to serve as your practice's virtual cognitive care extension – enabling you to provide immediate access to evidence-based care for patients with cognitive disorders and highly coordinated, guided support for the caregivers they rely on. Through our virtual care model, which we developed in collaboration with Mayo Clinic, Neuroglee Health is leaning in to disrupt the status quo. Our partners gain timely access to our team of expert multidisciplinary specialists and powerful, award-winning digital tools: a patient app, care partner app, and clinician dashboard, which optimize patient and caregiver engagement, deliver actionable data-driven insights, and enable coordination across the patient's extended care team. When combined, Neuroglee Health helps patients improve cognition, enhance quality of life, and prolong patient independence, while reducing provider and caregiver burnout. We are on a mission to improve the lives of individuals with cognitive conditions and their loved ones. Join us at www.neuroglee.com.

Neuron23™ Inc. is a leading clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases. Neuron23 combines recent advances in human genetics with a state-of-the-art drug discovery and biomarker platform using advanced techniques in machine learning and artificial intelligence to advance therapeutics for devastating diseases. The Company’s focus areas are neurodegenerative diseases, neuroinflammatory diseases, and systemic autoimmune and inflammatory diseases. Founded in 2018, Neuron23 has assembled a world-class team of experts and entrepreneurs located in South San Francisco, CA.

Neuvotion is developing breakthrough solutions for facilitating and restoring movement. Our approach combines targeted neurostimulation and AI (artificial intelligence) to deliver unparalleled therapeutic value for patients with a movement disorder or impairment from stroke or injury. Neuvotion products allow doctors and therapists to leverage state-of-the-art technology, while monitoring patient progress in-person or remotely.

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Nexilico is an early-stage biotechnology startup that employs the power of computational biology and AI to address challenging problems in medicine and biotechnology. As a pioneer in the next generation in silico microbiome technologies, Nexilico advances scientific understanding about the role of microbiomes in health and disease and leverages that information to develop novel microbiome-based technologies

At NextGen Jane, we believe in enriching your Quality of Life, expanding your Agency, and enabling your Pursuit of Data. All good revolutions are anchored in coherent philosophies championed by an impassioned base. This is our revolution, to empower women with the information needed to make smart decisions and take true health ownership. Armed with our SmartTampon platform that serves as a sentinel system for your reproductive health, we hope to impact how you manage your health, from menarche to post-menopause. If you dig it, join us. It is hard to create new ways of engaging with our health in rigid systems within a complex care system, but not impossible. Help us re-engineer our future, in our image.

nference leverages the top academic minds, world-class researchers, and real-time access to multimodal, patient-level data to accelerate drug development innovation, generate evidence, and improve clinical trial processes. nSights, our flagship software platform, delivers the most comprehensive biological and clinical insights into patient care.

Nimble Therapeutics is a biotechnology company dedicated to delivering on the promise of oral peptide therapeutics. Leveraging a paradigm-shifting peptide drug discovery and development engine, Nimble is advancing its internal pipeline and continues to support several partnered programs. The Nimble platform combines massively parallel solid-phase synthesis, unrivaled chemical and structural diversity, sophisticated assays, and powerful machine learning and computational methods.

NImmune is a late-stage precision immunology biopharmaceutical company that develops best-in-class biomarker-driven immunoregulatory therapeutics. Underpinned by advanced computational modeling and bioinformatics coupled with biomedical research capabilities to pioneer innovation in immunoregulatory drug development, NImmune’s business model enables the rapid and capital-efficient clinical development of high conviction drug candidates into New Drug Application (NDA) filing and commercialization. NImmune’s clinical development pipeline includes omilancor, a Phase 3-ready lead clinical candidate targeting LANCL2, an oral, once-daily, gut-restricted, first-in-class therapeutic for Ulcerative Colitis and Crohn’s disease with registration-directed pivotal clinical trials planned for 2023.

Noah Medical is a medical technology company based in San Carlos, California, founded in 2018. The company specializes in developing advanced medical robotics aimed at enhancing diagnostic procedures in pulmonology. Its flagship product, the Galaxy System, is a robotic platform that integrates real-time navigation, augmented fluoroscopy, and tomosynthesis to improve the accuracy of lesion localization, which is vital for early lung cancer diagnosis and treatment. With a team of over 150 engineers and industry experts, Noah Medical leverages extensive experience from leading healthcare companies. The company's mission focuses on saving lives through early diagnosis and treatment, particularly in robotic navigated bronchoscopy. Noah Medical has received recognition as a "Fierce 15" company of 2023 and has raised $150 million in funding to support its innovative approach. Its technology is designed to enhance procedural efficiency and diagnostic accuracy in healthcare facilities, particularly in pulmonology and oncology.

Nobias Therapeutics is a clinical-stage company developing novel small molecule therapeutics for rare diseases. Our unique access to rich genomic and health datasets and strong relationships with pediatric academic medical centers across North America allow us to rapidly advance drug discovery for genetically-defined rare diseases, with an initial focus on pediatric indications, but expansion opportunities in adults and non-rare indications.

Noetik is an AI-native biotechnology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision immunotherapies.

Northrop Grumman solves the toughest problems in space, aeronautics, defense and cyberspace to meet the ever evolving needs of our customers worldwide. Our 95,000 employees define possible every day using science, technology and engineering to create and deliver advanced systems, products and services.

Notable is a clinical-stage platform therapeutic company developing a new class of precision medicines: predictive precision medicines. Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatment: patient population by patient population, and cancer by cancer. By transforming historical standards of care, Notable expects to provide dramatic impact for patients and the healthcare community. Notable's proprietary Predictive Precision Medicines Platform replicates ex vivo the clinical response of patients to cancer treatments with high fidelity, through its optimized integration of biological assay conditions, dynamic signal analysis, and AI-driven in-silico translation into predictive algorithms. Using its high-fidelity platform, Notable can identify and select clinically responsive patients prior to their treatment and fast-track clinical development in this patient population. Notable has created a targeted, triple de-risked in-licensing strategy and a fast-track clinical development approach that delivers a product's medical impact and commercial value faster, higher, and more likely than traditional drug development.

NovAccess Global is a biomedical company accelerating and investing in novel cancer diagnostics and therapeutics.

In 2023 NeuraSignal, Inc. acquired the business of NovaSignal, the original developer of NovaGuide. NeuraSignal is a medical technology company with a mission to save lives by unlocking the power of cerebral blood flow data. The company's FDA-cleared NovaGuide Intelligent Ultrasound combines non-invasive ultrasound, robotics, and artificial intelligence to assess cerebral hemodynamics in real time. Using cloud computing and data analytics, NeuraSignal supports physicians in their clinical decision making in several neurological conditions including stroke, traumatic brain injury, and dementia. To learn more, visit www.NeuraSignal.com.

Novopyxis is a biotechnology company that specializes in the development of therapeutics and medical devices using proprietary mathematical algorithms for drug validation across various models.

Nth Analytics pharmaceuticals consultants: CDISC SDTM/ADaM, biostatistics, and SAS programming.

Develops a diagnostics platform.

NuMedii is a biopharmaceutical company that discovers and de-risks effective new drugs by translating Life Sciences Big Data into therapies with a higher probability of therapeutic success.

nView medical, based in Salt Lake City, UT, is a startup whose mission is to make surgery safer, faster, and consistently accurate. nView develops imaging technology — bringing breakthrough AI solutions for image creation, image processing, and image visualization to surgery and interventional radiology. nView medical backers include the National Science Foundation (NSF), the National Institutes of Health (NIH), the State Of Utah, the National Capital Consortium for Pediatric Device Innovation, MedTech Innovator, HealthTech Arkansas, Dr. Kevin Foley, M.D., and Fusion Fund (Palo Alto, CA). Its founder, Cristian Atria, has had a progressive career with GE Healthcare in positions that range from development engineer to general manager with P&L responsibility. He has successfully assisted start-up and public companies with technology transfers, licensing, product development, regulatory approvals, and commercialization.

Objective Biotechnology's mission is to develop high-impact technologies that enable comprehensive measurement and manipulation of biological systems at multiple scales, unlocking new research capabilities.

Ocean Genomics works with biopharma, academic researchers and advocacy to empower discovery and development. We provide our advanced computing platforms for gene expression analysis, and biomarker and target discovery, and our vast and fast-growing gene expression database. We also provide integrated programs ranging from single experiment analyses to multi-milestone efforts that include computational biologists, and use of all of our platforms, AI models and data assets.

At Oceanit, a rule-breaking practice of Intellectual Anarchy™ produces disruptive innovation, as we consistently discover the edges of thinking and create breakthroughs in science, engineering, and technology to change the world. Our teams create innovative solutions through engineering consulting in civil, coastal, and environmental engineering; information systems consulting; management consulting, including Design Thinking and scientific research. Empowering our teams to practice transdisciplinary thinking allows for extraordinary problem-solving across disciplinary boundaries. Our teams morph together and apart, aligning the best experts in each discipline to solve some of the world’s toughest problems Here at Oceanit, our mission is to create value from... Innovation through engineering and scientific excellence... produced in an environment where elements of such work and play are indistinguishable. We are proud of what we’ve created and what lies ahead. We are Oceanit.

Octagos Health is a dynamic and rapidly growing healthcare technology company dedicated to improving patient outcomes through AI-driven solutions. Octagos provides a cloud-based platform that aggregates remote and in-person device interrogations for all cardiac rhythm management (CRM) manufacturers, wearables (Holter, MCT, etc.) and remote physiologic monitoring (RPM).

Octant is a well-backed team of experienced scientists and entrepreneurs exploring new frontiers of biology. We are applying next-generation DNA sequencing, gene synthesis, and gene editing to revolutionize drug discovery in a quest for safer, more effective, and cheaper drugs.

At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine. In response to recent recruitment fraud, visit our Careers page to verify all job opportunities and read our guidance on this topic: https://odysseytx.com/careers/

Ofni Systems is an industry leader for 21 CFR Part 11 compliance and validation services. Their products for Part 11 compliant databases and spreadsheets are used by pharmaceutical, biotech and medical device companies across the globe, while its products for computer validation, auditing and FDA submissions ensure that their clients meet every requirement for electronic records and electronic signatures. The company provides live desktop support for superior customer support and training, and has been providing solutions to their clients since 1999. For more information, call (919) 844-2494 or visit http://www.OfniSystems.com.

Developing metabolomics assays and machine learning algorithms to produce “Biomarkers of Response” (BoR) that differentiate drug responders (R) from non-responders (NR).

Olio labs uses AI and ML to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. The only way to build and test the number of combinations required to find a better treatment is to automate as much of the therapeutic discovery and development pipeline as possible. We are a new type of scientist that is comfortable working at the bench and in the code base. Our custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one. We are currently backed by the amazing investors at SciFounders and YCombinator.

Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature’s operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Omics Edge is a bioinformatics company that integrates AI with bioinformatics to yield portable Polygenic Risk Scores that work across ancestries and ethnicities.

OmniAb is a leading-edge antibody discovery company that provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening. The company's discovery platform brings a high level of expertise and innovation to therapeutic antibody discovery.

OmniGuide's corporate culture has grown from the roots of an innovative idea from MIT to a global company that has successfully adapted to changes in the market. INSPIRATION Our purpose is to help reduce complications, every day. We achieve this with our creative energy and enthusiasm for fresh ideas. Our motivation is to continually remind ourselves that when we get up in the morning, patients who need our therapies are counting on us. EXCELLENCE The pursuit of excellence lies at the heart of everything we do. We are builders, redefining what it means to support great outcomes. We have the courage to think different and will ensure that OmniGuide remains committed to ideas that benefit patients and their outcomes.

OmniTier Inc. develops easy to use, end-to-end, genomic analysis on-premise and cloud based systems that achieve greater accuracy and faster run-times than competing offerings.

Onc.AI is venture-capital backed company committed to developing robust, clinically validated, imaging-AI powered clinical management solutions focused on immunotherapy optimization. Using patented, radiomic-based AI models, Onc.AI has developed a clinical decision support platform using routine diagnostic imaging scans specifically for planning and guidance of first-line immune checkpoint inhibitors (ICI) treatment plans.

Oncobox is transforming cancer care with precision medicine by leveraging the power of artificial intelligence and systems biology. Through the integration of deep molecular profiling—which includes analysis of not only DNA mutations (exome) but also RNA gene expression (transcriptome)—and comprehensive data analytics, we achieve unmatched precision in identifying the most effective treatment strategies, markedly improving outcomes for patients battling late-stage cancers. The effectiveness of Oncobox's technology is backed by both prospective and retrospective studies. This approach has shown remarkable success, leading to a twofold decrease in disease progression and a significant increase in progression-free survival (PFS). Oncobox's innovative use of deep molecular profiling is setting new standards in the precision and efficacy of cancer treatment.

OptraHEALTH® is at the forefront of healthcare innovation, leveraging cutting-edge Artificial Intelligence to transform patient care and streamline operations for providers and payors alike. At the heart of this revolution is our flagship AI platform, HealthFAX™. HealthFAX™ isn't just another healthcare tool—it's a comprehensive AI ecosystem designed to redefine the entire patient journey. From the moment a patient considers seeking care to long after their visit, HealthFAX™ is there, invisibly orchestrating a seamless, efficient, and patient-centric experience. Imagine a healthcare world where: * Digital front doors welcome patients with personalized, AI-driven guidance * Intake processes are streamlined, reducing wait times and frustration * Intelligent triage ensures patients receive the right care at the right time * Accurate cost estimates eliminate billing surprises * AI-powered patient counseling provides round-the-clock support * Insurance information is clarified with ease, reducing administrative burdens But HealthFAX™ doesn't stop there. Post-visit, our AI continues to work tirelessly: * Automating report analysis for faster, more accurate diagnoses * Managing follow-ups to ensure no patient falls through the cracks * Providing actionable insights to continuously improve care quality In the age of value-based care and the No Surprises Act, HealthFAX™ is more than a technological advancement—it's a strategic imperative. By automating complex processes, ensuring regulatory compliance, and enhancing communication at every touchpoint, HealthFAX™ allows healthcare organizations to focus on what truly matters: delivering exceptional patient care. Join the AI-driven healthcare revolution with OptraHEALTH®. Together, we're not just improving healthcare—we're reimagining it.

As a global leader in digital pathology, OptraSCAN is dedicated to revolutionizing diagnostics and patient care through advanced technology. We specialize in providing cutting-edge digital pathology solutions, including state-of-the-art digital pathology scanners and whole slide imaging scanners, designed to enhance the accuracy and efficiency of diagnostic processes. Our extensive range of digital slide scanners includes brightfield slide scanners, histology slide scanners, and fluorescence slide scanners, enabling healthcare institutions to transition seamlessly from traditional microscopy to sophisticated digital pathology systems. Our whole slide scanners and digital pathology slide scanners offer high-resolution imaging that improves precision, streamlines workflows, and provides cost-effective results. OptraSCAN leads the way in digital histopathology with innovative solutions that integrate advanced artificial intelligence (AI). Our AI-powered pathology scanners and digital pathology artificial intelligence technologies are designed to boost diagnostic accuracy and efficiency. We offer comprehensive solutions including whole slide imaging scanners and computer-aided region detection systems. We are committed to making digital pathology accessible to all, providing compact and advanced scanning systems that overcome barriers to modern diagnostic methods. Our digital pathology solutions include cloud-based LIMS (CLOUDPath), image analysis tools (OptraASSAYS), and up to 10 TB of complimentary cloud storage. By choosing OptraSCAN, you partner with a leading digital pathology company that is shaping the future of diagnostics with high-quality digital pathology scanners and integrated whole slide imaging solutions. Our goal is to ensure that healthcare systems worldwide can seamlessly adopt and benefit from our transformative digital pathology technologies.

Ora Biomedical, Inc. is a new pharmaceutical company in the longevity biotechnology sector that identifies and characterizes healthy aging therapeutics for further clinical and commercial development. Ora Biomedical separates itself from other longevity biotech companies by building in large-scale drug discovery and validation at the core of our scientific operations. With robust preclinical discovery at the heart of our approach, we identify novel aging targets and new interventions for known targets. Most importantly, we will leverage large-scale operations to perform drug studies that combine known and novel healthy aging interventions to identify those that produce breakthrough increases in healthy lifespan and/or mitigate disease-mediated pathology.

OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, through a range of private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed's team of over 100 professionals is based in New York City, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets.

Orbital Therapeutics is building a first-in-kind platform at the intersection of RNA technology, delivery methods, data science and automation to develop an expansive portfolio of RNA-based medicines to treat disease in humans.

Ordaos is a human-enabled, machine-driven drug design company that creates novel and customized mini-proteins. Their mission is to help biopharma partners deliver life-saving treatments by creating bespoke mini-proteins to aid drug hunters.

Orthogonal is a product development and consulting firm that creates software for medical hardware such as smartphone apps talking to devices that operate directly on the human body to treat sickness and injury. Our solutions take on some of the toughest healthcare problems facing our loved ones, healthcare system, and society. Working at Orthogonal, you will immediately be exposed to projects designed to: •Revolutionize the rapid detection of COVID-19 and other infectious diseases. •Improve the minute-by-minute lives of millions of people suffering from the lifetime affliction of diabetes by managing the delivery of insulin. •Transform the early diagnosis of Alzheimer's disease. •Give patients an at-home means to stimulate specific nerves to treat chronic conditions that drag down their quality of everyday life. •Power the next generation of omics-based cancer-detection systems. Specifically, Orthogonal develops Software as a Medical Device (SaMD), digital therapeutics (DTx), and other types of connected medical devices. We accelerate the product innovation pipeline at medical device, diagnostics, and pharmaceutical manufacturers to modernize patient care and gain competitive advantage. Orthogonal's industry-leading experience with SaMD enables us to rapidly develop, launch, and continuously improve connected, compliant products – and we offer this innovative approach to clients, so they can build their own SaMD product development workflows. Over the last decade, we've worked with partners ranging from startups to Fortune 500 firms to develop and bring their connected devices to market in a highly regulated space.

Orthogon Therapeutics is a drug development company focused on designing innovative antivirals and anti-infectives. Their initial focus is on treating BK and JC polyomavirus infections in transplant patients.

Health tech startup developing artificial intelligence tools for ear exams.

OTraces has developed a blood-based disease testing platform that uses math- and physics-based noise suppression techniques never before employed in human disease testing, and has thereby achieved 90%+ accuracy in the detection of cancer tumors as measured by predictive power.

Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the potency (OutSpacers™), specificity (Co-LOCKR™), and safety (EGFRopt™) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes. At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.

Overjet is the world-leader in dental AI. Founded by experts from MIT and Harvard University, Overjet builds artificial intelligence that helps dental organizations give patients the highest quality of care. Our FDA-cleared technology is the first objective standard for making oral health decisions — so that dentists can detect pathologies with precision and educate patients with confidence.

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner. We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

Owl Therapeutics, a spin-out of Gryphon Bio, is a clinical-stage biopharmaceutical company created to develop best-in-class, artificial intelligence (AI)- and diagnostic-powered therapeutics for traumatic brain injury (TBI) and brain health. The company has rapidly built a promising, diversified pipeline of small and large molecule medicines poised to address the highly unmet needs of patients with neurodegenerative disease. Owl is led by a proven, cohesive, interdisciplinary, and internationally recognized team with deep scientific, clinical, and business experience in drug development and commercialization.

Developing a single cell immunoprofiling platform.The company’s tools quantify and assess what types of cells are in samples based on the composition of surface proteins.

Pacific Northwest National Laboratory advances the frontiers of knowledge, taking on some of the world’s greatest science and technology challenges. PNNL is a U.S. Department of Energy national lab with distinctive strengths in chemistry, Earth sciences, biology, and data science that are central to our scientific discovery mission. PNNL’s research lays a foundation for innovations that advance sustainable energy through decarbonization and energy storage and enhance national security through nuclear materials and threat analyses. PNNL collaborates with academia in its fundamental research and with industry to transition technologies to market.

Paige is using the power of AI to drive a new era of cancer discovery and treatment. To improve the lives of patients with cancer, Paige has created a cloud-based platform that transforms pathologists' workflow and increases diagnostic confidence as well as productivity, all on a global scale. Paige is the first company to receive FDA approval for a clinical AI application in digital pathology. The same Paige technology empowers pharmaceutical companies to more effectively evaluate treatment options for patients and design new biomarkers for drug development so that every patient gets precise treatment options. Learn more about Paige: https://www.paige.ai

Palisade Bio (Nasdaq: PALI) is a biopharmaceutical company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. The Company believes that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care. Palisade Bio’s lead program, PALI-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing. The Company’s second lead program, PALI-1908, is being evaluated in preclinical development for the treatment of fibrostenotic Crohn’s Disease.

Panome Bio can help you profile and discover biomarkers with our Next-Generation Metabolomics capabilities, comprehensive workflows and personalized data analysis reports. Our Next-Generation Metabolomics platform is making major advancements in the metabolism field by going beyond pairwise comparisons and making complex experiments with large and complicated datasets possible. Cutting-edge technology and computational methods are used to extract only the biologically-relevant chemical compounds to give you a clearer view of phenotype. We provide a global and unbiased view of the metabolome through a suite of complementary LC/MS assays that captures the breadth of diverse metabolites in biological systems. We have the ability to complement your metabolomics data with proteomics to better understand pathways and metabolism through our partnership with Somalogic. Somalogic's SomaScan® 7K Assay is a high-throughput proteomics assay that screens 7,000 proteins per sample simultaneously.

Panorama Medicine is a VC-backed startup founded by a multidisciplinary team of world-renowned computational and experimental RNA biologists. Panorama has created PAN, a drug discovery platform that integrates genomics, big data, and computing to develop therapeutic interventions for RNA defects in disease. Research by Panorama and other companies has demonstrated that aberrant RNA splicing underlies a significant number of human diseases. Building industry leading algorithms and vast amount of public and proprietary datasets, Panorama has built the PAN platform to predict splicing events as well as design and screen modalities to address the underlying causes. We look forward to collaboration with the global drug development community to advance medicine and contribute to human knowledge of biology.

Since its founding in 1993, NVIDIA (NASDAQ: NVDA) has been a pioneer in accelerated computing. The company’s invention of the GPU in 1999 sparked the growth of the PC gaming market, redefined computer graphics, ignited the era of modern AI and is fueling the creation of the metaverse. NVIDIA is now a full-stack computing company with data-center-scale offerings that are reshaping industry.

Paradigm Health is rebuilding the clinical research ecosystem by creating a platform that enables equitable access to trials for all patients, while enhancing trial efficiency and reducing the barriers to participation for healthcare providers. Incubated by ARCH Venture Partners and backed by leading healthcare and life sciences investors, Paradigm Health aims to break down barriers across the trial ecosystem through one seamless infrastructure implemented at healthcare provider organizations, bringing potentially life-saving therapies to patients faster.

CONNECTING THE HUMAN BRAIN What if we could restore or enhance function using the power of AI and advanced technology? Our direct data interface enables this connection. MISSION We are building a high data-rate brain computer interface (BCI) to provide technology solutions for people with neurological and brain-related conditions. Our first clinical application will help severely motor-impaired people communicate, enabling social connection and restoring independence. ABOUT Paradromics was founded in 2015 by a team of engineers and neuroscientists, received early support from both NIH and DARPA, and is currently backed by venture capital.

Paragon 28 was established in 2010 as an orthopedic foot and ankle company. The name "Paragon 28" was chosen to show that we are exclusively a foot and ankle company, with the "28" representing the number of bones in the foot. We will remain true to that vision. Paragon 28 was started as a small, family-based company and we have kept those core ideals as we have grown. Our mission is to strategically build a company around the core principles that drive innovation and quality. Relentlessly working to advance the science behind foot and ankle surgery, Paragon 28 is passionate about and committed to: - Creation and Innovation: Blending different surgical philosophies from various global thought leaders to develop bio-mechanically and clinically relevant surgical solutions. - A Focus on Service: A customer service based, dedicated, and highly trained distribution network to the foot and ankle market. - Efficient Practices: Meeting the needs of increasing pricing pressures and reimbursement while continuing to develop cutting-edge surgical implants. - Practical and Comprehensive Solutions: Creating complete surgeon-centric systems, specialty instruments, and next generation implants to solve real world issues faced by foot and ankle surgeons. - Research Motivated: Improving clinical outcomes through meaningful and unbiased research. We are ready to embrace research data regardless of marketing impact. Motivation, competition and the desire to learn are unique characteristics that are incredibly valuable to our success. Paragon 28's work environment is modern and exciting. We are seeking experienced and energetic individuals to join our team in areas of Quality, Engineering, Marketing, Sales, Administration and Accounting.

Parallel Bio created a human 'immune system in a dish' to discover drugs and immunotherapies more likely to work in patients.

Parallel is a next-generation skin health company providing effective, targeted solutions powered by microbiome science, genomics, and machine learning. At Parallel, everything we do is grounded in science and innovation. We believe that the future is precision medicine and we believe that what we’re building is vital to that vision. Here, consumers and patients can access best-in-class expertise and clinical guidance, a personalized genomic assessment to understand their skin microbiome, as well as personalized, targeted microbiome skincare products and prescriptions (if needed). With one of the largest data sets in the world on the skin microbiome, a 10,000-deep bacterial library, and patents pending, Parallel was just honored by Fast Company as a "World Changing Idea."

Pathos was borne from the belief that cancer is a collection of hundreds of rare diseases and can be best described by pathways accounting for the pathophysiology of patients. We license or co-develop clinical-stage therapeutics to ensure highly efficacious drugs are developed for the patients most likely to benefit and with significant unmet needs. Our patient selection strategies are optimized for the fastest path to approval to improve patient outcomes as quickly as possible. Our aim is ultimately to accelerate the translation of real-world data into breakthrough therapies for patients that need them most.

Tackling a global health threat like antimicrobial resistance is not for the faint of heart, but the experienced and innovative team at Pattern Bioscience is on a mission to do it. Each year, drug-resistant bacterial infections claim more than a million lives globally and cost our healthcare system billions of dollars. Traditional diagnostic methods for bacterial infections remain rooted in slow, cumbersome, decades-old technology that contributes to sub-optimal treatment and the misuse of broad-spectrum antibiotics. The Pattern system is different. We’re developing the world’s only culture-free, rapid diagnostic technology that will reduce the time needed for pathogen identification (ID) and antibiotic susceptibility test (AST) results from days to hours. Our technology combines single-cell analysis of microorganisms with machine learning tools to deliver fast, clinically actionable information. The result? Patients get the right treatment faster, to save lives, prevent side effects and reduce healthcare costs.

Pattern Computer, Inc., a Seattle-area AI & ML company, uses its proprietary Pattern Discovery Engine™ to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems. As the Company applies its computational platform to the challenging fields of drug discovery and diagnostics, it is also making major pattern discoveries for partners in other sectors, including biotech, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance. Highlights: • Innovative / Proprietary Technology • Pattern Discovery Engine™ discovers and generates valuable hypotheses and insights into complex data, revealing novel patterns that cannot be discovered using conventional techniques or tools • Pattern produces exceptionally valuable assets within some of the most fiercely competitive domains … and commercializes them • Multiple high-growth markets: immediate focus most daunting yet immediate promise for life-changing & life-saving contributions to society including: • Life Sciences • XAI • Commercial Journey along with us as we move from creating our high-value assets to capitalization/commercialization of them- taking AI by storm with our focus on Third Wave AI.

Peptilogics was founded in 2013 to advance novel peptide therapeutics and harness the power of a design-based approach to drug discovery. Our approach bridges untapped chemical space to engineer peptides to treat some of the most challenging diseases. Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics through their computational platform.

At Pera Labs, we develop digiceuticals and ai-powered solutions for difficult health problems such as fertility. The flagship component of our platform technology for fertility treatments is called SPERMAN, an artificial intelligence based sperm sorter system which provides automated solution for time consuming and labor intensive sperm assessment AND sperm selection procedures. SPERMAN helps fertility clinics perform highly accurate sperm assessment and separation in minutes not days. We take a holistic approach to fertility treatments. Therefore, starting from the assessment of sperm and egg cells all the way to newborn screening, our innovative platform technology can provide more efficient and affordable fertility treatment strategies. We are looking for investors, distribution and implementation partners. Join us for making fertility journey affordable and efficient.

We're PercayAI, an AI venture providing fundamentally different augmented intelligence software across a variety of healthcare applications, including a variety of healthcare applications, including life sciences, drug discovery, payment integrity, and medical claims. Founded in 2019, PercayAI is made up of an interdisciplinary team with expertise across life sciences, technology and enterprise business who think differently about technology and its impact on our life.

Perimeter Medical Imaging AI is a pioneering medical technology company driven to transform cancer surgery with advanced imaging tools. We can't imagine how frustrating it is for surgeons to do everything they can and still have to make the "dreaded call" to the patient. That's why we developed our OCT technology that provides 10x the resolution of X-ray and ultrasound at 2mm imaging depth for real-time insight, so surgeons can act in the moment with greater certainty. A Toronto-based company established in 2013, with U.S. headquarters in Dallas, Texas, Perimeter seeks to harness the power of big data, artificial intelligence, and machine learning technology to further our mission of improving the standard of care, providing better long-term outcomes for patients, and reducing healthcare costs.

Persephone is pioneering the use of synthetic biology for microbial products that impact patient and infant health. We are building an end-to-end platform to industrialize the development of engineered cells that restore health to damaged human ecosystems. The company was founded in the summer of 2017 by synthetic and metabolic engineering pioneers, Stephanie Culler PhD, and Steve Van Dien PhD.

Phantom Neuro is creating the first minimally invasive peripheral neural interface, the Phantom X. Our technology allows complex electronic systems, like prosthetic limbs, to operate like natural extensions of the human body. We are a group of forward thinking individuals on a mission to help people with function-limiting injuries.

PharmaNest is an image analysis and contract research company focused in the development and validation of novel standards for the quantification of Fibrosis for drug discovery and development.

PhaseV is leveraging cutting-edge algorithms such as reinforcement learning and causal ML for adaptive trial design and closed-loop execution, in order to improve trial success rate while maximizing resource and time efficiency. Our novel methodology and advanced technology also enable the detection of hidden signals in data while analyzing clinical trial results and extracting actionable insights.

Phenome Health is a research organization dedicated to preventing disease and taking the guesswork out of healthcare. We are driving a revolution by moving past the disease-focused “find it and fix it” era to wellness and prevention that enables all of us to live longer and healthier lives.

We are a bioinformatics-based precision medicine platform company translating patient-specific and population-based medical big data into novel pharmacological clinical treatment decision support products and services. We offer a proprietary technology, the PredictMed Platform, designed to help clinicians and health systems optimize precision in the selection of appropriate medications, drug combinations and dosages that improve each patient's health, while also reducing adverse reactions. Our PrecīsMed platform represents a significant step forward in accurately assessing a patient’s complete medication profile. Physicians can finally see the full spectrum of medications present in the patient, and identify appropriate dosing levels for therapeutic effectiveness. PrecīsMed can accurately assess prescribing trends, medication adherence and EHR coverage, as well as define medication concentrations in patients with comorbid disorders.

Phenomix Sciences is a precision medicine obesity biotechnology company on a mission to conquer obesity globally through the use of proprietary testing and personalized lifestyle guidance. The company offers the MyPhenome™ test, exclusively licensed from Mayo Clinic, which measures DNA and metabolites related to obesity to improve weight-loss effectiveness. Phenomix Sciences is committed to advancing the understanding of obesity treatment through precision medicine and believes in the power of knowledge and accurate diagnosis.

Phesi has the industry’s most comprehensive and dynamic clinical trials database and predictive analytics tools to help trial sponsors make quick and informed decisions to expedite drug development. Our distinguished team works side-by-side with its clients to analyze data, answer questions, and offer informed solutions to benefit study sponsors, investigators, and ultimately patients. Phesi has been applying its innovative technology and deep expertise to help life sciences companies for over 10 years. Our experts work with study sponsors to drive solutions from clinical development planning through trial implementation to optimize protocol designs, select the best investigator sites, shorten enrollment cycle times, select and manage CROs, and much more.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. Phio was co-founded by Nobel Laureate Craig Mello, who was awarded the Nobel prize in 2006 for his discovery of RNAi, which has broad therapeutic applications. Our founders opened up a whole new field of biology when they discovered RNAi, and we continue their pioneering efforts today through our work with INTASYL. We’re committed to discovering and developing innovative cancer treatments for patients, creating new pathways for a cancer-free future. For additional information, visit the Company's website, www.phiopharma.com. #INTASYL #siRNA #RNAi #Phio #immunooncology

Photon Biosciences' core technology is a new ultrasensitive detection platform that combines bioengineered proteins with a uniquein vivobiomineralization process that results in a number of different genetically expressible luminescent bionanoparticles that are non-bleaching and non-blinking with luminescence intensities that rivals and surpasses many fluorescent organic molecules. The excitation and emission wavelengths of these expressible bionanoparticles can be tuned with the composition of the mineralization process and span much of the visible and near infrared regions of the electromagnetic spectrum. Because of its unique photophysical properties, PBS® has been developed into new ultrasensitive probes for biomolecular research, detection technologies, and cellular imaging.The company is developing a test to detect contamination in donated platelets.

PhotoSound Technologies, Inc. was founded in September 2015 in Houston, Texas USA to develop and commercialize new biomedical imaging technologies based on optics and photoacoustics. Photoacoustic tomography (PAT) is a biomedical imaging modality combining the molecular sensitivity of optical probes with the spatial resolution of ultrasound that is ideal for a multitude of applications that can be used for pre-clinical research.

Neutralizing Antibody Discovery

Phythera Therapeutics, Inc. was started to test, develop and improve promising small molecule-based drugs for oncology and inflammation markets. Many small bioactive phyto-molecules used in biomedicine have been derived from plants (hence –Phythera Therapeutics). The cocktail of drugs is expected to be better than one molecule for managing complex diseases with no available treatments. The only medicine which can manage HIV is a cocktail of drugs. We have something of the same magnitude but for oncology, which is viewed as “one drug- one IND” by US FDA. We see the potential of drugs carrying many small bioactive molecules to substantially improve the treatment of cancer, either as an auxiliary or even as the main treatment method. The same is true for inflammation. Optimizing and improving these small molecules to maximize their efficacy to combat metastatic cancers, and converting them into potent and robust treatments of untreatable conditions like metastatic cancer and persistent inflammation is Phythera’s main overarching goal. We leverage our expertise in 3D cell biology and transcriptomics to test the small molecule compounds to define and improve their efficacy in 3D tissue model systems, either as a single compound or as a combination of several most potent small molecule drugs. The team’s proven deep expertise in stem cell biology enables us to study the impact of our candidate molecules on the most elusive and most malignant cancer stem cells and develop drug combinations, optimized for a specific disease. Last but not least, our team has a strong interest in regenerative medicine approaches for inducing tissue regeneration and improving tissue homeostasis, the key to wellness and enduring health. Small molecule compounds derived from plants possess many of the properties promoting tissue regeneration and modulating homeostasis in tissue. Enhancing these properties and converting them into new treatments is Phythera’s 2nd overarching goal.

Solving unmet needs in vascular access care

PinkDx is an early-stage company whose vision is to positively impact the health of women throughout their life journey. We focus on addressing the medical problems that women uniquely face by applying sophisticated scientific approaches to resolve them and provide answers that have an immediate, positive impact on their lives. Our first indication will focus on overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer. Led by a team of diagnostics industry veterans, PinkDx is privately held, with funding from prominent biotechnology investors, including Catalio Capital Management, The Production Board, Mountain Group Partners, Byers Capital and Mayo Clinic.

2024 marks 100 years since Hans Berger made the first EEG recording of the brain. Despite a century having passed, we still do not fully understand what brainwaves are telling us. From diagnostics to wellbeing, we are building technology that bridges the gap between research and real-world EEG applications. Foundation Model for the Brain.

Polares medical is a medical device company with a novel device for treating mitral valve regurgitation.

The scope of experience of Polaris’s executive team spans nine decades & several fields, including military service, medicine, & federal research & development. These experiences have allowed the team to cultivate timely knowledge of pandemic-era mental health needs, & develop deeply unique qualifications to address these needs. The team has garnered numerous awards, ranks, titles, & accomplishments, ranging from captain to engineer, Purple Heart recipient to medical doctor, virologist & immunologist, 9/11 responder to Iraq War veteran, & PhD to Homeland Security Public Health Officer amid the threats of SARS & anthrax. In 2017, inspired by their work at the Defense & Veterans Brain Injury Center & the US Department of Veterans Affairs, a veteran & a scientist coalesced their visions seeded in service around the urgent need for 21st-century innovation in behavioral healthcare. Drawing upon decades of experience in biomedical technology, public health, & molecular biology, they founded a company to take aim at the mental health crisis that results in 22 veteran suicides each day. Partnering with the Illumina Accelerator & scientists from Mount Sinai & the Max Planck Institute of Psychiatry, the team developed the first-to-market, patented genomic biomarker assay to identify PTSD risk in 2018. As a veteran-owned business, our roots remain in our founding mission to improve the lives of US military service members & veterans living with behavioral health conditions, such as post-traumatic stress disorder (PTSD). In 2020, global public health events & an evolving behavioral health landscape revealed that the number of people standing to benefit from advances in diagnostics & treatment is broadening by the day. Guided by a calling to serve, we expanded our mission to encompass: - Veterans & active-duty US military service members, - First responders, frontline workers, & individuals in high-risk occupations, & - Trauma-exposed communities at large.

Polybiomics is a biotechnology company that revolutionizes the analysis of live cells by enabling simultaneous measurements of multiple cellular features from the same sample in real-time, connecting data types to create actionable knowledge.

Praedicare Inc. is a System of Systems based end-to-end drug development company [from drug discovery to phase IV trials] that uses preclinical wet lab models mathematically mapped to patients for quantitative prediction of clinical trial outcomes, significantly reducing clients' risk, time, and costs of developing safe and effective new drugs. Praedicare is headquartered in Dallas, Texas, but has international offices and has clients from around the globe.

Praesidia Biotherapeutics is built with the vision of being a patient focused and clinician driven drug development company championing unmet clinical needs. Praesidia's proprietary first in class Tunable Linker Technology is revolutionizing the ways to maximize.

Pramana, Inc., is a health technology company reimagining digital pathology through its autonomous AI-enabled whole-slide imaging solutions. Built upon extensive industry experience and patented technological innovation, Pramana enables pathologists and physicians to accelerate precise diagnosis with reduced manual intervention, minimizing human errors and improving operational efficiency. Pramana is headquartered in Cambridge, Mass., with R&D and manufacturing sites in Bangalore, India; Rochester, Minn.; and Toronto, Canada.

We've experienced the significant gaps in our collective ability, as a medical and research community, to access and understand disease-defining biology when it matters most. To address this, we've developed a simple blood test to uncover actionable disease-defining transcriptional biology.  Our unique genome-wide platform profiles circulating chromatin and the DNA methylome to deliver resolution into the dynamic activity of individual genes and pathways in diseased tissues from just 1mL of plasma.  By partnering with developers of new medicines and advancing our own diagnostic tests, we're working towards a world where new medicine development efforts succeed more frequently, and where anyone can receive a minimally invasive diagnosis and treatment that's precise to the biology of their disease.

PreciseDx® is innovating oncology diagnostics, leveraging Artificial Intelligence (AI) for revolutionary, morphology-driven, disease analysis. Combining AI with our patented Morphology Feature Array® (MFA), PreciseDx provides access to unmatched disease insights and accurate, actionable intelligence for more comprehensive decision-making throughout the cancer care continuum.

PrecisionLife is the clinical-stage precision medicine company for complex chronic diseases. Creating better diagnostic tools and more personalized treatment options for patients with unmet medical needs. Our analytics and AI is unique in its understanding of causal disease biology. Identifying biomarkers to stratify patients by molecular mechanism of either their disease or drug response and link individuals to the drug targets, trials and treatments that will benefit them. With these insights we significantly increase the probability of success throughout the biopharma and healthcare value chain. Accelerating, informing and de-risking drug discovery and clinical development, building highly predictive diagnostics, and in launching more personalized and preventative medicines. To learn more, visit precisionlife.com.

Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from neurological illnesses. We are building the only brain–computer interface that is designed to be minimally invasive, safely removable, and capable of processing large amounts of data.

Our mission at Predictive Oncology is to change the landscape of oncology drug discovery and enable the development of more effective therapies in the treatment of cancer. By harnessing the power of machine learning, scientific rigor and biologics, we can improve the probability of success and advance drug compounds with a higher degree of confidence. We invite you to follow us to stay up-to-date about our latest developments.

Predicine is a global molecular insights company that is committed to advancing precision medicine in oncology. Predicine has developed a breakthrough cell-free DNA- and cell-free RNA-based liquid biopsy technology enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, and minimal residual disease and early cancer detection. The company has launched a portfolio of blood-, urine- and tissue-based diagnostic assays for oncology. Through its business operations in Silicon Valley, Houston, Shanghai, Singapore, and Boston, Predicine partners with leading biopharma companies, institutions and governments to support personalized healthcare on a global scale.

Predicta Biosciences is a precision oncology company integrating cutting edge multiomics and liquid biopsies to develop innovative diagnostic and therapeutic products. Predicta's diagnostic product portfolio removes the burden of bone-marrow biopsies, through small blood-based samples, and enables best-in-class treatment decision-making for immunotherapies. Utilizing the data from the diagnostic platform, Predicta has an in-house therapeutic pipeline of novel immunotherapy targets in pre-clinical discovery and development.

Our mission at Predictive Oncology is to change the landscape of oncology drug discovery and enable the development of more effective therapies in the treatment of cancer. By harnessing the power of machine learning, scientific rigor and biologics, we can improve the probability of success and advance drug compounds with a higher degree of confidence. We invite you to follow us to stay up-to-date about our latest developments.

The convergence of unbiased spatial analytics and explainable AI ushers in a new era of precision pathology. The novel insights from our platforms reveal the existence of intermediate cell types and their functional states as well as communications between cells. Our solutions empower clinicians/researchers to accelerate drug discovery, optimize clinical trials, advance companion diagnostics, personalize therapeutic options, and improve clinical workflows. info@predxbio.com

Prellis Bio is hiring Immunologists! We are expanding our Externalized Immune System, EXIS™, platform with applications in antibody discovery, immunogenicity, and vaccine screening all in the same platform. Prellis Biologics, Inc. is a privately held company based in the San Francisco Bay Area, CA. Apply at www.prellisbio.com.

Prenosis, decision support tools use artificial intelligence to rapidly synthesize proprietary biological data and historical clinical data to predict future outcomes

Prevencio is Revolutionizing Blood Tests For Cardiovascular Disease || Powered by Artificial Intelligence (AI) || Preventative Medicine for Heart Health Prevencio's purpose is to prevent the preventable. 80% of cardiovascular disease, including heart disease and stroke, are preventable (CDC). Prevencio's personalized blood tests provide earlier detection and prevention which can diminish unnecessary procedures and related side effects, as well as improve patient outcomes. Published in top-tier cardiology journals and presented at leading cardiovascular meetings, Prevencio's patented, proprietary technology has been used to create seven life-saving cardiovascular tests, with more in development.   Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, individual biomarkers, genetic markers and clinical risk scores. To learn more visit us at: www.prevenciomed.com

Prime Discoveries develops rapid, novel diagnostics for emerging pathogen infections with a focus on cost effective, massively scalable and easily automatable assays. Prime leverages multiple patented advanced technologies in microbial diagnostics including RT-LAMP, Rapid PCR, and mNGS (Next generation sequencing) to enable samples to result in under 1 hour with minimal lab infrastructure and technical expertise. Prime's products are best in class for Covid, Influenza, Sexually Transmitted Infections and new drug resistant microbes. All of Prime's assays are locally developed in the United States and can serve millions of people. Founded in NYC in 2017, Prime's scientists have extensive backgrounds in microbiology, computational biology, lab automation and AI from Genentech, Cooper Genomics, Recombine, Phosphorus, and NYU. Prime is advised by leading experts in the fields of genomics and public health including Dr. George Church and Esther Dyson. Prime is supported by academic institutions, venture capital firms and angel investors including New York University, Charles Zegar, BoxGroup, Akron Fusion Ventures, Beresford Ventures, Cannonball Capital, Liquid 2 Ventures, Francois Nader (Moderna, Acceleron, Shire), Unshackled Ventures, Doberman Forward, and others.

Harnessing the Power of Cytokine Monitoring and Host-Response Understanding to Transform Healthcare Cytokines, pivotal biomarkers of inflammation, are essential in tracking the progression of infections, helping physicians tailor more effective treatments. Annually, over 10 million patients in the U.S. are diagnosed with infections, and the post-COVID-19 era has highlighted the value of cytokine monitoring. However, the current methodologies are costly and slow, undermining its potential. Our solution introduces point-of-care cytokine testing that matches central lab accuracy, completed in just 5-10 minutes, and at a significantly lower cost. This enables continuous, real-time monitoring, offering timely, actionable insights to both physicians and patients exactly when needed. Proactive Diagnostics is transforming how infections are assessed and managed, to improve care in several critical areas: - Enhancing clinical outcomes - Minimizing unnecessary antibiotic use - Shortening hospital stays - Reducing patient readmissions Our AI-driven, cloud-connected platform leverages unique data collection capabilities to deepen our understanding of individual host responses to various inflammatory stimuli. Such capabilities can also play a critical role in other important clinical areas such as the treatment of Autoimmune Diseases, where monitoring host response can inform therapy adjustments and drastically improve lives; or in the treatment of Cancer, where Cytokine levels can help optimize the administration of groundbreaking immunotherapies and adjust treatments to harness the immune system's power more effectively against tumor cells. This transformation in cytokine monitoring could be the key to a new era of personalized, predictive, and preventative medicine, where each patient's treatment is as unique as their response to disease.

Profluent is an AI-first protein design company. Founded in 2022, we develop deep generative models to design and validate novel, functional proteins to revolutionize biomedicine. Based in Emeryville, CA, we are backed by leading investors including Spark Capital, Insight Partners, Air Street Capital, AIX Ventures, and Convergent Ventures. To learn more about our mission to decode the language of life with AI, visit profluent.bio.

ProFound Therapeutics is pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines. The company’s ProFoundry Platform uses state-of-the-art protein detection technologies to systematically identify and validate proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

Prognos Health is a real-world data (RWD) company that unlocks the power of data to improve health. Prognos offers the leading managed RWD marketplace, accelerating the development and delivery of innovative therapies and improving health outcomes by offering fully integrated and harmonized lab and health records on more than 325 million de-identified patients. Prognos Health's platform provides a comprehensive and integrated view of patient health, enabling researchers, payers, and providers to make better decisions about care.

Prologue is designing powerful new medicines by unlocking the viral proteome. The company’s state-of-the-art DELVE™ Platform systematically identifies and evaluates viral proteins and their unique features for their potential to precisely regulate human physiology. By co-opting viral evolution, Prologue is expanding the functional boundaries of proteins encoded by the human genome to create new programmable medicines. Prologue was founded by Flagship Pioneering in 2021.

Promaxo is a medical technology company that develops and commercializes customer-centric MRI systems and MRI based technologies that enhance patients' experiences and outcomes. The Promaxo MRI system is designed for image-guided interventions including live MRI guided biopsies, treatment planning, robotic surgeries, and radiation.

Proscia is a software company accelerating pathology's transformation toward a data-driven discipline. Our Concentriq® digital pathology platform and AI-powered computational pathology software are redefining the pathology laboratory and enhancing cancer diagnosis.

Protillion Biosciences is a Stanford University spinout commercializing disruptive technology for therapeutic antibody and binder discovery. We have developed an entirely novel, powerful and high-throughput protein display platform designed to revolutionize traditional approaches to the design and development of protein-based drugs.

Prudentia Sciences, a Cambridge based technology company, is dedicated to accelerating drug pipelines and maximizing return on investment, envisioning a future where healthcare innovations reach their full potential. Prudentia’s platform enables comprehensive due diligence and valuation of drug assets.

PsychoGenics is a preclinical CRO with expertise in CNS and orphan disorders. Our mission is to provide the best validated disease models and comprehensive preclinical capabilities to help companies discover the next generation of treatments for severely disabling CNS and orphan disorders, and reduce the attrition rate in clinical development. We are known for our cutting-edge translational approach to research, our customized solutions, the breadth and quality of our work, as well as for our ability to identify statistically relevant phenotypic changes that help our clients quantify the efficacy of their treatments before they move into the clinic. With an extensive portfolio of highly predictive disease models and unparalleled experience performing studies for biopharmaceutical companies of all sizes, we enable clients to deliver much needed superior clinical candidates to patients. Our capabilities include behavioral testing, electrophysiology, translational EEG, quantitative histology, molecular biology, and microdialysis. We offer a variety of validated mouse models including in-licensed transgenic models that support research in areas such as Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, autism spectrum disorders, psychosis and schizophrenia, spinal muscular atrophy, muscular dystrophy and a broad array of pain models.

PulmoSIM Therapeutics is the pharmaceutical subsidiary of VeriSIM Life, developing breakthrough therapies for rare and progressive respiratory diseases to improve patient outcomes and quality of life. Our immediate focus is to address the unmet needs in pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF) by targeting the underlying biology to alleviate the need of combination therapies. PulmoSIM Therapeutics' pipeline includes 2 drug assets. PT001 is a U.S. Food & Drug Administration designated Orphan Drug and has successfully completed preclinical study. PT001 has demonstrated positive efficacy with key disease-reversal data for the treatment of PAH. The monotherapy differs significantly from current PAH combination therapies by targeting the disease's underlying biology. We are working hand-in-hand with a world-class strategic advisory board and clinical and manufacturing partners to rapidly transition the program to clinical studies. PT002 is undergoing advanced preclinical study for the treatment of IPF. We leverage BIOiSIM, a first-in-class artificial intelligence bio-simulation platform to accelerate our drug development by bridging the translational gap between preclinical and clinical phases. Learn more about BIOiSIM at www.verisimlife.com. Get in touch if you are interested in learning more about our programs and working with us.

Purdue University is an academic institution that offers a wide range of educational services and conducts research.

Q uses a systems biology approach called panomics to build a comprehensive, quantitative snapshot of your health by combining advanced non-invasive imaging, chemistry, genetics, vitals and your medical history.

Quiver is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map "Genomic Positioning System" through state-of-the-art proprietary engineering and AI/ML approaches.

The QTI team has been on an incredible journey, starting with a shared mission to create disruptive innovation to expand access to medical imaging while ensuring superior patient experience and improving health outcomes. We anchor our efforts in medical imaging because when the body can be scanned often and without harm, health conditions can be detected before symptoms appear. Chief among the new advancements in medical imaging is 3D body imaging. Today QTI focuses on our breast imaging technology, which is native 3D, high resolution, and generates reproducible image quality regardless of operator or breast size or tissue type. Current breast imaging paradigm leads to unnecessary concern and cost. ▪️Unlike mammography, QTI technology is effective in screening women with dense breasts, or 40% of women in US. ▪️35% of women aged 40-70 do not get screened. Of the 65% of women who get screened, 15% suffer unnecessary callbacks for ultrasounds, MRI, or biopsies. 80% of biopsies are benign. ▪️QTI’s technology can be a much-needed alternative for high risk women under 40, as cancers in younger women are usually aggressive and survival outcomes are poor. Our QT Imaging Breast Acoustic CT™ Scanner is the only true 3D imaging device, FDA cleared for use as a transmission and reflection low frequency soundwaves imaging system for a patient’s breast. There is no ionizing radiation or compression like in mammography or contrast dyes injections like in MRIs. The technology uniquely quantifies breast density. Surface-to-volume ratios and volumetric doubling time growth rate can be calculated to determine significance of lesions and improve specificity. This breast scanning system gives women the choice they deserve to ensure their breast health over time; for healthcare providers, a technology that is accessible, affordable, and accurately visualizes internal structures of the breast; and, for investors, a market segment extension and a purposeful investment opportunity.

Quantori is the end-to-end data, technology, and digital services partner of choice for leading biopharma and healthcare organizations across the globe. We develop cutting-edge data and technology systems, applications, and infrastructures for biotech, pharmaceutical, and healthcare companies to accelerate drug discovery and improve patient outcomes. Our innovative approach harnesses the power of data engineering and informatics, machine learning, emerging technologies, and cloud expertise to bridge the gap between meaningful data and patient success, supporting every phase of the drug development process. Quantori also boasts a growing healthcare business that helps organizations optimize volumes of complex data sets to drive data to knowledge, knowledge to actionable insights, and insights to value. Quantori’s data scientists and informaticians understand the nature of data at a granular level, which is required for powering the future of precision medicine. • 20+ Years Serving the Life Science & Healthcare Sectors • Deep Domain Expertise • Over 800 experts including scientists, software engineers, data scientists • Blue-Chip Roster of Biopharma Clients • 1,500+ Digital IT Projects Contact Quantori today to learn how we can help accelerate your innovation pipeline through the power of data and digital IT. Website: www.quantori.com Email: contact@quantori.com Twitter: @Quantori_USA

Quris-AI is an artificial intelligence innovator that is disrupting drug development. Its machine-learning bio-platform better predicts which drug candidates will safely work in humans, avoiding tremendous costs of failed clinical trials. Quris-AI is led by a track-record team of top scientists and strategic investors. Its first AI-based drug is now prepping for clinical testing.

Our mission is to empower physicians with Al - saving physicians time, reducing burnout, and improving the quality of patient care.

A healthcare software company developing artificial intelligence (AI)-powered solutions, RADLogics provides machine learning image analysis solutions to improve radiologists' productivity while enhancing patient outcomes. Based in New York, NY, US, and Tel Aviv, Israel, RADLogics is one of the pioneers in using AI & machine learning image analysis and advanced big data analytics to search and analyze imaging data from CTs, MRIs, PET scans, and X-rays to help reduce diagnostics turnaround time from hours to minutes by automating detection and report generation functions. The company's patented AI medical image analysis platform enables rapid development of AI algorithms, and provides seamless integration into existing radiology workflow.

Rancho BioSciences is a fee for service life science company leveraging open source tools and public domain data in Pharma, non-profit foundations and academia.

RapidAI is the global leader in using AI to combat life-threatening vascular and neurovascular conditions. Leading the next evolution of clinical decision-making and patient workflow, RapidAI is empowering physicians to make faster decisions for better patient outcomes. Based on intelligence gained from over 10 million scans in more than 2,000 hospitals in over 100 countries, the Rapid® platform transforms care coordination, offering care teams a level of patient visibility never before possible. RapidAI — where AI meets patient care.

Collaborative robots have reshaped automation by enabling a wide spectrum of new applications in different industries – but a significant dexterity gap still remains even with these robots. Manipulation of delicate, fragile, or brittle items is still out of reach for robots. Inspired by our human fingertips which provide unmatched dexterity, we have set out to reduce this gap by adding tactile sensing similar to the sensing in our fingertips to enable robotic manipulation of more delicate items. Introducing the Tactile Fingertip. Ras labs has combined material science innovation with data science and precision engineering to provide the first state of the art, Tactile Fingertip for robotic gripper fingers. Our sensor is based on our patented Electroactive Polymer which can be fabricated in many configurations. Both squishy and a level of firmness. Think our revolutionary technology could help your business? Send us a message. We'd love to chat!

Ravata Solutions is a fertility and reproduction company that specializes in hardware and diagnostics to transform the IVF laboratory with automated assisted reproductive technologies (AART) and enhance human disease model development for pre-clinical studies.

RealSeq Biosciences’ core expertise includes innovative proprietary technologies for bias-free small RNA/miRNA NGS library construction, targeted NGS tools, and cf-RNA analysis (liquid biopsy) that form the basis of the Company’s life science research programs and product development.

Real Time Genomics develops analytical solutions that reduce the cost and complexity of extracting knowledge from raw genomic data. We deliver validated, accurate results that are redefining personalized medicine. ___________________________________________________________________________________ At Real Time Genomics, we have a passion for genomics. Our core competence is a commitment to know, anticipate and deliver to the needs of leading biological researchers. The company has deep computational expertise in algorithms, coupled with extensive product development capabilities and a seasoned commercial team with over 100 years of success in bringing genomics' innovation to the life sciences industry. Today,we offer solutions for genomic analysis to practitioners of next generation sequencing (NGS) technologies. These solutions include complete analytical platforms for genomics and metagenomics. We can install these platforms to your compute environment or provide you access to them through cloud computing.

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is based in Salt Lake City, Utah.

Founded in 2017, Redesign Science is a platform biotech working at the interface of physics-based molecular simulation and deep learning to create generative AI for drug discovery. We deploy our platform technology to develop first-in-class Protein Interaction Modulators against validated targets known to drive progression of multiple oncogenic and inflammatory diseases.

Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology. By applying these insights, we believe we have a differentiated approach to drug protein targets based on their motion, enabling us to select and advance unique product candidates that can be developed into novel therapies for patients. Located in Cambridge, Massachusetts, our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you're creative, collaborative and passionate about making a difference in the lives of patients, join us!

Remmie Health is a digital health technology venture that delivers next-generation, AI-enabled, ear-nose-throat care for easier, accessible diagnosis, timely intervention, and exceptional patient care. Remmie is a patient-centric, primary care telemedicine/at-home examination device + API + AI system that enables patients/consumers to receive virtual/hybrid care from healthcare professionals, covering 22+ most commonly occurring respiratory conditions, causing over 120 million annual visits as the leading reason for ambulatory care, impacting every family 2-9 times a year. The winner of the Muse Innovation Fellowship, UCLA Knapp Venture Competition, and Rice Business Plan Competition, Remmie Health is a UnitedHealthcare Accelerator (powered by Techstars) and Plug and Play portfolio company. The company is based in Seattle, WA.

Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease.COVID-19: Renalytix has entered into a joint venture with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”), Kantaro Biosciences, LLC (“Kantaro”), to develop and scale production of COVID-19 antibody test kits.

Reprieve Cardiovascular, Inc. is developing innovative and groundbreaking therapies that aim to improve the lives of more than 25 million heart failure patients around the world. Reprieve is bringing intelligence to decongestion management to safely accelerate fluid removal for heart failure patients. In 2022, Reprieve initiated the FASTR Trial (pilot study) to compare decongestive therapy administered by the Reprieve Decongestion Management System to Optimal Diuretic Therapy in the treatment of patients diagnosed with acute decompensated heart failure. Reprieve is a privately held medical device company, headquartered in Milford, Massachusetts, USA.

Resero Analytics creates software and data products to help Pharmaceutical companies, CROs, and Regulators to better manage their Data, to apply Analytics that will extract more value from their data, and to Report it more promptly and more accurately. Our primary focus is on Toxicology and its translation to human drug safety.

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries.

restor3d enables surgeons to improve the reconstruction and repair of the human body through 3D printed implants with enhanced anatomical fit and superior integrative properties. Leveraging expertise and experience in 3D printing of key biomedical materials spanning a wide range of properties, restor3d seeks to improve medical device solutions.

Our mission is to optimize the release cycle, reduce cost, and eliminate compliance risk of releasing promotional materials in the pharmaceutical industry, while improving quality and consistency. ‍ We achieve this by applying deep industry knowledge in cutting-edge technology to automate the compliance requirements and best practices for our customers. We strive not only to uphold the highest standards of accuracy and compliance, but also to enable the generation of data-driven, personalized, and engaging content that results in positive patient outcomes. At the heart of our offerings is our AI-driven platform that learns from regulations, industry best practices, and our customers’ historical actions. Recommendations provided by our platform significantly reduce promotional material release time, and this level of efficiency has already earned us the trust of a Top 5 pharmaceutical company. At Revisto, we believe in transparency and understand that trust is earned through consistent performance and open communication. We are committed to delivering results for our customers and fostering relationships built on mutual respect and shared success.